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SUMMARY 
Preventative interventions often demand that resources be consumed in the 
present in exchange for future benefits.  Understanding these trade-offs, in a context of 
resource constraints, is essential for policy makers.  Cost-effectiveness analysis is one 
tool to inform decision-making.  
Targeted testing and treatment (TTT) for latent tuberculosis infection (LTBI) 
consists in identifying people at high risk for LTBI for preventive treatment to decrease 
the risk that they will develop active tuberculosis disease (ATBD).  The state of 
Tennessee began conducting TTT statewide in 2001.  This study uses a decision tree to 
evaluate the cost and outcomes of TTT for LTBI in Tennessee, compared to passive 
ATBD case finding (PACF).   
Key event probabilities were obtained from the Tennessee TTT program and from 
the literature.  Outcomes are measured in terms of Quality Adjusted Life Years (QALY).  
The cost-effectiveness threshold was set at $100,000/QALY saved.  One-way sensitivity 
analyses around factors related to study design (exclusion of patient costs, secondary 
transmission, discount rate and analytical horizon), the program’s environment 
(prevalence of LTBI and drug resistance, ATBD treatment costs) and program 
performance (program maturity, treatment initiation and completion rate, testing in low-
risk group, test characteristics, screening costs) were conducted, as was probabilistic 
sensitivity analysis (PSA) which takes into account the uncertainty in multiple parameters 
simultaneously.  
The base case, with a 25-year time horizon and 3% discount rate, shows that TTT 
prevents 47 ATBD cases, and saves 31 QALYs per 100,000 patients screened for LTBI at 
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a societal cost of $12,579 (2011 US$) per QALY saved.  Sensitivity analyses identified 
value thresholds that would trigger a change in preferred policy.  PSA shows that the 
likelihood that TTT would be cost-effective is low.   
Decision makers interested in implementing TTT should carefully assess the 
characteristics of the local TB epidemic and expected program performance to determine 
whether TTT is preferable over PACF from a cost-effectiveness viewpoint.  
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CHAPTER I 
INTRODUCTION 
 
Justification 
Targeted testing and treatment (TTT) for latent tuberculosis infection (LTBI) is a 
preventative intervention that consists in identifying people at high risk for LTBI so they 
can be tested and, if indeed infected, treated to decrease the risk that they will later 
develop active tuberculosis disease (ATBD).  The purpose of this research is to evaluate 
whether, and under what circumstances, it is worthwhile, from an economic viewpoint, 
for public health authorities to conduct TTT in a low TB incidence setting such as the 
U.S.   
Implementing any health intervention entails consuming resources to produce 
health benefits.  While needs are unlimited, resources are scarce, and their allocation to a 
particular use makes them unavailable for other uses.  In the case of preventative 
interventions like TTT, uncertainty can make this trade-off even more complex: 
prevention often demands that resources be consumed in the present in exchange for 
benefits that will accrue in the future.  In addition, it may also require that many receive 
the intervention while only a few will experience said benefits.  As a result, while 
knowing whether a preventative intervention is effective is essential, it is also important, 
in a context of resource constraints, for policy makers to determine whether the trade-off 
of resources for health outcomes is worthwhile, or whether a different policy choice 
would yield greater benefits for a given resource cost.   
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Economic evaluation is “the comparative analysis of alternative courses of action 
in terms of both their costs and their consequences” (Drummond et al., 2005) to 
determine whether a policy or program represents “value for money”.  The intervention 
of interest is compared to a baseline, such as the current standard of care, so that the 
difference in cost and health outcomes between the two approaches can be computed.  
Thus TTT can be compared to a situation in which LTBI is left to run its natural course, 
and cases of ATBD in a population are instead diagnosed as they occur over time, which 
is referred to as passive ATBD case finding.  The intervention of interest will be either 
more or less costly and either more or less effective, than the baseline.  Economic 
evaluation is especially useful when the intervention of interest is both more costly and 
more effective than the comparator: an incremental cost-effectiveness ratio (ICER), 
which represents the cost per additional unit of health outcome obtained thanks to the 
intervention of interest, can be calculated.  Decision makers can then determine, based on 
their willingness-to-pay or cost-effectiveness threshold, whether this cost is acceptable to 
them: if the ICER is below the cost-effectiveness threshold, the intervention of interest is 
cost-effective.   
Cost-benefit analysis, cost-effectiveness analysis and cost-utility analysis are 
three techniques available to conduct economic evaluation.  All three use the same 
approach to identifying and measuring costs, but differ in their measurement of health 
effects.  Unlike cost-benefit analysis, cost effectiveness and cost-utility analysis do not 
assign a monetary value to outcomes.  Cost-effectiveness relies instead on natural units, 
such as ATBD cases diagnosed or cured, which are generally easily understandable to 
decision makers.  However, this approach has limitations: it makes comparisons difficult, 
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even among interventions that target the same condition (e.g. interventions that prevent 
cases of ATBD and those that cure ATBD).  Such outcome measures also do not convey 
stakeholders’ utility/preference for the outcome in question.  Cost-utility analysis 
overcomes these challenges by using measures such as Quality-Adjusted Life Years 
(QALY).  QALYs are not disease-specific, take into account both survival and quality of 
life, and explicitly incorporate the notion of value and preference in the rating of health 
states. 
To map out interventions’ inputs, processes and outputs, economic evaluation can 
use tools such as decision analysis.  Whether large scale TTT for LTBI is a worthwhile 
strategy is a complex question, which requires considering many parameters with 
uncertain value, and drawing on evidence from a range of sources.  Decision analysis 
helps disaggregate complex problems into smaller elements whose dynamics can be more 
readily described.  Essential elements can then be combined into a model of the original 
problem, using tools such as decision trees, to explicitly identify the sequence of events 
and the linkages between them.  Decision trees are visual representations of the model.  
They use basic probability theory to calculate the expected value of each course of action 
or strategy under comparison in the model.  Additional tools such as Markov loops are 
useful to model situations in which the duration and timing of events is important (e.g., 
events that have a chance of repeating over time such as the annual risk of developing 
active TB disease).  Finally, sensitivity analysis, which consists in recalculating model 
results using alternative values of one or more parameters of interest, is used to evaluate 
the impact of uncertainty on the results, assess their robustness and identify threshold 
values that would trigger different policy choices. 
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Economic evaluation and decision analysis techniques have been applied to 
testing and treatment for LTBI since the 1980’s.  However, published studies report 
widely different estimates of the economic value of combating TB by targeting 
individuals with LTBI, and are somewhat conflicted in their conclusion regarding the 
value of preventive TB control strategies.  Several limitations are noted, that may lead to 
overestimating the efficiency of TTT: the studies that have been published tend to focus 
on either testing or on treatment for LTBI.  In particular, treatment evaluations take as 
their starting point a cohort of patients who have already been diagnosed with LTBI, and 
leave out of the analysis the costs and other parameters associated with screening and 
testing a much larger cohort of individuals, the majority of which will return a negative 
result, in order to identify those with LTBI.  In many cases, the probabilities used in the 
model to represent treatment completion, a key determinant of effectiveness, were 
derived from clinical trials or small observational studies and may differ from that 
obtained in routine programmatic conditions in busy public health departments.  Another 
limitation of the literature is the failure to account for the prevalence of drug resistance in 
the target population, which may limit the effectiveness of preventive therapy.  The 
published literature may also have underestimated the cost associated with ATBD and the 
benefits to be derived from the intervention: most studies only consider direct medical 
costs of treating disease.  Economic losses associated with morbidity and premature 
mortality are rarely included, and losses in quality of life in survivors have only recently 
begun to be described, measured and incorporated into QALY calculations.  Finally, 
sensitivity analyses, when conducted, have been only included one-way and two-way 
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sensitivity analysis, that are do not fully capture the impact that uncertainty and variation 
in model parameters can have on cost-effectiveness. 
The TB Control Program of the state of Tennessee has been carrying out Targeted 
Testing and Treatment statewide since 2001, the only large-scale initiative of its kind, 
and has collected extensive data about patients’ characteristics and program performance.  
Tennessee’s experience presents a unique opportunity to evaluate the cost-effectiveness 
of TTT in programmatic conditions.  This research seeks to apply economic evaluation 
measures to the Tennessee example to evaluate the cost-effectiveness of TTT and identify 
factors that drive costs and outcomes, while palliating some of the limitations noted in the 
existing literature: considering TTT as a comprehensive intervention that includes risk 
screening, LTBI testing and LTBI treatment; using data generated in routine program 
conditions to estimate the likelihood that patients will be screened, tested and treated; 
accounting for drug resistance and other factors that affect the intervention’s efficacy; 
taking patient costs into consideration; and considering the impact of uncertainty on cost-
effectiveness through probabilistic sensitivity analysis.  Study results should have 
implications for the research itself, for the state of Tennessee’s TB Control Program, and 
for the larger public policy debate on TB control in the U.S. 
 
Background 
The incidence of tuberculosis is at an all-time low in the U.S., where less than 
10,000 cases of active TB disease were reported in 2012, and the goal of eliminating TB 
seems more than ever within grasp.  Incidence first fell below 10 cases per 100,000 pop., 
the threshold for low incidence, in 1983. However, the failure to commit sufficient 
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resources to TB control in the late 1980’s, poor clinical management leading to the 
development of drug resistance, and the HIV epidemics spurred instead an upswing in TB 
incidence that culminated in 1993.  Although incidence has since then resumed its 
downward trend, target dates for elimination of TB as a public health threat have been 
repeatedly set, and missed.  In 2000, a report by the Institute of Medicine (IOM) adopted 
2035 as the new target date for TB elimination (IOM, 2000). 
Achieving elimination is deemed desirable because the health and economic 
impact of ATBD remains significant.  Although the disease is treatable, it is still fatal.  
Anti-tuberculosis treatment is lengthy and burdensome, as observation of daily drug 
intake by a health worker to guarantee treatment adherence is recommended practice.  In 
addition, lung impairment is a common sequela among survivors.  Tuberculosis disease 
also has a significant economic impact on patients, their household, and society: it results 
in high health care costs (although TB care is provided free-of-charge to patients through 
public health clinics) and causes losses in productivity.  Patients can experience severe 
short-term disability, and must be isolated as long as they are infectious: patient and 
caregivers’ income suffer accordingly.  Finally, the economic burden of tuberculosis on 
society also includes the considerable cost of maintaining the public health infrastructure 
needed to monitor and control the disease.   
TB control policymaking and implementation mobilizes public health authorities 
at all levels of government.  At the local level, city and county health agencies play little 
policymaking role, but deliver public health services directly to the population.  In the 
case of tuberculosis, local health departments evaluate TB suspects, perform the 
necessary tests to diagnose tuberculosis disease and tuberculosis infection, provide 
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treatment drugs and supervise treatment according to state protocols and guidelines.  
They also take measures to contain further spread of the disease, such as investigating 
contacts, tracking patients to ensure treatment adherence, and even initiating legal action 
against non-compliant patients. At the state level, TB control units within Departments of 
Health tailor national guidelines to formulate specific state policies.  State TB programs 
also distribute federal and state funding to local health departments.  At the federal level, 
the Department of Health and Human Services’ Centers for Disease Control and 
Prevention (CDC) allocate federal appropriations for TB control to states, conducts 
research and demonstration projects, and most importantly play a key leadership role by 
spearheading the adoption of evidence-based technical guidelines and policy frameworks. 
The National Plan to Eliminate Tuberculosis was formulated in answer to the 
2000 IOM report and guides current TB control policy.  To achieve disease elimination in 
the United States, it lays out a national TB control strategy articulated around three 
priority interventions.  The first is the timely detection of cases of ATBD and their 
appropriate treatment to ensure cure, stop transmission and prevent the development of 
antibiotic resistance.  The second intervention, closely linked to the first, is to conduct 
contact investigations, to identify and test individuals who have had contact with 
tuberculosis patients, determine whether they might already be suffering from ATBD, or 
have been infected, and treat them accordingly.  The third component in the national 
strategy is TTT: to screen populations that are at increased risk of harboring tuberculosis 
infection to identify individuals with LTBI, and provide prophylactic treatment to prevent 
progression from latent to active disease.   
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Since the mid-1990s, curbing the resurgent TB epidemic has been achieved 
primarily by strengthening ATBD case finding and contact tracing.  To eliminate ATBD 
by 2030, experts argue that solely diagnosing and treating individuals with ATBD and 
their contacts is insufficient, as it only tackles incident cases.  Efforts to implement TTT 
must also be stepped up, as an estimated 15 million people in the U.S. carry latent TB 
infection, and are at risk of evolving to ATBD at some point in their life.  For TB to be 
eliminated, the pool of persons at risk for ATBD must shrink: this can be achieved by 
providing prophylactic treatment to individuals who carry LTBI.  The standard 
recommended regimen of 6 to 9 months of the drug isoniazid (INH), for instance, can 
decrease the risk that an infected person will develop ATBD by 90%.  As only ATBD 
cases are infectious, preventive treatment for LTBI has the added benefit of also cutting 
down on secondary transmission: ATBD cases are prevented before they have a chance 
to infect others. 
Targeted Testing and Treatment was developed as a strategy in response to a 
change in the distribution of the disease in the population.  TB is now a “focal disease” 
(Binkin, 1999), increasingly confined to a number of high-risk groups, notably non-
Whites, nursing home residents, prisons and jails inmates, migrant workers, the homeless, 
and the foreign-born originating from countries were TB is endemic.  As a result, 
recommendations on how public health authorities are to search for LTBI cases have 
evolved over time.  Indiscriminate mass screenings are no longer recommended, because 
they are inefficient (Starke, 1995).  Policy guidelines (CDC, 2000) now recommend a 
targeted approach: only high-risk groups should be the focus of LTBI testing efforts.  
Increased risk can be due to at higher risk of already being infected with LTBI (as in the 
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case of individuals from countries where TB is highly prevalent); a higher risk of 
progressing from LTBI to ATBD (as in HIV+ individuals) and/or a higher risk of 
experiencing poor outcomes once ATBD develops.   
The foreign-born from countries where TB is endemic, as a high-risk group, are 
of particular importance to TB control efforts.  Demographically, they represent a 
sizeable portion (10%) of the general population (Census Bureau, 2002).  In addition, the 
foreign-born have accounted for over 50% of TB cases every year since 2001.  Screening 
for TB has long been part of the immigration process, but attention has focused primarily 
on detecting ATBD.  Immigrants with LTBI who do not have an abnormal chest X-ray 
will not be identified during their visa application.  Temporary visitors are not screened 
for ATBD or LTBI.  Neither are those who enter the country illegally, or overstay their 
visas.  Targeted Testing and Treatment represents a way to palliate the limitations of 
existing passive ATBD case finding policies among the foreign-born.  
However, TTT has implementation challenges and uncertainties.  The first set of 
challenges is related to the nature of TB infection and disease.  Not everyone with LTBI 
(only 10% in HIV-negative persons) would ultimately develop TB: only a minority of 
treated individuals, therefore, truly stands to benefit from TTT.  Second, the tools used 
for LTBI testing and treatment have limitations.  The Mantoux tuberculin skin test (TST) 
for LTBI may return false positive or false negative results, especially in low incidence 
settings.  Also, determining whether the test result is negative or positive can be difficult, 
even for trained health care workers.  Third, treatment for LTBI creates is a risk of 
(potentially fatal) hepatitis. In addition, it drastically reduces but does not completely 
eliminate, the risk of ATBD.  Furthermore, the standard INH regimen is not effective in 
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the case of people infected with an INH-resistant strain of TB.  The last set of limitations 
has to do with implementation inefficiencies: a proportion of patients to whom a TST is 
applied will not return for the test result to be read, patients who test positive may refuse 
treatment, and obtaining patients’ compliance with a 6-9 months treatment regimen when 
they are not feeling sick has proved difficult in practice.  All these limitations and 
programmatic challenges can undermine the impact of TTT on health outcomes.   
To date, the Tennessee TB Control Program stands alone in the nation in having 
implemented a statewide Targeted Testing and LTBI Treatment program as part of its 
routine TB control activities. This state-funded initiative was developed to address the 
above-average ATBD case rate and the doubling in the percentage of foreign-born cases.  
Since 2002, all individuals presenting at any one of the state’s 95 public health clinics for 
any reason are asked a series of questions aimed at determining whether they are at 
increased risk of LTBI, active disease reactivation or poor ATBD treatment outcomes.  A 
positive answer to any one of the questions classifies the individual as high risk.  High-
risk individuals are then counseled about TB and LTBI, and offered a test for LTBI.  If 
the test result is positive, they are started on a course of treatment for LTBI.   
An evaluation of the program’s feasibility and yield has found that from March 1, 
2002 through December 31, 2006, 168,517 patients were screened for TB risk.  Among 
them, 125,200 received a TST.  Seven percent of all persons who were tuberculin tested 
had a positive test result. The study concluded that, based on treatment efficacy, and 
observed initiation and completion rates in 2002-2006, TTT could be credited for 
preventing 184 future cases of ATBD in the screened cohort. The study also highlighted 
the benefits of targeting high-risk individuals: the number needed to test to prevent one 
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case of ATBD was 150 among the foreign-born, and 9,834 among low-risk persons.  The 
study estimated that total program cost from initiation through 2006 (including start-up 
costs), was $6.4 million, of which approximately $800,000 was in start-up and annual 
management costs, $3.1 million was in screening costs, and $2.5 million was in LTBI 
treatment costs, but did not address whether the initiative represented a cost-effective use 
of these resources, relative to what would have happened had TTT not been conducted. 
 
Objective 
The overall objective of this study is to evaluate whether it is cost-effective to 
conduct Targeted Testing and Treatment among groups at high-risk for LTBI, notably the 
foreign-born, or whether it is preferable to diagnose and treat cases of ATBD once they 
have developed, a strategy referred to as “passive ATBD case finding” (PACF).  First, 
the study assesses the incremental cost and health outcomes associated with TTT, relative 
to PACF, based on the experience of Tennessee’s TTT program.  Additionally, the study 
seeks to determine the independent impact of various factors related to study design, 
program context, and program performance, on cost-effectiveness, to inform discussions 
about the replicability of TN’s experience and the generalizability of the findings to other 
low-incidence settings. 
 
Study Methods 
All modeling assumptions are summarized in Appendix B.  This study uses a 
decision tree (Treeage, Williamstown, MA) to model the costs and health outcomes of 
Targeted Testing and Treatment for LTBI, compared to a baseline strategy of passive 
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ATBD case finding in a cohort of public health clinics’ clients.  Among them, the 
majority are free of LTBI:  they have no risk of ever developing ATBD given that they 
never were infected, and will not incur any TB-related cost or loss of health.  Others are 
unknowingly infected with LTBI and are at risk of developing ATBD in the future. The 
remaining patients, a small proportion, have had ATBD in the past, and are assumed not 
to be at risk of developing ATBD again.  
Under PACF, the decision tree for infected patients branches out according to two 
important parameters: anti-TB drug resistance and HIV status. The tree first divides 
patients into subgroups by resistance status.  Most infected patients carry a form of TB 
infection that is sensitive to INH, the drug most commonly used for LTBI treatment.  
Among those that are resistant to INH, the tree again distinguishes between those 
resistant to INH only and those resistant to both INH and rifampin (multidrug resistant 
TB) which will affect both the cost of ATBD treatment and its success.  A proportion of 
patients in all resistance subgroups are co-infected with HIV, which increases both their 
risk of developing ATBD and dying from it.   
Under PACF, all individuals infected with LTBI, regardless of resistance or HIV 
status, immediately enter the Markov loop that represents the path they will follow over 
the remainder of their lifetime as a series of one-year cycles.  Every year, infected 
individuals face three possible but mutually exclusive pathways: 1) they can develop 
ATBD; 2) they can die from causes unrelated to TB, or 3) they can remain in a state of 
LTBI.  If they develop ATBD, it is assumed that they are diagnosed and treated 
appropriately. They can either die from ATBD, or survive.   
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Patients who develop ATBD and patients who die from causes other than TB 
during a given cycle exit the study cohort for good at the end of that cycle.  Patients who 
remain in the state of LTBI at the end of an annual cycle progress to the next cycle, 
during which they again face the possibility of dying from other causes, developing 
ATBD or remaining latently infected.  The remainder of the cohort continues to cycle 
through the Markov loop until the termination condition is met. 
Under TTT, eligible patients (infected and non-infected—since their true status is 
not known) undergo risk screening and are categorized as high risk or low risk.  In each 
risk category, the tree branches out successively according to the likelihood that patients 
will receive a skin test, that the skin test will be read and that the result will be positive, 
that they will begin treatment, experience adverse drug events and complete treatment.  
For patients in the “Infected” arm, each path ends with the Markov model described 
previously, after taking into account INH resistance and HIV status. For patients in the 
“Non-infected” arm, all paths end immediately as patients are never at any risk of 
developing ATBD.  
The base case scenario, which represents the most reasonable set of assumptions 
about the two strategies, adopts a societal perspective.  It includes direct medical costs as 
well as patient costs associated with receiving treatment for LTBI and ATBD, and 
productivity losses associated with morbidity and premature mortality from ATBD and 
from adverse reactions to LTBI treatment.  Costs and outcomes are calculated over an 
analytical horizon of 25 years.  A discount rate of 3% per year is used to calculate the net 
present value of future costs.  Costs are reported in 2011 U.S. dollars.   
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Outcomes are measured in terms of ATBD cases and QALYs.  QALY weights 
were obtained from the literature, with 0 representing full health/no health loss and 1 
representing death.  In the base case scenario, each case of ATBD was assumed to cause 
another 0.46 cases, of whom 1/3 would occur at the same time as the index case, 1/3 after 
5 years, and 1/3 after 20 years (Shepardson, 2013).  Outcomes were also discounted at 
3% per year.  The number of years of life lost to each death resulting from ATBD or 
adverse drug events (ADE) was calculated based on the age distribution of the infected 
cohort, the timing of the deaths and the 2006 period life table.  The ceiling incremental 
cost-effectiveness ratio used as a threshold to adjudicate on cost-effectiveness was 
$100,000 per additional QALY saved. 
Key information about the TTT intervention in Tennessee was obtained from the 
state’s Patient Tracking Billing and Management Information System (PTBMIS).  
Clearance for use of the data was obtained from the Tennessee Department of Health.  
The sample used to derive event rates for the decision tree included 135,966 patients.  
Twenty-one percent of sample patients were born foreign-born, of whom 98% percent 
were from a country where TB is endemic.  The risk screening classified 55.4% of 
patients as high risk, 44.3% as low risk, and 0.3% had had TB previously.  Over the study 
period, 70.4% of patients received a TST, 85.5% of tests’ results were read and recorded, 
and 9.4% were positive.  A total of 3,925 patients started LTBI treatment, and 52.5% 
complete the entire course of therapy.  Six-to-nine months of INH was the most 
frequently prescribed regimen (86%). 
Model parameters obtained from the Tennessee sample include the percentage of 
patients previously treated for ATBD, the percentage of patients classified at high risk, 
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and the percentage of patients in both high and low risk groups who received a TST, 
whose TST result was read and recorded, who tested positive for LTBI, who initiated and 
completed treatment for LTBI, as well as the HIV prevalence rate.  Annual rates (2002-
2006) for all these parameters were also calculated for sensitivity analysis. 
Average rates of INH resistance and multidrug resistance were computed based 
on annual state surveillance reports (CDC, 2008).  The rates observed in the foreign-born 
were used to model resistance in the high-risk group, and the rates in US-born patients 
were used as a proxy for the low-risk group.  The age-adjusted risk of developing ATBD 
during each Markov cycle was derived from work by Horsburgh et al. in which annual 
age-stratified reactivation rates were computed depending on size of TST reaction and 
time since infection, using data from clinical trials on INH efficacy (Horsburgh et al. 
2004).  For HIV-positive patients, the corresponding rate was adjusted by a factor of 9.9 
(Horsburgh et al. 2004).  Estimates of INH preventative efficacy were also based on 
clinical trial results (IUAT, 1982).  Completing 100% of any LTBI treatment regimen 
was assumed to prevent 90% of expected cases; completing at least 80% of a regimen 
was assumed to prevent 68% of expected cases.  Patients who completed less than 80% 
of a regimen were assumed to derive no protection.  The age-adjusted rate of ADEs in 
persons treated with INH was based on results reported by the Seattle-King County 
Department of Health for 1989-1995 (Nolan et al., 1999).  The fatality rate for hepatitis 
from any cause was used as a proxy for the fatality rate for INH-related ADEs (Millard, 
1996).  The risk of dying from drug-sensitive or resistant-to-INH-only ATBD was 
operationalized as the average case fatality rate for 2002-2006 in Tennessee.  The 
numerator was the number of deaths for whom ATBD was reported as the underlying 
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cause, and the numerator was the total number of ATBD cases reported in Tennessee in 
the same period.  The mortality rate for MDR TB was obtained from U.S. reports on 
2006 MDR TB treatment outcomes to the World Health Organization (WHO, 2010).  The 
mortality rate in HIV-positive patients was obtained from an observational study of 
mortality by HIV status that used data from the U.S. surveillance system (Shah et al., 
2010).  The age-adjusted all-cause mortality rate for each Markov cycle was calculated 
based on the National Vital Statistics System’s 2006 period lifetable. 
On the cost side, patient cost profiles were compiled, based on national and state 
LTBI screening and treatment guidelines and program staff’ description of local practice, 
to estimate the type and quantity of health services consumed during TTT.  LTBI 
treatment was assumed to be self-administered.  Health services’ unit prices were 
obtained, from the 2011 Medicare’s Physician Fee Schedule and Clinical Laboratory Fee 
Schedule for the state of Tennessee.  For staff time cost estimates not reflected in the 
Medicare Fee Schedules (e.g., time spent by staff on administering the TB risk screening 
questionnaire), the March 2011 release of the Bureau of Labor Statistics’ Occupational 
Employment Statistics for health care professions in Tennessee was used.  Drug costs 
were obtained from the 2011 Red Book (Red Book, 2011).  To account for ATBD 
treatment costs, estimates of ATBD diagnosis and treatment costs were abstracted from 
the literature and updated to 2011 US$ using the medical component of the CPI, and the 
median values for drug sensitive and MDR ATBD, augmented by 1% per year to account 
for changes in health care services over time, were used. 
As health services associated with TTT/LTBI would be provided free of charge to 
patients, patients’ direct costs included the cost of transportation to the health department, 
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and the time cost of seeking services.  Travel costs were estimated based on data about 
commuting distances from the American Community Survey and U.S. General Services 
Administration standard reimbursement rates.   
Patients’ indirect costs include the opportunity cost of time spent seeking care for 
LTBI, productivity losses associated with morbidity from ATBD disease in non-
prevented cases, and the value of life lost to premature mortality from ATBD and ADEs.  
The opportunity cost of time was based on Bureau of Labor Statistics data for 
production/non managerial wages.  Productivity losses associated with non-fatal ATBD 
disease were based on the results of a study of the cost of patients hospitalized for MDR 
TB (Rajbhandary, 2004), which used the human capital approach, updated to 2011 US$ 
using the Bureau of Labor Statistics (BLS)’ Employment Cost Index.  The value of life 
lost from premature mortality due to non-prevented ATBD cases and fatal ADEs used 
published estimates of the Net Present Value of Lifetime Earnings (NPVLE), also 
updated using the BLS’s Employment Cost Index and adjusted for the age distribution of 
infected patients in the cohort.   
Both start-up and annual management costs were included.  They consisted 
primarily of staff time costs for planning and training.  It was assumed that no capital 
expenses were necessary as public health departments are already organized to provide 
TB services.  Salary information was obtained from the Tennessee Department of Health 
and updated to 2011 US$ using the BLS’s Employment Cost Index.  Program costs were 
directly allocated to all patients screened for risk over the study period. 
To gauge the robustness of the results and identify parameters that influence 
variation in costs and outcomes, one-way sensitivity analyses around factors related to 
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study design, the program’s environment and program performance were conducted.  
Study design parameters varied in one-way sensitivity analyses included the scope of the 
study (impact of patient costs and secondary transmission) and assumptions about time 
preference (discount rate and analytical horizon).  Ecological factors included the 
prevalence of LTBI and drug resistance in the population screened, the cost of ATBD 
treatment, and the sensitivity and specificity of the LTBI test.  Factors related to program 
performance included the LTBI treatment initiation and completion rates, the testing rate 
among low-risk patients, program maturity and the cost of risk screening.  These 
sensitivity analyses identified thresholds that would trigger a change in optimal policy 
choice. 
Probabilistic sensitivity analysis (PSA) using a Monte Carlo simulation with 
10,000 replications was conducted.  To identify variables for inclusion in the PSA, all 
point estimates in the model were replaced with distributions, and a tornado diagram was 
produced.  Variables that accounted for more than 1% of the total variance, as well as all 
variables that were shown in the one-way sensitivity analysis to have an impact on cost-
effectiveness and on the choice of optimal strategy, were retained for the PSA.  Cost-
effectiveness acceptability curves, which show the probability that TTT is the preferred 
option given different cost-effectiveness thresholds, were also derived. 
 
Results 
In the base case scenario, using a societal perspective, a 25-year time horizon and a 
3% discount rate, PACF results in the occurrence of 303 ATBD cases and the loss of 554 
QALYs, for a total cost of $36,724,998 dollars, in a hypothetical cohort of 100,000 persons 
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screened for LTBI risk.  With TTT, 256 ATBD cases would occur, and 523 QALYs would 
be lost, for a total cost of $37,114,935.  Therefore, TTT prevents 47 ATBD cases, and saves 
31 QALYs per 100,000 patients screened for LTBI.  The incremental cost effectiveness ratio 
(ICER), i.e., the incremental cost per additional QALY saved, is $12,579 (2011 US$).  As 
the ICER is lower than $100,000, TTT is cost-effective and the preferred strategy. 
The first set of sensitivity analyses sought to show how study design affects cost-
effectiveness results.  Two analyses related to the boundaries of the study, as they varied 
the way in which the costs and benefits of TTT were defined.  The first variation 
consisted in a switch from a societal to a health system perspective, which resulted in 
excluding patient costs from the list of relevant costs.  Excluding patient costs should not 
affect outcome calculations, but should decrease total costs.  Whether it increases or 
decreases cost-effectiveness would depend on whether the difference in total costs 
between the two alternatives increases or decreases relative to the base case scenario 
results.  Results show that all other things being equal, the ICER increases to $97,503 per 
additional QALY saved when patient costs are excluded.  As this is still below the 
$100,000 threshold, TTT remains the preferred policy option. 
The second sensitivity analysis concerned the scope of health benefits resulting 
from ATBD prevention, and consisted in varying the number of secondary cases that 
each ATBD case is assumed to generate.  As expected, the cost-effectiveness of TTT 
improved as the number of secondary cases per index case increased.  From a societal 
perspective, TTT was cost-effective as long as each index case was assumed to generate 
at least 0.07 secondary cases.  From a health system perspective, the threshold was much 
higher (0.44 secondary cases).   
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Two additional study design aspects considered in sensitivity analysis, the 
discount rate and analytical horizon, relate to decision makers’ time preference.  Varying 
the discount rate affects both cost and outcomes, and TTT’s cost-effectiveness should 
decrease with higher discount rates, as the NPV of future benefits decreases while 
intervention costs, undiscounted, remain the same.  Indeed, when the rate switches from 
3% (base case) to 5%, the ICER per QALY saved increases more than five-fold to 
approximately $63,000. From a health system perspective, PACF becomes the preferred 
strategy when the discount rate is 4% or higher. 
Varying the analytical horizon also reflects whether decision makers are willing 
to consider a program’s long-term impact or whether they are focused on short-term 
results.  Results show that a longer-term perspective is necessary to demonstrate TTT’s 
value.  From a societal perspective, the analytic horizon must be at least 16 years for TTT 
to be cost-effective.  Beyond 32 years, it is both cost saving and more effective.  From a 
health system perspective, it takes at least 25 years for TTT to be the preferred strategy. 
The second set of sensitivity analyses is related to the characteristics of the 
environment in which TTT is implemented.  Three contextual factors are considered: the 
cost of diagnosing and treating ATBD, the prevalence of LTBI in the population 
screened, and the prevalence of INH resistance.  The cost of diagnosing and treating 
drug-susceptible (DS) and MDR TB were varied separately, and TTT’s cost-effectiveness 
was expected to improve as the cost of treating ATBD increased.  From a societal 
perspective, TTT is cost-effective even when the cost of DS ATBD is as low as $1,000 
per case.  Once the cost reaches $34,000 per case, TTT is cost-saving.  From a health 
system perspective, the cost per ATBD case treated must be at least $24,000 for TTT to 
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be cost-effective.  On the other hand, varying the cost of MDR TB diagnosis and 
treatment has no impact on cost-effectiveness.  TTT remains the preferred strategy over 
the entire range of values ($5,000 - $100,000) explored in the sensitivity analysis.  
LTBI prevalence was expected to be positively linked with cost-effectiveness, as 
screening and testing efforts’ yield would be greater in settings where LTBI is more 
prevalent.  Results show that the overall prevalence of LTBI in the screened population 
must be at least 6% for TTT to be cost-effective from a societal perspective, and at least 
8% from a health system perspective.   
As LTBI treatment with INH is not effective in patients infected with an INH-
resistant strain of TB, INH prevalence in TTT’s target population should negatively 
affect cost-effectiveness.  Indeed results show that, from a societal perspective, TTT is 
the preferred strategy as long as less than 27% of all persons with LTBI are INH-
resistant.  Resistance levels that high are very unlikely.  From a health system perspective 
however, INH resistance would only need to reach 11% for PACF to become the optimal 
strategy.   
The third set of sensitivity analyses explored the impact of program performance 
on cost-effectiveness.  The first analysis assessed whether the efficiency of the program 
changed as the program matured, by using annual estimates of the Tennessee’s TTT 
program to calculate a separate cost-effectiveness ratio for each year in the study period 
(2002-2006). TTT was the preferred strategy four out of five years from a societal 
perspective, and three out of five years from the health system perspective. Total and 
incremental cost fluctuated relatively little from year to year, but variation in outcomes 
was substantial.  As a result, cost effectiveness varied widely as well.  However, no 
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evidence of a trend was found.  Therefore the results do not support the hypothesis that a 
relationship (positive or negative) exists between program maturity and economic 
efficiency. 
The second sensitivity analysis concerned three performance measures chosen by 
the Tennessee TB Control Program to establish performance objectives for the TTT 
initiative: the LTBI treatment initiation and completion rates, and the LTBI testing rate in 
low-risk patients.  From a societal perspective, at least 26% of infected patients must 
begin treatment for TTT to be cost-effective.  If the initiation rate is above 57%, TTT is 
cost-saving, all other things being equal.  From the perspective of the health system, the 
threshold rate to ensure TTT’s cost-effectiveness is 53%. 
Treatment completion also affects cost-effectiveness.  At least 44% of patients 
must complete LTBI treatment for TTT to be cost-effective from a societal perspective.  
Below 29%, PACF would be both less costly and more effective (as it would generate a 
lesser QALY loss).  On the other hand, if the completion rate is above 61%, TTT is both 
more effective and less costly.  From a health system perspective, TTT is also dominated 
if less than 29% of patients complete treatment, and it does not become cost-effective 
until the completion rate reaches at least 58%.   The third program performance indicator 
varied in a sensitivity analysis is the testing rate among low-risk individuals.  From the 
health system perspective, TTT remains cost-effective as long as the TST application rate 
in low-risk patients remains below 82%, all other things being equal.  From a societal 
perspective, the cost-effectiveness of TST increases as the rate decreases, but no matter 
what percentage of low-risk patients receive a TST, the ICER remains below the 
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$100,000 cost-effectiveness threshold.  If the 20% goal adopted by the program was met, 
TTT would actually be both more effective and less costly than PACF. 
Next in the assessment of the impact of programmatic performance, a sensitivity 
analysis varied the sensitivity and specificity of the Mantoux skin test for LTBI.  From a 
societal perspective, the Mantoux skin test must be identify at least 58% of infected 
patients (sensitivity) or 96% of non-infected patients (specificity) for TTT to be cost-
effective.  From a health system perspective, the criteria for cost-effectiveness are much 
more stringent: the test must be 100% sensitive or 100% specific for the ICER to fall 
under the $100,000 threshold. 
The last sensitivity analysis related to program performance concerned the cost of 
risk screening.  The cost to administer the risk-screening questionnaire was set at $11.66 
in the base case scenario.  Results show that from a societal perspective, TTT is the 
preferred strategy as long as risk screening costs remain below $39 per person screened.  
However, from a health system perspective, TTT ceases to be cost-effective once risk-
screening costs amount to more than $12 per person. 
After conducting deterministic sensitivity analyses to assess the individual impact 
of key model parameters on the cost-effectiveness of TTT, probabilistic sensitivity 
analysis (PSA), which takes into account the uncertainty in multiple parameters 
simultaneously, was also performed.  First, all model parameters so far represented by a 
point estimate were replaced with triangular distributions.  For parameters whose values 
were obtained from the Tennessee PTBMIS database, highest and lowest annual values 
observed between 2002 and 2006 were used as maximum and minimum values.  For 
parameters whose value was obtained from the literature, maximum and minimum values 
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reported in the literature were also used.  For all other parameters, notably costs, the point 
estimate +/- 25% were used as maximum and minimum distributional values.  Then two 
tornado diagrams that used costs and health outcomes, respectively, as their dependent 
variables, were created for the societal perspective model and for the health system 
model.  For both models, all variables that represented more than 1% of the total 
variation in either the cost tornado diagram or the health effect tornado diagram were 
retained for the PSA.  The PSA used Monte Carlo simulation with 10,000 replications.  
When conducted from the societal perspective, the PSA results show that TTT is the 
preferred strategy only 20.5% of the time given the value ranges used and the $100,000 
per QALY threshold.  A Cost-Effectiveness Acceptability Curve (CEAC), which plots 
the probability that TTT is the preferred strategy at various levels of willingness-to-play, 
shows that even if WTP doubled to $200,000, TTT would be the preferred strategy only 
25% of the time. 
From the health system perspective, the PSA results indicate that TTT would be 
cost-effective less than 1% of the time.  The CEAC indicates that doubling the WTP to 
$200,000 would only make TTT the preferred strategy 5% of the time. 
 
Discussion 
This study sought to contribute to knowledge on TB control strategies by 
palliating some of the limitations noted in the existing literature on TB prevention.  The 
model used a societal perspective that included patient costs, while also reporting results 
from the more limited health system perspective; it considered all steps from risk 
screening to treatment completion in the TTT process, and accounted for INH resistance 
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prevalence and other effectiveness dampening factors.  The results of the base case 
scenario, which was designed to reflect the most reasonable assumptions about the costs 
and impact of the Tennessee TTT initiative, show that TTT was very cost-effective 
relative to what would have been observed with PACF, as the cost per QALY saved was 
only $12,579 from a societal perspective and $97,503 from a health system perspective.  
However, deterministic sensitivity analyses highlighted the important impact that 
variation in key parameters would have on cost-effectiveness, including identifying value 
thresholds that the choice of optimal policy.  Finally, PSA showed that when uncertainty 
around influential parameters is taken into account, the likelihood that TTT would be 
cost-effective is low.  While the study has limitations and caveats are in order, the 
findings have important implications for research, for the Tennessee TB Control 
Program, and for the larger policy debate on TTT and on TB elimination. 
The first lesson learned from the study results concerns the importance of study 
design decisions on cost-effectiveness results.  The influence of the chosen study 
perspective is particularly notable.  The cost-effectiveness criterion chosen for the study 
($100,000 per QALY saved) proved harder to meet when the analysis is conducted from 
the health system perspective, which excludes patient costs.  Decisions about study 
design should therefore be made very carefully, and study design should be taken into 
account when evaluating the validity and relevance of research results, particularly when 
there is a need to compare and contrast the findings of studies conducted in different 
contexts and from different viewpoints. 
The results also show the limitations of conducting only deterministic sensitivity 
analysis to evaluate the robustness of the results.  In all one-way sensitivity analyses, with 
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the exception of that around test characteristics, wide value ranges over which TTT 
proves cost-effective can be identified.  When all parameters are varied jointly, and 
randomly over a sensible range, the likelihood that TTT will be preferred over PACF to 
control TB efficiently is relatively small, especially from the perspective of the health 
system.  PSA is a useful way to assess whether parameter uncertainty undermines the 
robustness and generalizability of base case scenario results.  
The results also have implications for the Tennessee TB Control Program.  
Results suggest that the TTT program achieved cost-effective results during the study 
period.  The results of the sensitivity analyses around the rate of LTBI treatment 
initiation, treatment completion and screening in low-risk patients confirm that program 
performance matters.  The average LTBI treatment initiation and completion rates 
observed in Tennessee over the study period are very close to the thresholds identified in 
sensitivity analyses under which PACF would actually be the preferred strategy, and 
maintaining the upward trends observed from 2002 to 2006 should be a priority.  Another 
important study finding concerns the sizeable impact that including patient costs has on 
cost-effectiveness estimates conducted from the societal perspective.  This might be an 
important consideration when advocating for continuing the intervention or advocating 
for additional resources.  Finally, all other things being equal, the per-patient risk 
screening cost was also very close to the threshold over which TTT ceases to be cost-
effective from a health system perspective.  Allocating more resources to risk screening, 
unless it is accompanied with an increase in cases of LTBI identified, and treatment 
initiation and completion rates, is therefore difficult to justify.   
Results also have implications for the broader policy discussion.  Study findings 
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suggest that decision makers interested in implementing TTT in a given setting would 
need to carefully assess the characteristics of the TB epidemic in that setting to 
determine, in light of expected program performance, whether TTT should be preferred 
over PACF from a cost-effectiveness viewpoint.  The recommendation in the National 
Strategic Plan and in national TTT guidelines to tailor efforts to the local epidemiology is 
also validated, as are efforts to implement LTBI testing and treatment interventions in 
settings where LTBI is more prevalent, such as homeless shelters or prisons, if a 
sufficiently high level of treatment initiation and completion can be maintained.   
  
	  	   28	  
CHAPTER 2 
BACKGROUND 
 
TB Control Policy and Implementation: a Public Sector Responsibility 
Because tuberculosis is a communicable disease, tuberculosis control constitutes a 
public health intervention.  Public actions taken to contain tuberculosis fall into two 
broad categories: 1) medical services that must be provided to individual tuberculosis 
patients to diagnose and treat their disease, and 2) public health measures, such as 
isolation of infectious individuals and surveillance, that limit the spread of infection and 
monitor the disease burden.  The World Health Organization (WHO) recommends that 
countries establish a National TB Control Program within the national health system to 
coordinate the response to the TB epidemics, and political will and government 
responsibility are the first basic components of the “DOTS” (Directly-Observed 
Treatment, Short-course) strategy, the WHO’s framework for global TB control (WHO, 
2002).  The United States does not have a universal health system, which precludes 
establishing a strongly centralized, vertical, “top-down” TB control program.  However, 
over time the public sector has developed a structure for TB control policy making and 
implementation that assigns a role to local, state and national public health agencies, and 
allocates responsibilities among the three levels while respecting the tenets of federalism.  
 At the federal level, within the Department of Health and Human Services 
(DHHS), the Centers for Disease Control and Prevention (CDC) play a key leadership 
role in TB control, notably through the Division of TB Elimination (DTBE).  However, 
the states, rather than the national government, are constitutionally empowered to protect 
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the health and welfare of the population, so the CDC does not have regulatory authority 
over state and local TB control entities.  Instead it provides guidance by spearheading the 
development and periodic update of evidence-based policy frameworks (such as the Plan 
to Combat Extensively Drug-Resistant Tuberculosis) and technical guidelines on various 
aspects of TB control (e.g., preventing the transmission of tuberculosis in health care 
settings).  Some of these policy documents are developed internally (CDC, 2002), but 
most are produced in collaboration with partners within the federal government or among 
clinical experts, academic institutions and professional organizations (such as the 
American Thoracic Society) whose endorsement increases the scientific legitimacy of the 
guidelines and recommendations and the likelihood that they will be implemented in the 
field.  An important partner of CDC in TB policy making is the Advisory Council on the 
Elimination of Tuberculosis (ACET), which was created in 1997 by an act of Congress 
and is composed of clinical experts, academics, and representatives from state and local 
TB control programs appointed by the Secretary of DHHS to provide recommendations 
regarding TB elimination. 
CDC also plays a key role in orchestrating the response to the TB epidemics by 
distributing approximately US$ 100 million in annual federal appropriations for TB 
control to states under a cooperative agreement mechanism that takes into account local 
epidemiology while encouraging enforcement of national guidelines and standards.  
CDC’s DTBE also provides on-going technical support through its Field Services and 
Laboratory branches, and ad hoc technical assistance (e.g., during TB outbreak 
investigations) to state and local TB programs.  It engages in clinical, epidemiological 
and operations research as well as in demonstration projects to test the applicability of 
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new technologies or programmatic approaches.  It maintains the national TB registry and 
publishes detailed annual statistics and analyses on TB incidence and treatment 
outcomes.  Finally, it develops educational materials and conducts training to strengthen 
and standardize local TB control practices (Binkin, 1999), an essential contribution to 
ensure that expertise and know-how remain available at the local level even in areas 
where the incidence of TB has decreased to an extent that might discourage the 
commitment of local resources.  
State governments have become the central authorities in the nation’s public 
health system.  In each of the 50 states, the department of health includes a TB control 
unit.  Depending on the disease burden, this unit may be staffed by a few individuals with 
other responsibilities or by a larger team dedicated solely to TB, with an extensive roster 
of key responsibilities both in policy making and policy implementation.  As policy 
makers, the states have the latitude to tailor the broader framework of national guidelines 
to formulate specific state policies.  State TB programs also distribute federal and state 
funding to local health departments.  Additionally, they work directly with the state 
legislature and the state board of health to develop legislation and regulation supporting 
TB control activities.  The state TB control program also investigates outbreaks and takes 
action accordingly (including requesting CDC’s assistance).  It maintains the state-level 
TB registry and forwards all needed data to the CDC.  It is also state-level institutions 
that provide chronic care or detention facilities for TB patients.  TB drug procurement 
and distribution to local TB clinics are also a state responsibility (Binkin, 1999).  
At the local level, health agencies serving municipalities, counties and districts 
directly deliver public health services to the population.  In the case of tuberculosis, local 
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health departments are responsible for providing clinical services, and play little policy 
making role: public health clinics evaluate TB suspects, perform the necessary tests to 
diagnose tuberculosis disease and tuberculosis infection, provide treatment drugs and 
supervise treatment according to state protocols and guidelines.  They also interface with 
private providers, to ensure that TB suspects identified in the private sector are referred 
for evaluation, and that patients who choose to be followed up privately are treated 
according to national clinical guidelines.  In addition, local TB programs are responsible 
for carrying out public health actions aiming at containing further spread of the disease, 
such as conducting contact investigations, tracking patients to ensure treatment 
adherence, and even initiating legal action against non-compliant patients.  Importantly, 
since TB is a reportable disease, they also collect and report data to the state on TB 
incidence and treatment outcomes (Binkin, 1999).  
 
The Public Policy Goal: Tuberculosis Elimination 
With the exception of the years 1990 to 1992, the United States has met the 
WHO’s definition of a low-incidence country (<10 cases of active tuberculosis disease, 
or ATBD, per 100,000 population per year) since 1983.  In 1989, ACET issued its 
Strategic Plan for the Elimination of Tuberculosis in the United States, which proposed to 
accelerate the decrease in incidence to the point where tuberculosis would be eliminated 
as a public health problem by 2010.  That threshold has been defined internationally as an 
annual rate of incidence of less than 1 case per 1,000,000 pop. (WHO, 2008).  ACET’s 
strategic plan also included an intermediate target of 3.5 cases per 100,000 pop. by 2000.  
However, the failure to commit sufficient resources to TB control in the late 1980’s, poor 
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clinical management leading to the development of drug resistance, and the HIV 
epidemics spurred instead an upswing in TB incidence between 1983 and 1993.  Even 
though the number of cases identified each year and the annual case rate subsequently 
resumed their decline, the ACET plan’s goals were not met.  By 2000, the case rate was 
5.8 per 100,000.   That same year, an influential report by the Institute of Medicine set 
2035 as the new target date for TB elimination (IOM, 2000).  In responses to the report, 
CDC and other partners have laid out an updated strategy to reach this goal (CDC, 2002; 
Stop TB USA, 2010). 
 
Why Eliminate TB: the Health and Economic Cost of TB in the U.S. 
Achieving elimination is desirable because the health and economic impact of 
tuberculosis remains significant.  Nationwide, although the number of reported TB cases 
has decreased to record low levels, tuberculosis remains a cause of premature mortality, 
morbidity, and disability.  Even though tuberculosis is a curable disease, it resulted in 
death for 569 persons (7.6% of reported cases) in 2010, the latest year for which this 
information is available (CDC, 2013).  In cohorts of patients with multidrug-resistant 
(MDR) or extensively-resistant (XDR) forms of the disease, the mortality rate can be as 
high as 20 to 50%.  ATBD is most frequently a pulmonary disease, but it can also 
develop in and compromise other organs such as the spine, bones, lymph nodes, and the 
brain (in which case it can trigger meningitis).  Anti-tuberculosis treatment is lengthy and 
burdensome: at least 6 months of daily medication are required for drug-susceptible 
tuberculosis, up to 18 to 24 months in the case of MDR/XDR TB.  During the intensive 
phase (the first two months), the treatment must be observed, i.e., the patient must 
swallow his daily medication in the presence of another person, generally a health care 
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worker, which requires that either the patient visit the clinic daily or the health worker 
conduct home visits.  During the continuation phase, observation is not required, but 
monthly clinic visits are necessary to replenish the patient’s drug supply and monitor that 
the patient is continuing to take treatment and is not suffering from drug-induced side 
effects.  These side effects, although relatively infrequent, can be severe, resulting in 
additional morbidity and interruption of TB treatment (Yee et al., 2003).  Lastly, among 
TB survivors, over half are left with significant, life-long lung impairment which has 
been estimated to account for 70% of the health lost per TB case (Miller, 2009).   
Tuberculosis disease also has a significant economic impact on patients, their 
household, and society: it causes losses in productivity and results in high health care 
costs.  Patients can experience severe short-term disability, and must be isolated as long 
as they are infectious: patient and caregivers’ income suffer accordingly.  Moreover, 
diagnosis costs are high.  Active TB disease is typically diagnosed with sputum smears (a 
laboratory test in which a specimen of sputum is smeared on a slide, colored and fixed, 
then examined under a microscope to detect the presence of mycobacteria in the sputum), 
a sputum culture (to differentiate M. Tuberculosis from other mycobacteria), and a chest 
X-ray (to confirm visually the presence of disease in the lungs).  Drug susceptibility 
testing (DST) is conducted to detect resistance to antibiotics and genotyping (i.e., DNA 
analysis of the TB germ) is routinely used to uncover connections between cases and 
possible outbreaks.  At intervals, sputum smears and cultures are required again to 
document treatment success.  In addition, diagnostic costs are incurred not only for 
confirmed cases, but also for all people suspected of tuberculosis.  A study of the societal 
cost of tuberculosis in Tarrant County, Texas in 2002 found that while 108 TB cases were 
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confirmed in the county that year, another 111 TB suspects were evaluated but found not 
to have TB, at a cost to society of $325,000 or $2,900 per suspect (Miller et al., 2010). 
Although cost analyses of TB treatment available in the published literature report 
results that may be dated due to inflation and changes in medical technology since 
publication, they do provide insight into the disease’s economic impact.  Outpatient 
treatment alone costs upward of $4,000 per patient (Miller et al., 2009).  A study of TB 
hospitalizations has shown that about 50% of patients are hospitalized initially and/or 
during treatment for a median length-of-stay of 11 days per hospitalization episode and at 
a cost that varied between $6,400 and $13,000 per TB case in 1998 US dollars.  In the 
case of MDR-TB, much higher medical costs and productivity losses have been 
documented (Rajbhandary et al., 2004).  Hospitalization costs as high as US$500,000 
have been reported for patients with XDR TB who remain infectious (thus requiring 
isolation) longer.  Recent estimates of MDR TB drug costs vary between $25,000 and 
$500,000 depending on the regimen (Treatment Action Group, 2013). 
Finally, the cost of tuberculosis to society also includes the cost of maintaining 
the public health infrastructure needed to control the disease.  Most cost-of-disease 
studies include only medical costs and productivity losses.  But some analysts have 
pointed out that factoring in the cost of maintaining a disease control infrastructure, 
including TB control units at the national, state and local levels, would provide a more 
accurate estimate of the resources that could be saved was tuberculosis finally eliminated.  
No comprehensive analysis of the societal cost of TB in United States exists, but the 
Tarrant County study cited previously found that “when active, latent, and expected 
future TB cases are combined with associated surveillance and control activities, (…) 
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current and future spending totals [$41 million]” for that county alone, even though only 
108 cases were reported that year (Miller et al., 2010).   
The bulk of costs associated with tuberculosis control are absorbed by the public 
sector, in spite of efforts to engage other stakeholders, such as private health insurance 
plans and private providers, in the financing and provision of TB care (Miller et al., 1998; 
Halverson et al., 1997).  In the case of outpatient medical costs, this happens by default: 
because patients with tuberculosis often lack health insurance, and many private 
physicians lack clinical expertise in tuberculosis, a high proportion of TB patients receive 
TB clinical services at least partly from public health clinics.  In 2010, only 24.5% of 
cases were managed entirely by a private provider, while 69% were the sole 
responsibility of a public health department (CDC, 2012).  Some states have been able to 
shift a share of the financial burden of caring for TB patients to the state’s Medicaid 
program, by passing legislation granting Medicaid coverage to confirmed TB patients, 
regardless of income (Congressional Research Service, 2004).  However much of a relief 
this strategy may be for public health departments’ budgets, from taxpayers’ 
perspectives, it only shifts the burden from one public budget to another.  Inpatient care 
costs are also largely borne by the public purse, as Medicaid is by far the larger payer for 
TB hospitalizations.  A 1990 study in New York City estimated that 65% of hospital 
stays were covered by Medicaid (Arno et al., 1993).  Disease containment costs are also 
shouldered by the public sector because the public health system bears the legal 
responsibility of protecting the health of the public.  
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Targeted Testing and Treatment as a National TB Control Policy Tool 
Clearly articulated in the National Plan to Eliminate Tuberculosis, the national TB 
control strategy aims at TB elimination.  It rests on a three-pronged approach.  The first 
priority is the timely detection of cases of active tuberculosis disease (ATBD) and their 
appropriate treatment to ensure cure and prevent the development of antibiotic resistance.  
Second is to find and test individuals who have had contact with tuberculosis patients, to 
determine whether they might already be suffering from tuberculosis, or have been 
infected, and treat them accordingly.  This is achieved through contact investigations, 
which are conducted by public health departments whenever a case of ATBD is reported.  
These two pillars of TB control, in wealthy, industrialized countries as in resource-
constrained ones, allow TB programs to reap the “lowest-hanging fruit” among TB 
victims, whose identification and treatment will be highly cost-effective and possibly cost 
saving.  No comparison of treatment of active TB with a “do nothing” option is available 
in the literature, but many studies have established the cost-effectiveness of the WHO 
DOTS strategy, notably the use of a recommended drug cocktail and provision of 
treatment under observation, in low-income countries.  A study conducted in Canada has 
demonstrated the benefits of contact investigations: in Montreal, compared to passive 
case finding, “close-contact investigations resulted in net savings of $815 for each 
prevalent active case detected and treated and of $2,186 for each future active case 
prevented” (Dasgupta et al., 2000). 
The third component in the national strategy is to screen populations that are at 
risk of harboring tuberculosis infection to identify individuals with LTBI, and provide 
prophylactic treatment to prevent progression from latent to active disease.  In the 
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absence of such treatment, the risk of evolving from LTBI to ATBD in a healthy 
individual is approximately 10% over a lifetime.  The risk is greatest in the first few years 
after infection, then decreases gradually.  It increases again in older individuals, as the 
immune system weakens with age.  The risk is also heightened in individuals whose 
immune system is compromised by conditions such as cancer or HIV infection: the 
likelihood that an HIV+ person infected with LTBI will evolve to ATBD is estimated to 
be 10% every year.  Treatment for LTBI generally consists of a 6- to 9-month regimen of 
only one drug, isoniazid (INH).  The efficacy of INH to prevent reactivation of 
tuberculosis disease in infected individuals has been established in clinical trials 
conducted in many different populations and under a variety of conditions (Ferebee, 
1969; IUAT Committee on Prophylaxis, 1982).  LTBI treatment is self-administered, 
with monthly visits to monitor side effects and replenish the drug supply.  LTBI 
treatment ends when the patient has taken the required number of drug doses: unlike for 
ATBD, there is no laboratory confirmation of LTBI treatment success.  
An important pre-requisite to administering treatment for LTBI is the 
identification of individuals who have already been exposed to tuberculosis and carry the 
infection in its latent stage. The standard tool to diagnose LTBI is the Tuberculin Skin 
Test (TST), or Mantoux test: an injection of tuberculin solution under the skin of the arm.  
The injection spot is examined 48 to 72 hours later and the size of the induration (raised 
red area) is measured.  An induration larger than 10 mm is considered a positive response 
to the test in individuals with no risk factors (CDC, 2000).     
Recommendations on how public health authorities are to search for LTBI cases 
and treat them have evolved over time. When prevalence of infection and incidence of 
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disease was higher, a “scatter-shot” approach could be used, and widespread skin testing 
could be conducted without consideration of the actual risk of TB in the population being 
tested: for example, until the 1970’s, children would be screened periodically through the 
schools, and LTBI testing was a requirement for certification of school teachers (CDC, 
2000).  Indiscriminate mass screenings are no longer recommended, because they are 
inefficient in low-incidence settings as they are more likely to result in false-positive 
results (Starke, 1995).  Policy guidelines (CDC, 2000) now recommend a targeted 
approach, known as Targeted Testing and Treatment (TTT) for LTBI: only high-risk 
groups should be the focus of LTBI testing efforts; and which high-risk groups are 
targeted should be determined based on the characteristics of the local epidemic.  The 
concept of “high-risk” has three dimensions:  it refers to sub-groups that are 1) at higher 
risk of already being infected with TB (such as individuals from countries where TB is 
highly prevalent); 2) at higher risk of progressing from LTBI to ATBD (such as HIV+ 
individuals) and/or 3) at higher risk of experiencing poor outcomes if they develop 
ATBD.   
 
Epidemiology of TB in the U. S.: Who are the High-Risk Groups? 
The incidence of TB in the general population has steadily decreased since 19931, 
to an all-time low of 10,517 cases in 2011 (CDC, 2013).  The case rate (number of cases 
per 100,000 pop.) declined from 9.7 in 1993 to 3.4 in 2011.  The number of TB deaths 
also decreased substantially, from 1641 in 1993 to 569 in 2010 (CDC, 2013).  Thirty-two 
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states report fewer than 3.5 cases per 100,000 (the national intermediate goal for 2005).  
However, less encouraging trends are also discernible.  One current concern of policy 
makers is that the rate of decline in the number of cases has been slowing down (i.e., 
progress continues, but at a slower pace).  The average annual percentage decline in the 
TB case rate decreased from 7.3% per year during the 1993-2000 period to 3.9% between 
2000 and 2010 (CDC, 2012). 
Another concern is that TB is now a “focal disease” (Binkin, 1999), increasingly 
confined to a number of high-risk groups, notably non-Whites, people living or working 
in congregate settings (such as nursing homes, prisons and jails, migrant workers camps, 
homeless shelters) where transmission occurs more easily, and the foreign-born 
originating from countries were TB is endemic (Cain et al., 2008).  In 2009, for example, 
the national incidence rate of 3.8 cases per 100,000 hid some important disparities across 
subgroups (CDC, 2010).  While the case rate was 0.9/100,000 among Whites, it was 7 
and 7.6/100,000 among Hispanics and Blacks, respectively, and as high as 23.3/100,000 
among Asians.  Incidence varies across geographical areas as well:  in 2009, only 2 cases 
were identified in Wyoming, while 2470 cases were diagnosed in California.  Rates can 
be as low as 0.7/100,000 in Maine, or as high as 6.8/100,000 in the District of Columbia.  
Even within states, high and low-incidence areas coexist:  the 2009 case rate for the state 
of Mississippi was 4.1/100,000, but the Jackson, MS, metropolitan area reported 10.5 
cases per 100,000 inhabitants.   
The surveillance system collects only limited information on TB patients’ socio-
economic background and behavioral risk factors, but the few indicators available hint 
that TB cases are more likely to be found in at-risk or marginalized populations:  in 2009, 
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41% of TB patients nationwide indicated that they were unemployed at the time of their 
TB diagnosis; in Mississippi, 20% were homeless.  In Arizona and West Virginia, 17.1% 
and 16.7%, respectively, were residing in a correctional facility.  In 14 states, more than 
10% of TB cases reported non-injection drug use, and in 30 states, more than 10% 
admitted to excessive alcohol consumption. 
The proportion of cases that are foreign-born has steadily increased, and their 
actual number has slightly increased. Foreign-born persons have accounted for over 50% 
(63% in 2012) of TB cases every year since 2001 even though they represent just 10% of 
the general population (Census Bureau, 2002).  In 2012, the TB case rate among US-born 
was 1.4 per 100,000 and 15.9 per 100,000 for foreign-born persons.  In 31 states, more 
than 50% of cases were foreign-born, and the foreign-born represented more than 70% of 
cases in 8 states (CDC, 2013). 
The top five countries of origin of foreign-born persons with TB in the US are 
Mexico (25% of foreign-born cases), the Philippines (12%), India (7%), Vietnam (8%) 
and China (5%).  This ranking has been consistent since 2001.  While TB prevalence is 
relatively low in Mexico, migratory flows with the US are extensive, and 23% of all 
foreign-born individuals living in the US originate from Mexico.  India, China, the 
Philippines and Vietnam are also key sources of US immigration, and are on the World 
Health Organization’s list of the 22 “high-burden countries” that contribute 80% of the 
world TB burden annually.  Similar patterns (concentration of TB among high-risk 
groups, low incidence in the native-born population, increase in the number and 
proportion of cases among immigrant groups) are observed in Canada and Western 
Europe (Broekmans et al., 2002). 
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Targeted Testing and Treatment: Implementation Challenges 
Several of the high-risk groups that would benefit from treatment for LTBI are 
already adequately served by existing policies, guidelines, and programs.  The 
identification, evaluation (for both ATBD and LTBI) and treatment of contacts of ATBD 
cases is routinely carried out by public health departments as part of the “standard” 
protocol put in motion when an active case of TB is reported (Wilce et al., 2002; Wallace 
et al., 2003).  Similarly, specific TB testing policies and guidelines exist to address the 
needs of nursing homes and medical facilities, and licensing and accreditation 
requirements ensure that these policies and guidelines are by and large implemented.  
Patients who are at higher risk of developing ATBD due to another medical condition 
receive treatment within the framework of the management of that condition.  For 
example, the treatment protocol for ankylosing spondylitis includes the administration of 
a course of INH, because patients suffering from this condition are treated with 
infliximab, a tumor necrosis factor blocker that has been associated with reactivation of 
LTBI.   
The situation is less satisfactory when it comes to high-risk individuals who don’t 
reside, work or frequent these specific settings, such as the foreign born.  Screening for 
TB has traditionally been part of the immigration process, but attention has focused 
primarily on detecting infectious cases of ATBD.  Individuals applying for an 
immigration visa to the US are required to visit a “panel physician,” accredited by the US 
government, in their country of origin, to be screened for symptoms and receive a chest 
X-ray.  If the chest X-rays shows abnormalities, sputum smears and culture are 
performed.  Infectious immigration candidates are required to complete treatment before 
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being granted a visa.  If the laboratory examinations are negative, the person is then 
admitted into the US with the understanding that upon arrival, he/she will present to a 
public health department (which is notified of the arrival) for follow-up.  Individuals 
already in the US on temporary visas who apply for adjustment of status to be granted 
permanent residence must also visit an authorized U.S. physician and be screened.  
Similar procedures and requirements exist for refugees being resettled into the US 
(Barnett, 2004). 
Flaws and loopholes in the overseas screening process had long been documented 
(Binkin et al., 1996; Maloney et al., 2006), and new guidelines were issued in 2007 to 
increase the likelihood that cases of ATBD would not be missed during the overseas 
screening (addition of culture as a requirement, shortening of the window granted to 
applicants to enter the US once the visa is granted, requirement that TB treatment 
overseas be administered under DOT, etc.) (MMWR, 2008).  But even in their current 
incarnation, TB-screening procedures linked to the immigration process do not offer 
many opportunities to attack the pool of latent infection in the foreign-born.  The 
principal limitation is the fact that only legal immigrants applying for long-term residence 
are screened for TB through the immigration process.  Temporary visitors are not 
screened for TB or LTBI.  Neither are those who enter the country illegally, or overstay 
their visas.  The overwhelming majority of foreign-born arrivals are therefore left 
unscreened: in 2002, while 1.1 million people applied for permanent residency in the US, 
over 50 million foreign residents entered the country (Dasgupta et al., 2005).  Yet, the 
study assessing the burden of TB in Tarrant County, Texas, found that in 2000, 25% of 
foreign-born TB cases were undocumented immigrants, and another 17% were temporary 
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visitors to the US (Wets et al., 2001).  Screening temporary visitors at entry is neither a 
practical nor a desirable strategy however (Tan et al., 2001).  In addition, immigrants 
with LTBI who do not have an abnormal chest X-ray will not be identified during their 
visa application.  They may still develop ATBD long after immigration:  US 
epidemiologic surveillance data shows that, among the foreign-born population, TB case 
rates declined with increasing time since US entry, but remained higher than among US-
born persons, even more than 20 years after arrival (Cain et al., 2008).  Lastly, all 
foreign-born originating from countries with a high incidence of TB can become infected 
during return visits. 
Therefore, broader and more intense population-based measures have been called 
for to adequately tackle the task of shrinking the reservoir of potential TB cases in the 
US.  One option is to intensify the search for LTBI cases among high-risk groups that are 
not adequately served by policies and guidelines that focus on specific settings, ensure 
that they do not suffer from ATBD, and offer them treatment for LTBI.  The foreign-born 
from high TB incidence countries have been identified as an appropriate policy target, 
and the CDC has issued recommendations to that effect (CDC, 1992; CDC, 1998).  
Targeted testing guidelines were released by CDC as early as 2000 (CDC, 2000). 
However, the recommendation for local and state TB authorities to set up TTT 
programs remains largely unheeded.  “Expansion of the treatment of latent tuberculosis 
infection has not occurred and remains limited in public health departments where it is 
considered low priority when resources are scarce.”  (Stop TB USA, 2010).  While the 
efficacy of INH in preventing reactivation of TB has been demonstrated in clinical trials, 
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questions remain about the feasibility and value of its large-scale administration in “real-
world” programmatic conditions.   
First, as indicated earlier, not everyone with LTBI would ultimately develop TB.  
In an HIV-negative population, as many as 90% of infected individuals would live out 
their life without ever experiencing ATBD.  Only a minority of individuals, therefore, 
truly benefits from the intervention (and its associated use of resources).  Second, the 
Mantoux test commonly used to diagnose LTBI has limitations:  the lower the prevalence 
of LTBI in the population of concern, the greater the risk of a false-positive result which 
may trigger unnecessary treatment (Rose et al., 1995).  The test also fares particularly 
poorly among immuno-compromised (e.g. HIV+) persons, for whom it is more likely to 
result in a false-negative result, even though they are also those who stand to benefit the 
most from the protection that the treatment provides (ref.).  Furthermore, the test does not 
distinguish between different types of mycobacteria.  A positive skin test can be due to a 
cross-reaction from infection with non-tuberculous mycobacteria (NTM) such as 
Mycobacterium avium.  Studies have shown that as many as 50% of 10-14mm Mantoux 
test reactions in health care workers may be caused by NTM (Von Rey et al., 2001).  In 
addition, the test requires two visits within 72 hours to be administered and read: many 
patients do not return, which results in a waste of the health care resources.  Finally, 
determining whether the test’s result is negative or positive can be difficult, even for 
trained health care workers.   
Third, treatment for LTBI also has its limitations.  It is not harmless: there is a 
risk of (potentially fatal) hepatitis.  Neither is it 100% effective: clinical trials have 
demonstrated that the risk of evolving to ATBD in a compliant patient will be decreased 
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by 68 to 90%, depending on the length of the treatment regimen, but not completely 
eliminated.  In addition, LTBI treatment with INH is not effective in the case of people 
infected with an INH-resistant strain of TB (the most common form of anti-TB drug 
resistance, which affected approximately 9% of US cases in 2009 [CDC, 2010]).  Finally, 
obtaining patients’ compliance with a 6 to 9 months treatment regimen when they are not 
feeling sick has proved difficult in practice, even in the case of close contacts of ATBD 
cases.  A study of 11 urban health departments found that even among TST+ contacts of 
known ATBD cases, less than 50% completed LTBI treatment (Marks et al., 2000).  All 
these limitations and programmatic challenges can reduce the impact of a TTT policy on 
health outcomes.   
 
Tennessee’s Targeted Testing and Treatment Initiative 
To date, the Tennessee TB Control Program stands alone in the nation in having 
implemented a statewide Targeted Testing and LTBI Treatment program as part of its 
routine TB control activities.  The state of Tennessee, population 6.3 million (2010 
Census), reported 164 TB cases in 2012, down from 299 in 2005, for a case rate of 2.5 
per 100,000.  The proportion of foreign-born TB cases in Tennessee has increased 
dramatically over the past 20 years (Tennessee Department of Health, 2006), from 6% of 
all reported cases in 1996 to 21% in 2005 and 36% in 2010.   
This trend mirrors the diversification in the state’s population in recent years.  
While the 2000 Census found that 2.8% of Tennessee residents were foreign-born, the 
American Community Survey estimated that this percentage had increased to 4.5% in 
2012 (U.S. Census Bureau, 2012).  Between 1990 and 2005, the number of foreign-born 
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residents in Tennessee increased by 277%.  The greatest concentration of foreign-born 
individuals is found in the Nashville and Memphis metropolitan areas.  Forty-five percent 
of foreign-born Tennesseans originate from Latin America, and 29% from Asia (OREA, 
2007).  Tennessee hosts the largest Kurdish community in the United States (11,000 
persons), as well as a sizeable Hmong refugee population. 
Tennessee’s Targeted Testing and Treatment Initiative is a program funded by the 
state legislature, at a level of approximately $5 million per year.  In 2000, when CDC 
released targeted testing and treatment guidelines, Tennessee’s case rate had been above 
the U.S. rate for nearly two decades, and the percentage of foreign-born cases had 
doubled in only the past five years.  Started in 2002 to address this situation, the targeted 
testing and treatment program has been implemented by the Tennessee Health 
Department in 95 public health clinics throughout the state (Haley et al., 2008).  It 
operates as follows: all individuals presenting at public health clinics in the State for any 
reason are screened with a questionnaire called the Risk Assessment Tool (paper-based 
the first year, then electronic).  This tool (Appendix A) is simply a list of yes/no questions 
aimed at determining whether the individual is at increased risk of TB infection, active 
disease reactivation or poor TB treatment outcomes.  People at greater risk of exposure to 
TB include the foreign born from countries outside of Western Europe, Canada, 
Australia, New Zealand and Japan, homeless individuals, people with a history of 
incarceration, and contacts of TB patients. People at greater risk of evolving to ATBD 
and/or experiencing poor treatment outcomes include people who have substance abuse 
problems, HIV infection, diabetes mellitus, silicosis, cancer of the head or neck, leukemia 
	  	   47	  
or Hodgkin’s disease, severe kidney disease, low body weight, or certain medical 
treatments (such as steroid treatment or organ transplants). 
A positive answer to any one of the questions classifies the individual as high 
risk, in line with the American Thoracic Society and CDC guidelines.  High risk 
individuals are then counseled about TB and LTBI, and offered a test for LTBI.  If the 
test result is positive, they are further evaluated (to rule out ATBD in particular), and 
started on a course of treatment for LTBI.  The program’s original goals were to initiate 
75% of TST-positive patients on LTBI treatment, to ensure that 75% of them would 
complete treatment, and to limit the proportion of TSTs administered to low-risk 
individuals to less than 20%. 
As part of routine program activities, extensive information has been collected on 
risk prevalence, risk screening and skin testing yields, LTBI prevalence, and LTBI 
treatment initiation and completion rates, that can be used to evaluate the program along 
different lines.  An evaluation of the program’s feasibility and yield has found that from 
March 1, 2002 through December 31, 2006, 168,517 patients were screened for TB risk.  
Among them, 125,200 received a TST.  Seven percent of all persons who were tuberculin 
tested (including those whose test was not read) had a positive test result.  Overall, 14 
skin tests were placed to diagnose one person with LTBI, but the number needed to test 
(NNT) to find one case of LTBI varied greatly by risk group, from 4 among foreign-born 
persons, to 24 for high-risk, non-foreign persons, to 85 among low-risk persons.  Based 
on the age of the patients tested, the size of their TST reaction, and their lifetime risk of 
developing ATBD, the study estimated that 718 cases of ATBD would be expected to 
occur over the lifetime of the 9,090 persons with a positive TST. The study concluded 
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that, based on treatment efficacy, and observed initiation and completion rates, TTT 
could be credited for preventing 184 cases of ATBD in the screened cohort. The study 
also highlighted the benefits of targeting high-risk individuals: the number of TSTs 
placed to diagnose one person with LTBI was 4 among foreign-born persons and 85 
among low-risk persons.  The number needed to prevent one case of ATBD was 150 
among the foreign-born, and 9,834 among low-risk persons. 
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CHAPTER 3 
OVERVIEW OF ECONOMIC EVALUATION METHODS IN 
HEALTH AND REVIEW OF THE LITERATURE ON THE 
ECONOMIC VALUE OF TARGETED TESTING AND TREATMENT 
FOR LTBI 
 
Economic Evaluation Methods 
Theoretical Underpinnings and Rules of Good Practice 
The methods used in economic evaluation of health interventions find their 
theoretical roots in welfare economics, and key welfarist concepts such as the notion of 
opportunity cost, utility and willingness to pay are essential to understand both the 
purpose of economic evaluation and the methods used to measure cost and health impact.  
However not all economic evaluation methods used in the health field were developed by 
economists: some originated in the medical field itself, and (sometimes unsuccessful) 
efforts to ground them in the welfarist paradigm followed, rather than preceded, the 
spread of their use by practitioners.   
To promote methodological consistency and research quality and enhance the 
comparability of evaluation results, various agencies have supported the development and 
dissemination of recommendations and guidelines.  In the United States, the US Public 
Health Service established the Panel on Cost-Effectiveness in Health and Medicine, a 
“non federal, multidisciplinary groups with expertise in [cost-effectiveness analysis], 
clinical medicine, ethics, and health outcomes measurement” in 1993 (Gold, 1996).  In its 
1996 report, the Panel relied on economic theory for many of the recommendations, but 
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“the implications of welfare economics were often modified in the interest of producing 
recommendations that were both pragmatic and ethically acceptable (Weinstein, 1996).  
The Panel’s recommendations have since been refined, as additional research was 
conducted on tools and methods, and relayed by other institutions and individuals 
(Haddix et al., 2002; Weinstein et al., 2003; Drummond et al., 2005) but they remain a 
valid point of reference for investigating the cost-effectiveness of health interventions. 
 
Key Economics Concepts 
Scarcity and Opportunity Cost 
The fundamental economic problem is that, while human needs and wants are 
unlimited, resources are scarce and finite.  Budget constraints exist for governments as 
they do for individuals.  Consequently, allocating resources to a particular use renders 
them unavailable for other uses: for example, resources allocated to public health are not 
available for education; resources spent on TB control cannot be spent on childhood 
immunizations.  These forfeited benefits represent an “opportunity cost,” equivalent to 
the value that could have been derived from allocating the resources in question to 
another purpose. 
 
Utility Maximization and Willingness-To-Pay 
Economic theory posits that individuals act rationally to maximize the 
satisfaction, or utility, they derive from the goods and services (or anything they desire, 
such as improved health) they can obtain given their resource constraints.  They have 
clear preferences for various goods and services and can rank them accordingly.  
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Willingness-to-pay is the maximum amount a person would be willing to pay, sacrifice, 
or exchange in order to receive something they desire: therefore, individuals’ willingness-
to-pay for various goods and services reflects the utilities they would derive from their 
consumption/possession.   
The utility obtained from consuming an additional unit of a good or service 
(marginal utility) decreases as the total quantity consumed increases.  If each additional 
unit provides less satisfaction, the consumer will be willing to pay less to obtain it.  
Utility is maximized when the last dollar spent on each good or service in the consumer’s 
“basket” yields the same marginal utility.   
In economics, different authors have defined the concept of utility differently over 
time.  Economic evaluation relies on the Von Neumann-Morganstern definition of utility: 
it is a measure of preference that is made under conditions of uncertainty. 
 
Time Preference 
In addition to preferences for different goods and services, individuals and society 
have a positive rate of time preference: they have a preference for benefits now as 
opposed to benefits in the future and a preference to pay for things later as opposed to 
now.  In economic evaluation, time preference is taken into consideration through 
discounting.  It is particularly important when the costs and benefits of a program do not 
always occur at the same time.  For example, TTT intervention costs are incurred in the 
present, but the benefits from ATBD prevention will be reaped throughout the rest of 
patients lives.  Costs and health outcomes are discounted according to how far in the 
future they are expected to occur.  It is standard practice to discount costs and health 
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outcomes at the same rate, as is exploring the impact of different discount rates on results 
(Weinstein et al, 1996; Haddix).  Exploring the impact of different discount rates is also 
recommended, decision makers’ time preference may vary depending on the nature of the 
program or intervention.  In particular, it may differ depending on whether the 
intervention aims at cure or prevention, and whether the goal of prevention is the short-
term imperative of curbing an outbreak or the longer-term wish to eliminate/eradicate a 
disease.  In the case of a program aimed at disease elimination, as is targeted and 
treatment for LTBI, prevention of cases much further in the future may be valued as (or 
almost as) highly as short-term prevention.  A discount rate at or closer to 0% may 
therefore be most appropriate.   
 
The Purpose of Economic Evaluation 
Because of scarcity and opportunity costs, choices must be made regarding 
resource allocation, for which criteria and decision rules are needed.  A key criteria is that 
efficiency (i.e., the amount of benefits, or utility, derived from the use of a given amount 
of resources) be maximized, thereby minimizing opportunity costs.  Economic evaluation 
is “the comparative analysis of alternative courses of action in terms of both their costs 
and their consequences” (Drummond et al., 2004) and seeks to assess whether a policy, 
program or technology represents relative “value for money”.  The intervention of 
interest is compared to a baseline, which does not have to be an active strategy, and can 
be the status quo or “doing nothing”.  One of the goals of economic evaluation in health 
care is to assess systematically the relative efficiency of different health care 
interventions, policies or strategies to assist decision makers in deciding what course of 
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action to follow.  While economic evaluation could be envisioned as a normative tool for 
decision making, many practitioners present it as an aid to decision making, and 
recognize that other concerns, such as equity, and social and political factors, influence 
policy choices (Weinstein et al., 1996). 
 
Types of Economic Evaluation 
Different types of evaluation methods are available to assess the worth of health 
interventions.  All use similar methods to identify and measure costs, and differ primarily 
in the way they handle the measurement of health outcomes. 
 
Cost-Benefit Analysis 
Cost-benefit analysis (CBA) seeks to weigh all benefits and costs of an 
intervention to calculate its net present value (NPV).  In CBA, all outcomes (including 
such hard-to-value benefits as cases of disease averted, prolongation of human life, or 
changes in levels of pain and suffering) are included and are assigned a monetary value.  
The use of a common metric of dollars allows for comparison of strategies and 
interventions that have different outcomes or are related to different policy areas, such as 
education, health and safety.   
 
Cost-Effectiveness Analysis 
Cost-effectiveness analysis (CEA) is a form of economic evaluation in which a 
health intervention or policy is compared to one or more alternatives in terms of its costs 
and benefits, the latter being measured in terms of a common, natural units (such as the 
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number of TB cases, the number of healthy days, or the number of years of life that will 
result).  The Panel on Cost-Effectiveness in Health and Medicine recommended the use 
of CEA over CBA precisely  
“because of its focus on health, rather than economic outcomes of investments in 
different types of preventive, curative and rehabilitative interventions.  Although 
cost-benefit analysis is better suited to making intersectoral comparisons, (…) the 
panel was asked to direct its attention to CEA, given its broader acceptance 
medical and public health community” (Gold, 1996). 
 
.Cost-Utility Analysis 
Cost-utility analysis (CUA) uses similar methods as CEA, but includes a quality-
of-life adjustment in the measurement and valuation of health outcomes.  It is useful 
when both changes in mortality and morbidity must be taken into account; when 
improvements in quality of life, not just life expectancy, are relevant to the analysis; or 
when the interventions being compared have different outcomes that cannot be compared 
directly.  Disability-adjusted life years (DALYs) and quality-adjusted life years (QALYs) 
are commonly used metrics to summarize quantity and quality of life into a single value 
that can be compared across patient groups and disease conditions. 
 
Decision Analysis Modeling 
Decision analysis is “a systematic approach to decision making under 
uncertainty” (Treeage, 2008).  All three types of economic evaluation can incorporate the 
use of decision analysis methods to clarify the probabilities, costs and outcomes of the 
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interventions being compared.  Whether large-scale TTT for LTBI is a worthwhile 
strategy is a complex question that requires considering many parameters with uncertain 
value, and drawing on evidence from a range of sources.  Decision analysis help 
disaggregate complex problems into series of smaller elements whose dynamics can be 
more readily described and quantified.  The most essential elements can then be 
combined into a model of the original problem, using tools such as decision trees.  The 
model explicitly identifies the sequence of events and the linkages between these events.  
Models have limitations, of course, as they must strike a fine line between simplifying 
complex real-life situations to increase understanding while making sure to reflect 
essential processes, and are therefore most useful as “aids to decision making” rather than 
prescriptive tools:  
“the most important thing to keep in mind in evaluating a health care evaluation 
model is that its outputs must not be regarded as claims about the facts or as 
predictions about the future.  Rather, its purpose is to synthesize evidence and 
assumptions in a way that allows end users to gain insight into the implications of 
those inputs for valued consequences and costs.  Its outputs are always contingent 
on its inputs, which is why it is so important that its inputs be as transparent and 
accessible as is practical.” (Weinstein et al., 2003) 
 
Decision Trees 
Decision trees are a visual representation of a decision analysis model, and are 
widely used in economic evaluation.  Figure 1 provides an example of a simplified 
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decision tree comparing targeted testing and treatment for LTBI to passive ATBD case 
finding, for illustrations purposes.  
A decision tree proceeds from left to right, starting with a decision node (square) 
that reflects the choice alternatives addressed in the model.  The number of arms that 
originate from this initial decision node reflects the number of strategies (at least two) 
under investigation.  From that point on, each possible chain of events in each arm is 
represented with a different pathway through a series of chance nodes (circles) that 
reflect the points of uncertainty in the tree.  The branches issuing from each chance node 
represent the possible events patients can experience at that point in the tree (Drummond 
et al., 2005).  For example, patients who test positive for LTBI either start or don’t start 
treatment.  The pathways are mutually exclusive (a given patient can only follow one of 
the pathways) and exhaustive (a given patient must follow one of the pathways) 
(Drummond, 2005). 
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Figure	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  comparing	  targeted	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  and	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  for	  LTBI	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  ATBD	  case	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A decision tree intended for CBA, CEA or CUA also includes health and cost 
outcomes. An outcome is the expected value of a chain of events.  Health outcomes in a 
decision tree are defined differently depending on the type of economic evaluation 
method used.  For example, the model in Figure 1 is designed for CEA: the outcome of 
interest is the occurrence of ATBD cases.  Each pathway resulting in a case of ATBD 
was assigned an outcome value of 1, while pathways where ATBD can not occur have a 
value of 0.  If the model was intended for CBA, a monetary value, corresponding to the 
WTP for preventing a case of ATBD, would replace the “1”. 
Cost outcomes represent the costs incurred by the patient or group of patients 
following a particular pathway.  For example, in Figure 1’s PACF strategy, patients who 
are infected with LTBI and develop ATBD incur the cost of diagnosing and treating 
ATBD.  Patients who are not infected with LTBI incur no cost.  In the TTT arm, patients 
who are screened as being at high risk but test negative for LTBI incur the cost of 
screening and testing, but no ATBD cost. 
The decision tree uses concepts from statistics and basic probability theory to 
calculate the expected value of each course of action.  The likelihood of the events at 
each chance node is represented as a set of probabilities.  For example, in the risk 
screening arm, patients have a 50% chance of being at high risk.  These are conditional 
probabilities, as they depend on the patient having followed the specific path that led to a 
particular node. The model weighs outcome value of each pathway by its probability, 
then sums up expected values for each strategy under consideration.  Model results 
highlight the sequence of decision that will maximize value (measured in monetary terms 
	  	   59	  
or in terms of health effects), minimize costs and balance multiple attributes.  
Calculations for the decision tree illustrated in Figure 1 would be as follows: 
PACF: 
0.15 x 0.10 x 1   = 0.015 
0.15 x 0.90 x 0   = 0  Sum = 0.015 ATBD cases 
0.85 x 0    = 0   
 
TTT: 
0.50 x 0.20 x 0.80 x 0  = 0 
0.50 x 0.20 x 0.20 x 0.10 x 1 = 0.002 
0.50 x 0.20 x 0.20 x 0.90 x 0 = 0 
0.50 x 0.80 x 0   = 0  Sum = 0.007 ATBD cases 
0.50 x 0.05 x 0.10 x 1  = 0.005 
0.50 x 0.05 x 0.90 x 0  = 0 
0.50 x 0.95 x 0   = 0 
 
Markov Loops 
Decision trees have been widely used in economic evaluations for the past four 
decades, but they have limitations.   Notably, they do not explicitly take into account the 
timing of events (Drummond et al., 2005), which are “implicitly taken as occurring over 
an instantaneous discrete period” (Drummond et al., 2005).  However, both timing and 
duration of events can be important in the case of risks (such as the risk of evolving from 
LTBI to ATBD) that are ongoing over time, as the value of both health effects and costs 
will depend on when the event occurs due to the need for discounting (Sonnenberg and 
Beck, 1993). This limitation could be addressed in a decision tree by repeating the same 
chance node over and over again.  However, this approach would result in a very “bushy” 
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tree when following up a cohort over more than a few time periods (Sonnenberg and 
Beck, 1993).  
Alternatively, Markov loops can be used as part of larger decision trees to model 
what happens to individual patients or cohort of patients through time when duration or 
timing of events, such as when in the future a person with LTBI will develops ATBD, 
matters.  Markov loops are constituted of a finite number of mutually exclusive health 
states that are relevant to a particular disease or health issue.  For example, a Markov 
model tracking the prognosis of patients with LTBI could include LTBI, ATBD and 
death from other causes.   Markov models also include a matrix of probabilities that 
represent the likelihood that groups/individuals will transition from one state to another 
during a given time interval.   Transition probabilities between states can remain 
constant, or change over time.  For example, the risk of developing ATBD can be 
modeled to take on an increasing value, to reflect the fact that it increases as persons 
infected with LTBI age.   Health states out of which patients cannot transfer (e.g., death) 
are called absorbing states.  The length of time a Markov cycle represents (e.g., a month, 
or a year) depends on the disease and interventions being investigated (Drummond et al., 
2005) but also data availability (Sonnenberg and Beck, 1993).   
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Figure 2: Example of a time-dependent process best modeled through the use of a 
Markov model 
 
 
Measuring Costs  
The Importance of Perspective 
The perspective of the study is the viewpoint from which it is conducted.  
Possible perspectives include, for example, that of the health system, the agency 
implementing a policy or program, the study sponsor, patients and society.  The 
perspective determines what costs and effects are considered relevant and included in the 
scope of the study.  For example, patient costs will be included in a study conducted from 
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a societal perspective, but will be left out if the analysis is conducted from the viewpoint 
of the health system.  Guidelines recommend that analysts specify clearly which 
perspective(s) they are adopting, and that all studies include the societal perspective, at 
least in a sensitivity analysis, because it is the broadest and is always relevant 
(Drummond et al., 2005). 
 
What is Meant by “Cost” in Economic Evaluation 
Economic evaluation aims to assess the opportunity cost of implementing a 
project, program or policy.  It is the cost that arises from the consumption of resources 
that cease to be available for other uses.  When conducting a cost analysis, it is therefore 
important to think in terms of resources (including time) used, rather than expenditures or 
budgeted funds, especially when the study is conducted from a societal perspective.  For 
example, when evaluating a program that relies on the work of volunteer, the value of 
their donated time must be taken into account, to avoid underestimating the program’s 
cost. 
 
Steps in a Cost Analysis 
A cost analysis includes three simple steps: after determining the study question, 
the interventions to be compared and the study perspective, the analyst must 1) establish 
a cost inventory listing the resources used in the implementation of each intervention or 
alternative under consideration; 2) determine the quantity of resources used; and 3) assign 
a value/unit cost to each resource.  Combining these three elements of information will 
allow the total cost of an intervention to be calculated.  
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Determining what resources, and in what quantities, are consumed in the 
implementation of a project, program or policy, a detailed description of the intervention 
in question.  For example, one of the components of implementing a targeted testing and 
treatment strategy is to assess clinic patients’ LTBI risk.  The resources used include 
primarily staff time, and it is necessary to know what type of health staff carries out the 
ask: it could be a nurse, or a nurse and a translator, or intake worker.  As salaries, i.e. 
time costs, are different for these various professions, descriptive precision matters. 
 
Assigning a Dollar Value to Costs 
Assigning a cost to resources used for health interventions can be a thorny issue.  
In condition of perfect market competition, the market price of a resource can be used as 
an appropriate indication of the cost of a resource.  However, in the health sector, perfect 
market conditions are rarely met: oftentimes, for example, health insurance arrangements 
will alter the relationship between the true resource cost of a service and the price tag at 
which it is provided to patients.  In the case of tuberculosis, most care if provided free-of-
charge by public health providers, so alternative ways must be found to establish the cost 
of services. In all situations, it is important to distinguish between “cost” and “charges”, 
and methods are available (through the use of “cost-to-charge ratios”, for example, to 
derive the former from the latter).  Techniques used to estimate the resource cost of 
health care services include microcosting (i.e., determining what resources are necessary 
for the service to be performed—in terms of staff time, materials, etc.) and costing each 
component separately; or using the market price of a comparable good, service or 
resource. 
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Measuring the Utility of Health States: Quality Adjusted Life Years 
Why use QALYs? 
Welfare economic foundations of cost-effectiveness analysis require that outcome 
measures represent utility of consumers (beneficiaries of health programs or society in 
general).  In cost-benefit analysis, this is achieved by representing health outcomes in 
monetary terms that reflect beneficiaries or society’s willingness to pay.  The types of 
outcome measures used in cost-effectiveness analyses (such as the number of disease 
cases that arise, the number who test positive for a condition, or number of lives saved), 
however understandable to decision makers and sensitive to the effects of the intervention 
being assessed, have two key limitations: as intermediate outcomes, they are usually very 
specific to the intervention of interest, which precludes comparison of results across 
health conditions or health policy areas.  They do not fully capture the effects of the 
intervention in terms of quality (morbidity) of and length (mortality) of life.  In addition, 
they do not reflect patients’, consumers’ or society’s preferences and utility for different 
outcomes (Gaber, 2000; Drummond et al., 2005).   
To remedy these limitations, measures of final outcomes like Quality Adjusted 
Life Years (QALY) or variants like Healthy Life Years and Disability-Adjusted Life 
Years, have been developed for use in CUA.  These measures are generic, take into 
account both quality of life and survival, and incorporate the notion of value.   
To calculate the number of QALYs associated with a health state, it is necessary 
to know how long a person is expected to stay in that health state, and the weight 
associated with the state to account for quality of life.  QALYs can also be summed up 
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across health states to determine health outcomes associated with a condition, or a path in 
a decision tree. 
 
Methods to Elicit Utility Weights 
Three widely used techniques to measure preferences for health outcomes are 
rating scales, the time tradeoff (TTO) and the standard gamble (SG).  Other tools include 
disease-specific quality of life instruments and multi-attribute health status classification 
systems. 
Rating scales, such as the visual analog scale or the “feeling thermometer”, ask 
respondents to rank outcomes or health states of interest from most to least preferred and 
placing them on a scale so that “the distances between the locations are proportional to 
the subject’s preference differences” (Drummond et al., 2005).  Some instruments vary 
from 1 to 10, others from 1 to 100; some include tick marks for intervals, other don’t.  
They also vary in the way they anchor the states of full health and death. 
The TTO method was developed specifically to measure health utilities.  Subjects 
are asked to choose between 2 alternatives: a period of time in the health state of interest 
versus a shorter period of time in full health.  The time in the health state of interest is 
varied until the respondents declare being indifferent between the 2 alternatives. 
The standard gamble is based directly on the Von Neumann-Morganstern utility 
theory.  Respondents are asked to choose between 2 alternatives, a given period of time 
in health state of interest and an alternative with 2 possible outcomes (the gamble): 
perfect health for the same period of time followed by death, or immediate death. 
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Rating scales are relatively easy to comprehend for respondents and “give the 
investigator a firm indication of the ordinal rankings of the health outcomes and some 
information on the strength of these preferences” (Drummond et al., 2005).  However, 
they have been found to be subject to measurement biases (such as “end of scale bias”) 
and not to consistently measure preferences on an interval scale.  As TTO and SG 
instruments are more cognitively demanding of respondents, methods have been devised 
to convert rating scale scores to TTO or SG scores (Torrance, 1982).   
To facilitate measurement of preferences, a number of pre-scored multi-attribute 
health status classification systems have also been developed to facilitate the 
measurement of preferences.  Examples include the Quality of Well-Being Health Utility 
Index (HUI), EQ-5D from the EuroQol Group and Short-Form 6D (SF-6D).  Each of 
these instruments ask respondents to rate their own health on a number of scales (for 
example, mobility, physical activity, social activity and symptom-problem-complex in 
the case of HUI).  Utility weights for each scale/level combination were previously 
measured on a random sample from the general population using a TTO or SG approach.  
Once respondents have measured their health on the various scales of the multi-attribute 
instrument, it is relatively easy to assign the corresponding utility weights and aggregate 
them to obtain the total utility score for the health state. 
 
Measuring and Interpreting Cost-Effectiveness Measures 
The Cost-Effectiveness Plane 
The cost-effectiveness plane (Figure 1) is a two-dimensional visual representation 
of the four types of situations that arise when two interventions are being compared for 
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cost and effectiveness (Black, 1990), with the baseline for comparison occupying the 
origin of the graph.  It is a four-quadrant graph, in which the X-axis represents the 
difference in costs between the two interventions, and the Y-axis represents their 
difference in benefits.   
When interventions fall in the South-East (SE) or North-West (NW) quadrant of 
the cost-effectiveness plane, the decision rule is clear: if the intervention of interest is 
both more effective and less costly than its comparator(s) (SE quadrant), it is said to be a 
dominant strategy, and preferred for implementation.  If it is less effective and more 
costly (NW quadrant), it should be discarded for being a dominated strategy, as it 
provides no value. Interventions that fall in the South-West (SW) quadrant are less 
effective, but they are also less costly, and may therefore be of interest to decision makers 
in certain contexts.
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However, in many cases, the strategy of interest will be simultaneously more 
costly and more effective: these are the interventions that fall in the North-East (NE) 
quadrant, and are of most interest in cost-effectiveness analysis.  
 
The Incremental Cost-Effectiveness Ratio 
The incremental cost-effectiveness (ICER) ratio is another tool to further relate 
the difference in health outcomes to the difference in costs and evaluate the incremental 
cost-effectiveness or cost-utility of an intervention.  The ratio includes incremental costs 
in the numerator, and incremental effects in the denominator. For interventions that fall in 
the NE quadrant (more costly, more effective) of the cost-effectiveness plane, 
interpretation of the ICER is straightforward: it represents the cost per additional unit of 
health (TB case prevented, or QALY saved) obtained thanks to the intervention of 
interest.  The ICER is a positive number, and the lower the number, the more cost-
effective the intervention is.   
Guidelines warn against using the average cost-effectiveness ratio (i.e., an 
intervention total costs divided by its total effects) to measure cost-effectiveness (Gold et 
al., 1996).   Such an approach may be convenient, as it does not require a comparison 
treatment but is misleading because it implies comparing the intervention of interest to 
“an alternative that is costless and results in immediate death” and “does not reliably 
indicate the way to achieve the greatest health benefit from a given expenditure (Garber, 
2000).  The use of average cost-effectiveness ratios has been shown to lead to lead to 
inappropriate rankings of program alternatives (Karlsson and Johannesson, 1996).  
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Economic evaluations can compare more than two policies, programs or 
interventions.  One of these could be the standard of care or a “do nothing” strategy.  In 
such a situation, it is not appropriate to compare every strategy to one baseline.  Nor is it 
necessary to calculate a separate ICER for every possible pair of interventions (Garber, 
2000).  The recommended approach is to rank all interventions in order of increasing 
health effect.  Then interventions that are strictly dominated (i.e., those that are more 
expensive and less effective than at least one alternative) should be eliminated.  ICERs 
can then be calculated between each intervention and the next more expensive strategy.  
The final step in the ranking involves eliminating from consideration those strategies in a 
situation of extended dominance, i.e., those for who the ICER is higher than that of the 
next, more expensive, alternative.   
  
Cost-Effectiveness Thresholds 
In cost-benefit analysis, the decision rule is simple: a positive NPV indicates that 
the intervention generates societal benefits that are superior to its costs, and is therefore 
worth implementing.  When multiple alternatives are compared, the program or policy 
with the highest net social benefit is the best policy choice.  Hard decision has been made 
upstream, when deciding on what value to assign to health outcomes, including life 
saved, to reflect willingness to pay.  In CEA and CUA some argue that there is no 
threshold above or below which a CE ratio is considered “cost-effective”: “the decision 
maker is left to make a value judgment about the intrinsic value of the health outcomes” 
(Haddix et al., 1996).  The 1996 report of the Panel on Cost-Effectiveness in Health and 
Medicine avoided recommending a particular cost-effectiveness threshold (Weinstein, 
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1996). The possibility that a unique, broadly applicable, threshold may not be appropriate 
for all individuals in society, or for all decision making contexts, has also been 
emphasized  (Ubel et al. 2003).   
However, the very language used to describe an intervention as cost-effective or 
not begs for the existence of a benchmark, and the idea of a precise threshold to facilitate 
decision-making has great intuitive appeal (Ubel et al., 2003).  Weber (2010) credits 
Weinstein and Zeckhauser with introducing the concept of a threshold, i.e., the “degree of 
cost–effectiveness an intervention has to show in order to be accepted in a given 
healthcare system” (Weber, 2010).  Different thresholds have been described in the 
literature, but the most prominently mentioned is the threshold level of US$50,000 per 
QALY.  The justification originally commonly given for adopting this threshold is that it 
represented the ICER per QALY gained for the use of dialysis for patients with chronic 
renal failure.  This procedure was covered for reimbursement under Medicare so the 
reasoning went that, “if the US government thinks that dialysis should be offered to all 
who need it, then interventions with similar or better cost-effectiveness should likewise 
be offered to everyone.”  (Ubel et al., 2003; Weber, 2010).  Although this threshold has 
been widely cited in the literature, its flaws have also been underlined.  A key problem is 
that it has been used for more than three decades without adjustment to reflect changes in 
health care technology and inflation (Ubel, 2003).  It has also been argued that it does not 
reflect societal willingness-to-pay (Hirth et al., 2000) 
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Sensitivity Analysis 
The Role of Sensitivity Analysis in Economic Evaluation 
Economic evaluation guidelines strongly recommend that sensitivity analyses be 
conducted (Weinstein et al., 1996; Garber, 2000; Weinstein et al., 2003).  The need for 
sensitivity analyses arises because of the various types of uncertainty, random and non-
random, inherent in any model.  Models usually incorporate data from multiple sources 
that were collected in different circumstances and under different assumptions.  Even 
when the data comes primarily a one trial, observational study or project, sampling 
variability makes estimates of event/transition probabilities, costs and effects uncertain.  
There may also be uncertainty about the structure of the model, and the generalizability 
of the parameters from one setting to another (Garber, 2000). 
Sensitivity analysis helps determine whether a model is sensitive to a particular 
uncertainty (i.e., whether varying a parameter’s value results in a change in the relative 
efficiency of the interventions; and if a model is sensitive to a particular uncertainty, at 
what value of the parameter the model recommends a change in strategy.  By assessing 
the impact that uncertainty about the model and its parameters has on analysis results, 
sensitivity analysis helps ascertain whether these results are robust.   
Part of the uncertainty is accounted for in the structure of the model itself : each 
chance node represents a range of possible but mutually exclusive events over whose 
occurrence the decision maker has no influence.  Other methods to deal with uncertainties 
that cannot be incorporated into the tree structure are deterministic sensitivity analyses 
and probabilistic sensitivity analysis (PSA). 
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Deterministic Sensitivity Analysis 
Deterministic sensitivity analysis is conducted by varying one (one-way 
sensitivity analysis) or more parameter at a time.  This type of analysis is deterministic 
because there is no randomness in the expected value calculation, as each parameter is 
handled as a point estimate.  Every path through the model has a deterministic weight in 
the expected value calculation based on its path probability.  Results do not change when 
the analysis is repeated using the same parameters.  Threshold analysis is a form of one-
way sensitivity analysis.  It seeks to identify more precisely the parameter value at which 
the conclusion about which strategy is optimal changes by varying the value of the 
parameter of interest in very small increments. 
Deterministic sensitivity analysis is informative when there is a need to isolate the 
contribution of one or two parameters to overall variation in model results.  However, it 
quickly reaches the limits when multiple parameters need to be varied simultaneously, 
especially when the results of the sensitivity analysis need to be displayed graphically. 
 
Probabilistic Sensitivity Analysis 
In many situations, it is useful to introduce random, or stochastic, elements into 
some parts of the analysis. Second-order Monte Carlo simulation is a technique that 
incorporates uncertainty in all model parameters.  It provides the same information as 
deterministic sensitivity analysis, but it can also be used to quantify the level of 
confidence that can be placed in the models’ results.   
In probabilistic sensitivity analysis, some or all of the cost and effect parameters 
in the model are represented by distributions instead of being represented as point 
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estimates.  During the Monte Carlo simulation, the model is run repeatedly (10,000 times, 
for example) using sampled values for each parameter, and expected values for cost and 
health effect are recalculated. 
 
Economic Evaluation of Diagnosing and Treating LTBI 
Review of the Literature 
Decision analysis and economic evaluation methods have been applied to testing 
and treatment for LTBI since the 1980s.  Early work focused primarily on determining 
which skin test reactors should be given INH therapy.  Clinical studies had shown that, 
on the one hand, the risk of TB reactivation varied with age and with the presence of risk 
factors (such as a healed lesions in the chest demonstrating a history of healed TB) and, 
on the other hand, that the risk of developing fatal INH-related hepatitis was increased in 
persons age 35 and older.  Decision analysis and economic evaluation provided useful 
methods to weigh the risk of reactivation against the risk of fatal adverse events in 
various populations to identify which age and risk groups should be targeted for 
intervention.   
A series of studies that assessed whether and to what extent INH prophylaxis was 
beneficial for individuals with latent TB infection, sought to challenge the American 
Thoracic Society’s recommendation (at the time) to administer INH chemoprophylaxis to 
all TST reactors, and to show that in patients under age 35 with normal chest X-rays (i.e. 
no evidence of lesions attributable to TB) and no predisposing conditions to tuberculosis 
reactivation, the risk of adverse events, notably fatal hepatitis, outweighed the benefits of 
tuberculosis prophylaxis in terms of life expectancy (Tsevat, 1988; Taylor, 1981; Rose, 
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1986).  In 1988, Rose et al. compared the cost-effectiveness of INH prophylaxis 
(compared to “doing nothing”) in cohorts at high and low risk for disease activation over 
the remainder of the cohorts’ lifetime. Low-risk individuals were a hypothetical cohort of 
55-year old white men with no risk factor other than a positive TST.  The high-risk 
cohort included 20-year old white men with a documented experience of TST conversion 
in the past 2 years (indicating recent infection).  Model outcomes included life 
expectancy and fatalities from TB and/or hepatitis.  The analysis found that providing 
prophylaxis to the high-risk cohort was a cost-saving intervention ($429 per person 
treated, in US$ 1985), while in the low-risk cohort it would cost an additional $126 per 
person (compared to doing nothing).  The cost-effectiveness of providing prophylaxis to 
low-risk individuals, in addition to high-risk ones, would cost between $11,600 and 
$17,000 per year of life gained, and between $32,000 and $48,000 per death averted, 
depending on whether medical costs associated with longer survival and the prevention of 
secondary cases were included or not.  
Conclusions favoring INH prophylaxis, in turn, were challenged when additional 
work focused on the range of variation around estimates of the lethality of both TB and 
hepatitis questioned the parameters used in the original analyses (Colice, 1990).  Jordan 
et al. sought to further refine the analysis by taking gender and ethnicity into account, in 
addition to age (Jordan et al., 1991).  Using age-, gender- and race-specific estimates of 
the risk of developing ATBD, dying from TB and developing INH-related hepatitis, they 
concluded that, for low-risk reactors, INH preventive therapy should be the preferred 
strategy for all 20-yr olds, all 35-yr olds except black women, but should not be 
administered in 50-yr olds of either sex, whether White or Black.  Among high-risk 
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reactors, INH was beneficial to all except 50-year old black women.  Among all sub-
groups, the benefits to be derived from prophylaxis in terms of extended life expectancy 
ranged from 3-19 days per patient treated among low-risk reactors and 1-44 days among 
high-risk reactors.  When measured in terms of deaths prevented (either from TB or from 
hepatitis), INH prophylaxis was shown to be beneficial to all groups, except, once again, 
for 50-yr old black women.  The authors could provide no theoretical rationale for this 
finding, and concluded that it could only lead one to “question the soundness of the data 
on which it rests.” 
A subset of studies has focused on the economic relevance of school-based 
screening for TB infection.  School-based mass screenings had been discouraged by the 
Public Health Service since the 1970’s, but in the context of the resurgence of TB in the 
1990’s, local TB programs in areas with large numbers of immigrants and refugees have 
reintroduced compulsory or voluntary screenings.  Results are mixed.  Some have 
reported a substantial net benefit (Mohle-Boetani et al., 1995; Chang et al., 2002; 
Brassard et al., 2005).  One study only reported program costs, but concluded that these 
costs were not significantly lower than ATBD costs (Doering et al., 1999).  One study of 
a screening program for high-risk students in Toronto schools found that program costs 
significantly outweighed potential cost savings (Yan et al., 1995). 
Over time, new concerns have emerged regarding the value of preventive therapy, 
notably as TB programs have documented low completion rates among patients treated 
for LTBI.  Studies were conducted to evaluate the relative cost and benefits of different 
durations of therapy and drug regimens, to assess whether shorter treatment with different 
drug combinations (rather than INH alone) might be more cost-effective, with the 
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assumption that shorter regimens would result in greater patient compliance.  One study 
compared the standard INH for 6+ months and a Rifampin/Pyrazinamide (RIF/PZA) 
regimen for 2 months to a “no treatment” baseline in a cohort of HIV-negative 
individuals based on treatment completion and ATBD-prevention data collected during a 
clinical trial comparing these two regimens.  The shorter regimen was more cost-
effective, even though drug costs were much higher, due to lower follow-up costs 
(shorter regimen = fewer visits = lower staff costs) and improved treatment adherence.  
However, reports of fatal toxicity led the CDC to issue recommendations AGAINST the 
use of the RIF/PZA regimen. 
Some studies have also focused on specific high-risk populations for whom the 
issue of compliance was particularly acute, such as the homeless, illicit/injection drug 
users and jail or prison inmates.  Surprisingly, continuing or restarting INH prophylaxis 
in patients released from short-term correctional facilities in Hartford, Connecticut was 
found to result in cost savings over 4 years, in spite of very poor adherence (only 21% of 
patients completed therapy), perhaps in part because the efficacy of the treatment (85% 
for 6 months of INH) was assumed to be high, and the savings resulting from ATBD 
cases averted in the future (including those resulting from averted transmission) were not 
discounted (Bandyopadhyay et al., 2002). 
A stream of studies has focused on the costs and benefits to be derived from 
providing LTBI treatment to HIV-infected individuals in developed and developing 
countries.  The first such analysis (Rose, 1998) assessed the cost-effectiveness of LTBI 
treatment in a hypothetical cohort of HIV-infected individuals with a CD4 count <201 
cells/mm3 and a positive TST.  The baseline scenario was no prophylaxis provided.  
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Comparison scenarios included 12 months of INH (which was then the recommended 
regimen for HIV+ individuals) as well as 6 short-course (2 to 6 months) prophylaxis 
regimens of various drugs, durations and dosage.  All probabilities were derived from 
clinical trials.  Outcome measures included expected 5-year survival rate, lifetime 
incidence of TB, life expectancy and the cost per QALY gained.  Eighty percent of 
patients were assumed to adhere to the prescribe regimen.  The study found that 
compared to no prophylaxis, all LTBI treatment options except one (a 3-month triple-
drug regimen with relatively high side-effects and low effectiveness) were cost-saving.  
These results held when individual assumptions about effectiveness and toxicity were 
varied in one-way sensitivity analyses.  However, when all assumptions were varied in a 
worst-case scenario (based on the most pessimistic data from clinical trials), no 
prophylaxis regimen was cost-effective. 
Finally, the most recent study published on targeted testing and treatment for 
LTBI focused on the use of the Quantiferon-TB Gold test (an alternative to the Mantoux 
skin test that does not require a return visit for results) to identify individuals with LTBI 
in a community with a high prevalence of commercial sex, homelessness and drug use in 
Tijuana, Mexico (Burgos et al., 2009).  To increase adherence to LTBI treatment, INH 
was administered under observation and a US$40 incentive was provided to participants 
every month.  Compared to no screening and treatment, the incremental cost-
effectiveness ratio was US$730 for detecting a case of LTBI, US$529 for preventing a 
case of TB, US$737 for preventing a death from TB, and US$108 for each QALY 
gained.  This study assumed a high LTBI treatment compliance rate (80%), and a fatality 
rate for ATBD of at least 16.5%, much higher than the fatality rate observed in the US.  
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In addition, the loss to patient follow up during the screening process (patients not 
returning to collect their test result, not returning to initiate LTBI treatment, etc.) was not 
taken into account, thus raising the suspicion that the model was biased in favor of LTBI 
screening and treatment. 
Decision analysis and economic evaluations focusing on the foreign-born have 
primarily assessed the value of interventions related to the immigration process.  One 
study has confirmed that excluding active TB cases from entering the US until they are 
no longer infectious is indeed a cost saving intervention (Qualls, 1998).  Work conducted 
in Canada has shown that in that country, adding tuberculin skin testing for LTBI to the 
current policy of screening legal immigrants for ATBD with a chest X-ray upon arrival 
would be a costly strategy relative to the benefits it would provide in terms of TB 
prevention.  In California, appropriate follow-up of B-category immigrants2 after arrival 
in the US was shown to be highly cost-effective, and at times cost-saving, from a public 
payer perspective, but unlikely to result in a large change in case rates, as it would reduce 
the number of TB cases by about 6 to 26 cases per year (out of a total of approximately 
3000) (Catlos et al., 1998).  
Following a different line of inquiry, Schwartzmann and colleagues (2005) 
demonstrated that, over a 20-year period, it would be more cost-effective for the U.S. to 
improve the operations of the Mexican National TB Control Program than to try and 
screen migrants from Mexico for LTBI: investing U.S.$35 million to expand the WHO 
DOTS Program in Mexico to 100% coverage would prevent 2591 cases of TB and 349 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
2	  i.e., immigrants with a chest X-ray indicating infection or old, healed TB, but whose 
laboratory results during overseas screening were negative	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TB deaths in the US.  Among the averted cases, 88% would have occurred among 
undocumented migrants and visitors who are ignored by current policies.  Tuberculin 
skin testing of legal Mexican immigrants and refugees to the U.S. only (as current rules 
require), on the other hand, would result in 401 fewer cases of TB for a cost of $260 
million (or approximately $650,000 per case averted), and would have no impact on 
undocumented aliens and temporary visitors.  These findings were robust in sensitivity 
analyses (Schwartzman et al., 2005).  
 
Limitations of Existing Literature 
Economic analyses available in the literature report widely different estimates of 
the economic value of combating TB by targeting individuals with LTBI, and are 
somewhat conflicted in their conclusions regarding the value of preventive TB control 
strategies.  Several limitations are noted in the published literature that may lead to 
overestimating the efficiency of TTT: in several studies, the probabilities used in the 
model to represent treatment completion (a key determinant of effectiveness) were 
derived from clinical trials, or from small observational studies.  Compliance with 
treatment observed within the framework of a trial or during short-term pilot studies is 
likely to differ from that obtained in routine programmatic conditions, as closer follow-up 
of participants may be provided.   
In addition, as noted earlier, the studies that have been published tend to focus 
either on testing or on treatment for LTBI.  Studies that have aimed at evaluating the 
effectiveness or economic value of treatment for LTBI without exception take as their 
starting point a cohort of patients who have already been diagnosed with LTBI.  At best, 
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they include the cost of administering the Mantoux test to these patients.  Invariably, they 
leave out the costs and other parameters associated with testing a much larger cohort of 
individuals, the majority of which will return a negative result, in order to identify those 
who have LTBI.  Screening for risk, diagnosing LTBI and administering INH 
prophylaxis are inseparable components of TTT.  Although separate evaluations could be 
conducted in order to increase the effectiveness or the value of individual steps in the 
overall process, assessing the worth of TTT against that of other TB control strategies 
such as passive ATBD case finding requires a comprehensive mapping of patients’ path 
through the entire process.   
Another limitation of the literature is the failure to take into consideration the 
prevalence of INH resistance in the target population, which may limit the effectiveness 
of preventive therapy (Khan et al., 2002).  Assuming that all cases of infection are 
sensitive to INH may be a defensible option in studies to assert efficacy, but this 
assumption needs to be examined when evaluating the worth of TTT at a population 
level.  Surveillance data shows that, among foreign-born individuals, the prevalence of 
LTBI varies depending on country of origin.  So does the prevalence of resistance to 
INH.   These limitations are all likely to overstate the case for TTT.  However, it must 
also be noted that the published literature may also have underestimated the cost 
associated with ATBD, and the benefits to be derived from its prevention.  Most studies 
only include the direct medical costs of treating the disease, even when the stated study 
perspective is that of society.  Economic losses associated with morbidity and premature 
mortality are rarely included, and losses in quality-of-life in survivors have only recently 
begun to be described, measured and incorporated into QALY weight calculations (Miller 
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et al., 2009).  A societal perspective that takes these disease costs into account should be 
beneficial to decision makers (such as legislatures) deciding on resource allocation to 
broad policy areas, even if results obtained from a health sector perspective remain useful 
to TB program managers.  
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CHAPTER 4 
RESEARCH DESIGN, METHODS AND DATA SOURCES 
 
Research/Evaluation Questions 
This research evaluates the cost-effectiveness of TTT in programmatic conditions 
modeled after the experience of the Tennessee TTT program.  The central question it 
addresses is whether conducting TTT among high-risk populations, notably the foreign-
born, is a cost-effective intervention compared to passive ATBD case finding (PACF).  
Through deterministic and probabilistic sensitivity analyses it also examines the extent to 
which variation and uncertainty in key model parameters would affect cost-effectiveness. 
 
Structure of the Decision Tree 
The decision tree compares two alternative strategies, Targeted Testing and 
Treatment  for LTBI and Passive ATBD Case Finding, in terms of costs and health 
outcomes.  For a summary of all modeling assumptions, refer to Appendix B.  The root of 
the decision tree is the same for both strategies, and describes the epidemiology of 
TB/LTBI among individuals that frequent public health clinics in Tennessee (Figure 5).  
A small fraction of them have had ATBD in the past.  These patients are assumed not to 
be at risk of developing ATBD again from the infection that caused the past TB episode, 
and therefore will not incur any TB-related costs or health loss.  Among the remaining 
patients, some are unknowingly infected with LTBI and are at risk of developing ATBD 
in the future, and some are free of LTBI.  The latter have no risk of ever developing 
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ATBD given that they never were infected, and like patients treated for ATBD in the 
past, will not incur any ATBD related cost or loss of health.   
 
Figure 5: Decision tree root for comparison of PACF and TTT 
 
 
The Baseline Strategy: Passive ATBD Case Finding 
The baseline strategy models a situation in which Passive ATBD Case Finding is 
the norm (Figure 6), and ATBD cases are diagnosed as they develop over time.  To 
model the fate of patients infected with LTBI, the decision tree branches out according to 
two important parameters: anti-TB drug resistance and HIV status. Most infected patients 
carry a strain of TB susceptible to INH, the drug most frequently used to treat LTBI.  
Among patients with INH drug resistance, some are assumed to carry a TB strain 
resistant only to INH, but sensitive to enough first-line drugs that the standard first-line 
treatment regimen for ATBD could be used successfully, were they to evolve to active 
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disease; the rest are infected with a multidrug-resistant (resistant to INH and rifampin) 
form of TB.  The distinction between drug resistance patterns in the tree structure is 
important: it identifies clearly the sub-group of patients most likely to benefit from LTBI 
treatment (INH-susceptible patients); and it makes it possible to model the impact of drug 
resistance (notably multidrug resistance) on the cost of ATBD treatment and on survival.  
Regardless of resistance patterns, a proportion of patients are co-infected with HIV, 
which increases both their risk of developing ATBD and dying from it. 
 
Figure 6: Baseline strategy: passive ATBD case finding (PACF) 
 
In the absence of a targeted LTBI screening and treatment program, individuals 
infected with LTBI (whether drug resistant or drug sensitive, HIV-positive or HIV-
negative) immediately enter the Markov loop (Figure 7) that represents the path they will 
follow over the remainder of their lifetime as a series of one-year cycles.  Every year, 
infected individuals face three possible but mutually exclusive pathways: 1) they can 
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develop ATBD; 2) they can die from causes unrelated to TB, or 3) they can remain in a 
state of LTBI.   
 
 
Figure 7: Markov loop 
 
If they develop ATBD, it is assumed that they are diagnosed and treated 
appropriately. Patients afflicted with drug sensitive TB, which can be treated within a 
year, remain in the ATBD state for one cycle.  As treatment for MDR-TB can last for 18 
to 24 months, patients with MDR-TB remain in the ATBD state for 2 cycles.  Once 
patients have developed drug-sensitive or multidrug-resistant ATBD, they can either die 
from TB, or survive.   
Patients who develop ATBD (whether they die or survive) and patients who die 
from causes other than TB during a given cycle exit the study cohort for good at the end 
of that cycle.  In the case of patients who die (either from TB or from other causes), it is 
because death is a terminal state.  In the case of patients who survive an episode of 
ATBD, it is because even though they are theoretically at risk of developing ATBD 
again, it is assumed that a new episode would be caused by a new infection, and not be a 
relapse from the same infection.  It is assumed that the likelihood of a reinfection would 
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be unaffected by previous LTBI prophylaxis, as would be the risk that the re-infection 
would result in ATBD. 
Patients who remain in the state of LTBI at the end of an annual cycle progress to 
the next yearly cycle, during which they again face the possibility of dying from other 
causes, developing ATBD or remaining latently infected.  The cohort continues to cycle 
through the Markov loop until the termination condition is met. 
 
Targeted Testing and Treatment for LTBI 
The comparison strategy in the decision tree corresponds to a situation in which 
public health clinics actively seek to identify individuals at higher risk of being infected 
with LTBI, developing ATBD, or experiencing poor outcomes; they offer testing for 
LTBI to these high-risk individuals, and, if the person is positive for infection, 
prophylactic treatment.  
During the risk screening, patients who were treated for ATBD in the past are 
identified.  They require no further assessment since, as in the PACF strategy, they are 
assumed to not be at risk of developing ATBD again. Patients with no history of TB, 
whether they are (unknowingly) infected with LTBI or not, proceed through the risk 
screening, testing and treatment process. The risk assessment results in patients being 
classified as either “High risk” or “Low risk”  (Figure 8).  
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Figure 8: Pathway followed by patients infected with LTBI under TTT 
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Figure 9: Pathways followed by patients who are not infected with latent TB under 
TTT 
 
High-risk individuals are to be tested for LTBI, per program guidelines.  
However, some may not receive the test, as they may have refused it or clinic staff may 
have missed the opportunity to offer it to them (Figures 8 and 9).  The TTT for LTBI 
algorithm seeks to minimize testing and treatment among individuals at low risk of TB 
infection and disease.  However, in program conditions, a proportion of low-risk 
individuals end up receiving a skin test (Figures 8 and 9).  It may be because they ask to 
be tested in spite of being told that they are at minimal risk, or because testing is a 
requirement for employment or school attendance.   
Among patients to whom the Mantoux skin test is applied, a proportion returns 
within 72 hours for the test result to be read and recorded, while the rest will fail to do so 
(Figures 8 and 9).  No further action is assumed to be taken for patients who did not 
receive a TST or did not return for its reading.  Up to this point, the structure of the tree is 
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the same for the “Infected” and “Non-infected” groups, since “true” status is not known.  
The next steps however vary depending on assumed status. For patients in the “Non-
infected” branch, the tree terminates, as they are not at any risk of developing ATBD in 
the future (Figure 9).  Patients in the “Infected” branch (both high and low risk) who did 
not receive a skin test or whose skin test was not read move into the same Markov 
process that was described in the PACF arm and models the natural course of TB 
infection and disease (Figure 8).   
Patients whose skin test result is read and recorded are then classified as “TST 
positive” or “TST negative” based on the size of the skin reaction.  The test result is to be 
interpreted differently depending on whether patients are in the « Infected » or « Not 
infected » branch.  In the « Infected » branch, TST-positive patients are true positives, 
and TST negative patients are false negatives (Figure 8). A proportion of true-positives 
will begin prophylactic treatment, which they may or may not complete.  As even a full 
course of treatment does not completely eliminate the future risk of developing ATBD, 
true positives will be, every year, at some risk (much decreased) of developing TB, 
remaining latently infected or dying from other causes as modeled in the Markov process.  
Patients who do not complete LTBI treatment follow the same path as those who do, but 
they have 1) lower LTBI treatment costs and 2) a higher risk of subsequently developing 
ATBD. 
False negatives, on the other hand, will not be offered prophylaxis, as they are 
erroneously thought to be non-infected.  In the future, they will, every year, face an 
undiminished risk of either, developing ATBD, dying from other causes, or remaining in 
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the LTBI state. Their pathway therefore also ends with the Markov loop described 
previously (Figure 7).   
In the “Not infected” branch, patients are at no risk of ever developing ATBD, so 
their pathway does not end up in a Markov loop (Figure 9).  TST-negative patients in that 
branch are true negatives, and TST-positive patients are false positives. The latter may be 
offered treatment.  They do therefore incur LTBI treatment costs, and face a risk of 
developing adverse reactions to INH, which may be fatal.  They may or may not 
complete the full course of preventive treatment. 
Among patients who are truly infected with LTBI (true positives and false 
negatives), the decision tree (Figure 8) shows that a proportion is infected with an INH-
resistant strain of tuberculosis. As in the PACF arm, the tree also further distinguishes 
between TB that is resistant only to INH and MDR-TB.  INH prophylaxis will only 
benefit INH-sensitive cases.  Finally, as in the PACF arm, HIV status must also be 
accounted for, as HIV infection increases the risk of developing ATBD and decreases the 
likelihood of cure, regardless of INH resistance patterns.  However, since HIV infection 
is one of the criteria that lead patients to be classified as high risk, all patients in the low 
risk group are assumed to be HIV negative.  Therefore there is no branching out of the 
tree based on HIV status. 
The model assumes that no new LTBI infection, HIV infection, LTBI screening 
or treatment occurs after Year 0.  This assumption simplifies the model and does not 
affect the comparison of strategies. 
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Study Perspective 
The analysis is conducted first from the societal perspective.  It includes direct 
medical costs as well as patient costs associated with receiving treatment for LTBI and 
ATBD (time costs/productivity losses, transportation costs), and productivity losses 
associated with morbidity and premature mortality from ATBD and from adverse 
reactions to LTBI treatment.  In a sub-analysis, the impact of using a health system 
perspective, limited to direct medical costs, is also explored. 
   
Study Horizon 
In the base case scenario, costs and outcomes are calculated over a 25-year 
period. The impact of varying the analytical horizon on cost-effectiveness results is 
explored in a sensitivity analysis.  
 
Discounting 
Intervention costs (i.e., the costs associated with risk screening, testing and 
treatment for LTBI, and adverse drug events), which are all incurred in year/cycle 0, are 
not discounted.  However, the streams of costs and health effects (cases of ATBD and the 
related QALYs lost) associated with TB cases that would occur in the future under either 
strategy are discounted. 
Costs and outcomes are discounted at the same rate, as recommended by the Panel 
on Cost-Effectiveness in Health and Medicine (Weinstein, 1996).  A discount rate of 3% 
per year was used in the base case scenario.  Alternative rates are used in sensitivity 
analyses.  
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Ethics Clearance 
Clearance was obtained from Institutional Review Boards at Georgia State 
University, Tennessee Department of Health and the Centers for Disease Control and 
Prevention.  The study was determined to be a public health program evaluation that did 
not constitute human subject research. 
 
Data Source and Sample Description 
Key information about the TTT intervention in Tennessee was obtained from the 
state’s Patient Tracking Billing and Management Information System (PTBMIS) 
database.  The data was originally extracted for a study of the intervention’s effectiveness 
(Cain, 2012). 
The data set included information about 178,526 patients with an initial public 
health clinic visit date within the study timeframe (March 1, 2002 to 31 December 2006).  
Among them, patients who indicated they were either close contacts of TB cases (21,618) 
or health care workers (22,549) were excluded from the analysis, regardless of other risk 
factors.  Close contacts of TB patients and health care workers are at increased risk of TB 
exposure and infection, and are targeted for testing and treatment for LTBI, but they are 
the focus of separate TB control policies, that should be enforced regardless of whether a 
targeted testing and treatment strategy is also being pursued.  It was not possible to 
determine from the data whether the contacts and health care workers in the dataset had 
come to the attention of the Tennessee TB Control program because they had been 
screened as part of the TTT program, or as a result of other TB control activities (i.e., 
recent contact investigation, or implementation of infection control regulations at health 
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facilities) conducted or supported by local public health departments.  These two 
categories of patients were therefore excluded from the analysis, to avoid biasing the 
analysis either in favor of the intervention (in the case of contacts, who show a higher 
LTBI infection rate) or against it (in the case of health care workers, among whom LTBI 
prevalence is lower).   
The remaining 135,966 patients formed the sampled used to derive event rates for 
the decision tree.  Among them, 78,801 (58%) were female.  A majority (72%) of 
patients were identified as White, and 24% as Black. Asians represented only 1.3% of the 
sample.  Almost 20% were identified as Hispanic. Overall 949 patients (0.7%) were 
known to be HIV positive.  Mean age was 30 years (standard deviation=16.77 years).  
The age distribution of the cohort of screened, LTBI-infected and treated patients is 
shown in Figure 10. 
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Figure 10: Age distribution of patients screened for LTBI risk, TST-positive and treated for LTBI
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Table 1 shows the distribution of risk factors for tuberculosis among the 
patients included in the study.  Exposure risk factors increase the likelihood that an 
individual may have been exposed to TB and become infected.  Medical risk factors 
increase the likelihood that, if infected, individuals would develop TB or experience 
poor outcomes.  Table 2 shows the distribution of patients by number of risk factors 
reported.  In this population, exposure risk factors were far more prevalent than 
medical ones. 
 
Table 1: Distribution of individual risk factors in the Tennessee cohort  
RISK 
% of patients 
Exposure risk 
Birth in a high-TB burden country 20.55% 
Travelled or lived in a high-risk area 10.03% 
In prison or jail in the past year 10.00% 
Homeless in the past year 8.00% 
In a homeless shelter in the past year 6.71% 
Child in contact with an adult with TB 6.19% 
Lived in any other type of congregate setting in the past year 4.08% 
In a alcohol/drug treatment facility in the past year 2.93% 
History of injection drug use  2.14% 
Lived in a long-term care facility in the past year 1.76% 
Known HIV positive 0.70% 
  
Medical risk  
History of diabetes 3.69% 
History of immunosuppressive condition or treatment 1.03% 
Known HIV positive 0.70% 
History of intestinal or gastric bypass 0.31% 
History of cancer of the head, neck or lung 0.29% 
History of end-stage kidney disease 0.23% 
History of chronic mal-absorption  0.15% 
History of lymphoma or leukemia  0.13% 
History of silicosis 0.06% 
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Table 2: Frequency of risk factors among cohort patients 
Number of risk 
factors 
Exposure risk 
factors 
Medical risk factors Total risk factors 
(exposure and 
medical) 
0 52.82% 94.02% 49.41% 
1 30.82% 5.28% 32.37% 
2 12.78% 0.59% 13.62% 
3 2.79% 0.09% 3.42% 
4 0.68% 0.02% 0.95% 
5 0.11% * 0.19% 
6 0.01% * 0.03% 
7 - * 0.01% 
 
Country of birth was recorded for 134,930 patients (99.24%). Seventy-nine 
percent were born in the United States.  The rest originated from 192 countries and 
territories, and 27,952 (98% of all foreign-born) were from a country where TB is 
endemic. Mexico accounted for almost 12% of all foreign-born, and Guatemala for 
1.71%.  No other country accounted for more than 1% of patients.  Foreign-born patients 
from high burden countries had been in the US for 4.9 years on average (standard 
deviation: 7.2 years) and 45.83% had been in the United States U.S. for less than 2 years 
at the time of the screening.  Seventy percent had been in the US for 5 years or less. 
After risk assessment, the patients fell into 3 risk categories: the majority (55.4%) 
were qualified as high risk, 44.3% were labeled as low risk, and a small number (0.3%) 
proved ineligible for the TTT program because they had ATBD in the past.  Over the 
study period, 95,796 patients received a TST, and 85.5% of these TST were read, of 
which 9.4% were positive.  A total of 3,925 patients started treatment for LTBI, and 
52.5% completed  80% or more of their prescribed regimen.  Four different LTBI 
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treatment regimens were used during the study period, with the 6-to-9-month of INH 
regimen by far the most-frequently prescribed (Table 3). 
 
Table 3: LTBI treatment regimens prescribed to cohort patients 
Regimen 6 to 9 months 
INH (daily) 
4 months 
RIF (daily) 
4 months 
RIF/INH 
2 months 
RIF/PZA (daily) 
No (%) of 
patients who 
initiated 
3,379 
(86.1%) 
702 
(17.9%) 
48 
(1.2%) 
11 
(0.3%) 
Note: Patients may have initiated more than one regimen, as regimen switches can occur 
during treatment in case of adverse drug reaction, adherence issue, etc. 
 
Event Rates and Transitional Probabilities 
Assumptions made regarding the model’s event rates and transitional probabilities 
are summarized in Appendix B. 
 
Proportion of Patients Previously Treated for ATBD 
The proportion of patients visiting TN public health clinics who were treated for 
ATBD in the past and are therefore ineligible for LTBI testing and treatment was 
obtained from the PTBMIS database.  The same probability is used for both the PACF 
and TTT strategies.  In the base case scenario, the proportion of patients previously 
treated for ATBD in the entire 2002-2006 cohort (0.31%) was used.  In the sensitivity 
analysis that evaluated program performance over time, the following proportions (Table 
4) were used. 
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Table 4: Percentage of patients previously treated for ATBD, by year 
Year 2002 2003 2004 2005 2006 2002-2006 
% of patients 
previously treated for 
ATBD 
0.11% 0.20% 0.45% 0.34% 0.35% 0.31% 
 
Probability of Being at High vs. Low Risk for LTBI and ATBD   
The risk distribution was obtained from the PTBMIS database.  Per program rules 
and practices, high-risk patients were those screened for risk that reported at least one risk 
factor for TB infection or disease and were not previously treated for ATBD.  Patients at 
low risk were screened patients who reported no risk factor and had no history of ATBD 
treatment.  In the base case scenario, the percentage of patients at high risk in the entire 
2002-2006 cohort (55.38%) was used.  Table 5 details the annual risk probabilities used in 
the sensitivity analysis that evaluated the program’s performance over time. 
 
Table 5: Proportion of screened patients found to be at high risk, by year 
Year 2002 2003 2004 2005 2006 2002-2006 
% at high risk 44.76% 50.15% 49.15% 52.20% 53.35% 55.38% 
 
Probability of Receiving a TST/Probability of TST Being Read 
The percentages of patients to whom a TST was applied and whose TST result 
was read and recorded were obtained from the PTBMIS database.  Rates were calculated 
separately for patients at low and high risk.  Patients with missing information concerning 
whether a test had been applied were conservatively coded as not having received a skin 
test, unless a test result was recorded, which was considered evidence that a test had been 
applied.  All patients who were coded as having received a test but whose test result was 
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missing were classified as “test not read.”  In the base case scenario, TST application and 
reading rates for the entire 2002-2006 cohort were used.  In the sensitivity analysis to 
evaluate program performance over time, annual rates were used (Table 6). 
 
Table 6: TST application, recording and positivity rates, 2002-2006  
Year 2002 2003 2004 2005 2006 2002-2006 
TST applied (%)  
High risk group 85.2 78.6 81.7 78.0 68.0 81.6 
Low risk group 75.1 73.4 67.0 57.3 50.6 64.7 
TST read/recorded (given that TST applied) (%)  
High risk group 79.2 78.1 82.3 84.5 86.2 82.5 
Low risk group 74.8 76.1 80.1 85.3 84.9 80.2 
TST positivity rate (%) 
High risk group 16.6 15.0 13.8 16.4 15.9 15.5 
Low risk group 2.1 2.3 2.6 2.9 3.3 2.6 
 
Sensitivity and Specificity of the Mantoux Skin Test 
Per national and TN guidelines, the Mantoux test interpretation (i.e., the decision 
by a health care worker to declare a test result positive or negative) takes into account not 
only the size of the dermal reaction but also the patient’s risk level in order to increase 
the test sensitivity and specificity (Table 7).   
 
Table 7: Mantoux skin test cut-off points for positivity 
 Cut off point for a positive skin test 
HIV-positive patients 5 mm and above 
Other high-risk patients 10 mm and above 
Low-risk individuals 15 mm and above 
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In the base case scenario, the Mantoux skin test was assumed to be 100% 
sensitive and specific (i.e., there were no false positive or false negative results).  The 
impact of less-than-perfect test characteristics was explored in sensitivity analyses.   
 
Mantoux Skin Test Positivity Rate 
The Mantoux skin test positivity rate was obtained from the PTBMIS database.  It 
is calculated as the percentage of read TSTs that were recorded as positive.  Separate rates 
were calculated for the high-risk and low-risk groups.  In the base case scenario, positivity 
rates for the entire 2002-2006 cohort were used. In the sensitivity analysis that evaluated 
the performance of the program over time, annual positivity rates were used.  All rates are 
shown in Table 6. 
 
Prevalence of LTBI 
In the base case scenario, the prevalence of LTBI in the PACF strategy is assumed 
to be the same as the Mantoux skin test positivity rate among all tested individuals 
(regardless of risk level), in line with the assumption made in that scenario that the 
Mantoux skin test is 100% sensitive and specific.  In the TTT arm, LTBI prevalence among 
individuals who did not receive a skin test and among those whose results was not read or 
recorded was assumed to be the same as among patients of the same risk level who did 
receive a test and the test was read.   
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Prevalence of Resistance to INH and Multidrug Resistance 
The prevalence of resistance to INH and INH/RIF (multidrug-resistance) among 
patients infected with LTBI was assumed to be the same as among cases of ATBD 
registered in the United States during the study period.  Average rates of INH resistance 
and multidrug resistance for 2002-2006 were computed based on information available in 
the national surveillance reports for each individual year in the period (CDC, 2008).   
The average rates of INH and INH-RIF resistance observed among foreign-born 
ATBD cases (10.40% and 1.40%, respectively) were used for the high-risk group, and the 
average rates observed in US-born patients (4.30% and 0.50%, respectively) were used 
for the low-risk group (Table 8).  Since there was very little variation in the prevalence of 
resistance from year to year, the average rates over the 2002-2006 period were also used 
in the sensitivity analysis that assessed the economic value of the program over time. 
 
Table 8: Prevalence of INH and INH-RIF resistance in the U.S., 2002-2006 
 Resistance to at least INH Resistance to INH/RIF 
US-born 
individuals 
2002 
2003 
2004 
2005 
2006 
4.10 
4.50 
4.50 
4.30 
4.30 
0.70 
0.50 
0.60 
0.40 
0.40 
Average rate 4.30% 0.50% 
Foreign-
born 
individuals 
2002 
2003 
2004 
2005 
2006 
10.8 
10.4 
10.2 
10.1 
10.4 
1.70 
1.20 
1.30 
1.40 
1.40 
Average rate 10.38% 1.40% 
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HIV Prevalence 
HIV prevalence among patients infected with LTBI was obtained from the 
PTBMIS database.  Only 0.70% were HIV-positive.  This overall rate was used in the “no 
intervention” strategy.  In the TTT arm, HIV infection is considered a risk factor for TB, 
and all HIV-positive individuals were classified as high risk.  Table 9 summarizes the 
HIV prevalence rates, obtained from the PTBMIS database, used in the analysis. 
 
Table 9: HIV prevalence rates in patients screened for LTBI risk, 2002-2006 
Group HIV prevalence 
High-risk group  
TST placed and read, TST+ 0.4% 
TST placed and read, TST- 0.4% 
TST placed, not read 1.3% 
TST not placed 1.8% 
Low-risk group 0% 
 
Risk of Developing ATBD 
It was assumed that patient who develop ATBD develop pulmonary TB, the most 
common form of the disease.  Since other forms of ATBD tend to be more severe (and 
costlier-to-treat), the risk of biasing the model in favor of targeted testing and treatment 
for LTBI would be limited. 
The percentage of patients that develop ATBD during each cycle was estimated 
based on work by Horsburgh et al. (2004), in which annual reactivation rates for various 
age groups were computed depending on size of TST reaction and time since infection, 
using data from clinical trials that established the efficacy of INH in preventing ATBD 
(see Appendix D). 
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Since all known close contacts were excluded from the analysis, all infected 
individuals were assumed to be non-conversion cases.  Conversion cases are cases that 
occur within two years of exposure/infection, when the risk of evolving from infection to 
disease is the highest.  Assuming that all infected persons were past their high-risk phase 
avoids biasing the analysis in favor of the intervention.  It was also assumed that the risk 
of developing ATBD was the same whether the individual was infected with an INH-
resistant or INH-sensitive strain (Burgos, 2003).   
To calculate the age-adjusted ATBD risk for each cycle in the Markov model for 
HIV-negative patients, the following steps were followed: 
1) Patients in the TN dataset were categorized according to the same risk categories 
used by Horsburgh (HIV+ with a TST result greater or equal to 5 mm, high risk 
patient with a TST result between 10 and 14 mm, high risk patient with a TST 
result greater or equal to 15 mm, and low-risk individual with a TST result greater 
or equal to 15 mm). 
2) For each category, the age distribution of patients in the cohort was calculated (in 
one-year increments/age groups). 
3) For each one-year age group in a given risk category, the number of ATBD cases 
expected during the first Markov cycle was calculated by multiplying the number 
of individuals in the LTBI state at the start of the cycle by the corresponding risk. 
4) The number of expected cases was then summed up across all age groups to 
calculate the total number of ATBD cases expected during the first Markov cycle. 
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5) This number was subsequently divided by the total number of individuals in the 
LTBI state in the cohort at the start of the cycle, to calculate the overall, now age-
adjusted, ATBD risk for cycle 1. 
6) Then, for each age band, the number of ATBD cases expected during cycle 1 was 
subtracted from the number of patients in the LTBI state at the start of cycle 1, to 
calculate the number of patients still susceptible to develop ATBD in cycle 2 of 
the Markov. 
7) Steps 3 to 6 were repeated for each of the subsequent Markov cycles for each risk 
category. 
Cycle-specific ATBD risks for HIV-negative patients are reported in Table 10.  In 
the base case (analytical horizon of 25 years), only the rates for cycles 0 to 24 were used.  
In the sensitivity analysis that explores the impact of shortening or lengthening the 
analytic horizon, the full table was used. 
To compute the annualized risk of evolving to ATBD in HIV-positive patients, 
the corresponding rate for HIV-negative patients was multiplied by 9.9, the risk ratio for 
HIV-positive patients compared to HIV-negative ones (Horsburgh et al., 2004). 
 
Table 10: Annual probability of developing ATBD during each Markov cycle in the 
absence of LTBI treatment 
Cycle Prob. of developing ATBD (HIV negative) 
0-2 0.0015 
3-8 0.0014 
9-14 0.0013 
15-27 0.0012 
28-98 0.0011 
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Outcome of ATBD Treatment (Death or Survival) 
All cases of ATBD that develop either in the absence of a targeted screening and 
testing program, or in spite of such a program, were assumed to be diagnosed and treated 
appropriately, and to not be at risk of experiencing a relapse.  Having initiated or 
completed treatment for LTBI was assumed to not affect the likelihood of survival if 
ATBD develops. 
The risk of dying from drug-susceptible or resistant-to-INH-only TB was 
operationalized as the average case fatality rate for the 2002-2006 period for the state of 
Tennessee.  For each year in the period, the numerator is the number of deaths for whom 
TB was reported as the underlying cause (Code A16-A19) in the WONDER online 
database of CDC’s National Center for Health Statistics (2012 release), and the 
denominator is the total number of TB cases reported in the state during that same year 
(CDC, 2004; CDC, 2006; CDC, 2007).  The risk of dying from MDR-TB (Table 11) was 
obtained from U.S. reports on 2006 MDR TB treatment outcomes to the World Health 
Organization (WHO, 2010).  The risk of dying from ATBD among HIV-positive patients 
was obtained from a study of TB mortality by HIV status that used data from the national 
surveillance system data (Shah et al., 2010). 
 
Table 11: ATBD fatality rates, by HIV and INH resistance status 
Type of TB HIV status ATBD fatality rate 
Drug sensitive HIV- 6.13% 
HIV+ 20% 
MDR HIV- 12% 
HIV+ 20% 
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Risk of Dying from Causes Other than TB 
The risk of dying from causes other than TB (Table 12) was estimated based on 
information published by the National Vital Statistics System of the Centers for Disease 
Control and Prevention’s National Center for Health Statistics.  The US life tables are 
based on death certificate data and takes into account mortality from all causes, including 
deaths from TB.  However, because TB deaths represent a small fraction (0.03% in 2006) 
of all deaths that occur annually in the United States, the risk of death from other causes 
was not recalculated to exclude TB deaths (Weinstein et al., 2003).   
The period life table for 2006 (Appendix C) was used to calculate a general 
mortality risk for each cycle of the Markov model adjusted for the age composition of the 
cohort at each cycle, in the following manner: 
1) The number of individual in each one-year age stratum in the cohort of TST+ 
patients was calculated. 
2) For each stratum, this number was multiplied by the corresponding risk of dying 
from all-cause mortality during the following year (taken from the period life 
table) to calculate the expected number of deaths during the year/cycle. 
3) The expected numbers of deaths were summed up across all strata, to calculate the 
total expected number of deaths in the cohort for the cycle. 
4) This number was then divided by the total number of individuals in the cohort at 
the start of the cycle, to calculate an age-adjusted all-cause mortality rate for the 
cycle. 
5) This process was repeated for all cycles, while considering the aging of the cohort 
over time (e.g., in the case of patients who were 25 years old when they were 
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screened, the all-cause mortality rate for 25-year olds is used to calculate the 
expected number of deaths in the first cycle.   In calculations for the second cycle, 
the mortality rate for 26-year olds is used. Calculations for the third cycle use the 
rate for 27-year olds, and so on.) 
Anti-TB drug resistance patterns and LTBI treatment were assumed not to affect 
the likelihood that patients infected with LTBI would die from causes other than TB.  The 
base case scenario, which posited a 25-year analytic horizon, used the rates for cycles 0 
to 24.  The full table was used in the sensitivity analysis that assessed the impact of the 
analytical horizon on cost-effectiveness results.  
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Table 12: All cause, age-adjusted mortality rates in persons with LTBI  
Cycle All-causes 
mortality 
Cycle All-causes 
mortality 
Cycle All-causes 
mortality 
0 0.0031 33 0.0182 66 0.0918 
1 0.0032 34 0.0191 67 0.0957 
2 0.0034 35 0.0201 68 0.0993 
3 0.0036 36 0.0211 69 0.1035 
4 0.0038 37 0.0222 70 0.1075 
5 0.0040 38 0.0233 71 0.1114 
6 0.0043 39 0.0245 72 0.1146 
7 0.0045 40 0.0257 73 0.1183 
8 0.0047 41 0.0270 74 0.1227 
9 0.0050 42 0.0284 75 0.1263 
10 0.0053 43 0.0298 76 0.1305 
11 0.0056 44 0.0313 77 0.1336 
12 0.0059 45 0.0328 78 0.1388 
13 0.0062 46 0.0345 79 0.1411 
14 0.0065 47 0.0362 80 0.1464 
15 0.0069 48 0.0380 81 0.1497 
16 0.0073 49 0.0399 82 0.1538 
17 0.0077 50 0.0420 83 0.1623 
18 0.0081 51 0.0442 84 0.1684 
19 0.0086 52 0.0465 85 0.1789 
20 0.0091 53 0.0490 86 0.1845 
21 0.0096 54 0.0515 87 0.1916 
22 0.0101 55 0.0542 88 0.2065 
23 0.0107 56 0.0570 89 0.2213 
24 0.0113 57 0.0599 90 0.2347 
25 0.0119 58 0.0630 91 0.2470 
26 0.0126 59 0.0663 92 0.2575 
27 0.0133 60 0.0696 93 0.2755 
28 0.0140 61 0.0731 94 0.3116 
29 0.0148 62 0.0766 95 0.3686 
30 0.0156 63 0.0804 96 0.4449 
31 0.0164 64 0.0837 97 0.5144 
32 0.0173 65 0.0880 98 0.6177 
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Probability of Initiating and Completing Treatment for LTBI 
The percentages of patients who initiated and completed LTBI treatment were 
obtained from the PTBMIS database.  Probabilities were calculated for each risk stratum 
(high vs. low) and further disaggregated by HIV status among high-risk patients. 
Any patient who received at least a one-month supply of LTBI treatment drugs was 
considered to have initiated LTBI treatment, while treatment completion was measured by 
the quantity of pills that were dispensed to patients, as recorded in the state’s pharmacy 
database.  Completers were further classified into two groups: 1) patients who completed 
100% of any LTBI treatment regimen; 2) patients who completed between 80% and 100% 
of any treatment regimen, as these thresholds were used in the decision tree to model the 
effectiveness of LTBI treatment.  
As drug resistance status cannot be determined at the latent phase of TB infection, 
LTBI treatment initiation and completion rates were assumed to be the same across 
resistance patterns.  In the base case scenario, treatment initiation and completion rates 
recorded in the entire 2002-2006 cohort were used.  In the sensitivity analysis that 
evaluated program performance over time, initiation and completion rates were calculated 
separately for each annual cohort (Tables 13-15). 
 
Table 13: LTBI treatment initiation rates, 2002-2006 
 Initiation rate 
Risk group 2002 2003 2004 2005 2006 2002-2006 
High-risk, HIV+ 83.3% 40.0% 33.3% 50.0% 62.5% 57.7% 
High-risk, HIV- 58.2% 39.7% 50.1% 54.4% 55.9% 52.1% 
Low-risk 42.2% 34.7% 39.7% 47.5% 52.0% 43.8% 
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Table 14: LTBI treatment completion rates, 2002-2006 
 
Completers 
% of completers… 
who completed 
≥100% of any LTBI 
regimen 
who completed ≥80% 
and <100% of any LTBI 
regimen 
High-risk, HIV+  53.3%  100% 0.0% 
High-risk, HIV-  58.0%  90.6%  9.4% 
Low risk 57.5%  92.0%  8.0% 
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Table 15: LTBI treatment completion rates by extent of completion, 2002-2006  
2002 2003 2004 2005 2006 
Overall By extent of completion Overall 
By extent of 
completion Overall 
By extent of 
completion Overall 
By extent of 
completion Overall 
By extent of 
completion 
HIGH-RISK GROUP, HIV NEGATIVE 
40% 
≥100%: 91.53% 
 
80-99%: 8.47% 
60% 
≥100%: 92.94% 
 
80-99%: 7.36% 
60.57% 
≥100%: 93.61% 
 
80-99%: 6.39% 
62.98% 
≥100%: 91.37% 
 
80-99%: 8.63% 
50% 
≥100%: 84.39% 
 
80-99%: 15.61% 
HIGH-RISK GROUP, HIV POSITIVE 
56.46% 
≥100%: 100% 
 
80-99%: 0% 
0% 
≥100%: 0% 
 
80-99%: 0% 
100% 
≥100%: 100% 
 
80-99%: 0% 
50% 
≥100%: 100% 
 
80-99%: 0% 
80% 
≥100%: 100% 
 
80-99%: 0% 
LOW-RISK GROUP 
64.81% 
≥100%: 74.28% 
 
80-99%: 25.72% 
51.92% 
≥100%: 100% 
 
80-99%:0% 
48.15% 
≥100%: 97.43% 
 
80-99%: 2.57% 
61.17% 
≥100%: 93.65% 
 
80-99%: 6.35% 
60.19% 
≥100%: 93.54% 
 
80-99%: 6.46% 
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Risk of Adverse Drug Events/Fatality Rate 
No serious adverse drug events (ADE) (i.e., adverse drug reactions requiring 
hospitalization or resulting in death) were reported in Tennessee during the study period.  
However, not including the risk of ADE in the analysis and in the decision tree would 
bias the analysis in favor of the intervention.  In addition, a total of 17 instances of severe 
(i.e., that resulted in hospitalization and/or death) INH-related liver injuries were reported 
to the Centers for Disease Control and Prevention’s passive surveillance system 
nationwide between 2003 and 2008 (MMWR, 2010), emphasizing the need not to ignore 
the risk.  Multiple studies in the literature report on hepatotoxicity risks in recent years, 
and report incidence rates that are relatively low but vary widely depending on diagnostic 
criteria and the age distribution of the study population. Studies that measured 
hepatotoxicity incidence through systematic laboratory testing for elevated AST levels 
before and during INH treatment have reported higher incidence levels than studies that 
relied on symptoms reported by patients and/or identified during clinical monitoring.  
Incidence was also shown to increase with age. 
In this study, the base case scenario used an adverse event incidence rate of 0.13% 
(Table 16).  This rate was derived from results reported by the Seattle-King County 
Department of Health TB Clinic (Nolan et al., 1999) between 1989 and 1995.  Among 
11,141 patients treated for LTBI in Seattle, 11 adverse events were reported (0.1%).  
These events occurred after a median of 9 weeks of treatment, with 10/11 occurring 
within 3 months of treatment initiation.  One patient (9.1% of all adverse events reported) 
required hospitalization.   
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Table 16: Expected, age-adjusted rate of ADEs in the Tennessee cohort 
Age group ADR rate in  
Nolan, 1999 
(per 100 
patients) 
No. of treated 
patients in TN 
cohort 
Expected No. of 
ADEs 
Estimated 
rate of ADEs 
in TN 
0-14 0 666 0  
15-34 0.08 4644 4 
35-64 0.21 3409 7 
>65 0.28 311 1 
  Total 12/9030 0.13% 
 
The rate of fatal hepatitis was set at 1.7/100,000, or equivalent to the rate of death 
due to hepatitis of any cause in the general population (Millard, 1996).  The incidence of 
hepatotoxicity and its case fatality rate were assumed to be the same regardless of anti-TB 
drug resistance and HIV status. 
 
Effectiveness of LTBI Treatment 
The effectiveness of LTBI treatment was based on clinical trial results reported in 
the published literature (IUAT, 1982).  When treatment completion was defined as 100% 
of any treatment regimen, LTBI treatment was assumed to prevent 90% of expected 
cases.  When treatment completion was defined as 80% of any treatment regimen, 
effectiveness was assumed to be 68%.  Incomplete treatment was conservatively assumed 
to provide no protection.  
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Cost Parameters 
Scope, Methods and Data Sources 
Medical Services 
Establishing the direct cost of an intervention requires information about the type, 
quantity and unit price of the resources consumed to provide this intervention. The 
PTBMIS database does not directly, or exhaustively, record patients’ use of health 
services.   To estimate the type and quantity of services used in targeted testing and 
treatment, patient cost profiles were compiled based on national and state screening and 
treatment guidelines and program staff’ description of local practice.   
For health services’ unit prices, the 2011 Medicare’s Physician Medicare Fee 
Schedule and Clinical Laboratory Fee Schedule (Centers for Medicare and Medicaid 
Services) for the state of Tennessee were used.  These fee schedules, developed by the 
Centers for Medicare and Medicaid, are a complete listing of fee maximums used by 
Medicare, Medicaid and Health Maintenance Organizations to reimburse health services 
providers on a fee-for-service basis.  They are frequently used in economic evaluations of 
health services because they were specifically designed to estimate the actual cost of 
providing these services.  The fees are set on the basis of the Resource-Based Relative 
Value Scale (RBRVS).  The RBRVS assigns to each procedure a relative value, 
measured in terms of Relative Value Units (RVU), based on the amount of “effort” 
required for its provision.  Relative values take into consideration three key factors: 
physician work (for 52% of the score), practice expense (44%), and malpractice expense 
(4%).  They are further adjusted for geographical location.  The physician work 
component reflects the physician’s time, mental effort, technical skill, judgment, stress, 
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and an amortization of the physician’s education. The practice expense reflects the 
expenses, in terms of supplies, equipment, non-physician labor and overhead, used to 
provide the service (American Medical Association).  
For staff time cost estimates not reflected in the Medicare Fee Schedules (e.g., 
time spent by staff on administering the TB risk screening questionnaire), the March 
2011 release of the Bureau of Labor Statistics’ Occupational Employment Statistics for 
health care professions in Tennessee was used (Bureau of Labor Statistics).   
 
Patient Costs 
Direct Costs 
As the health services, including visits, laboratory tests and medications, associated 
with TTTLTBI would be provided free-of-charge to patients, patients’ direct costs were 
assumed to include primarily the monetary cost of transportation.  No primary data was 
available regarding patients’ transportation means, travel times or transportation costs 
related to the TTT LTBI program. Patients were assumed to receive care at the health 
department in their county of residence, and to travel by motor vehicle.  This assumption 
was based on census data that showed that in 2000, more than 90% of TN residents drove 
alone or carpooled to work, while only 0.8% using public transportation, 1.5% walked and 
0.8% rode a motorcycle or a bike for their daily commute.  In addition, according to the 
2011 American Community Survey, only 2% of TN residents indicated that they did not 
have access to a vehicle (U.S. Census Bureau).  Patients’ travel distance to the local public 
health clinic was assumed to be equivalent to the average work commuting distance 
traveled in TN (18 miles).  The per-mile cost of transportation was estimated using the U.S. 
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General Services Administration federal standard reimbursement rate for privately-owned 
vehicles ($0.51 per mile in 2011)  (U.S. General Services Administration), which takes into 
account both the fixed and variable costs of driving a vehicle.  
 
Indirect Costs 
Patients’ indirect costs associated with TB infection, TB disease and their 
treatment include the opportunity cost of time spent seeking care for LTBI, productivity 
losses associated with morbidity from ATBD disease in non-prevented cases, and the 
value of life lost to premature mortality from ATBD. 
Estimates of the quantity of time spent seeking care for LTBI were based on 
assumptions about travel time and staff opinion regarding waiting time and time needed 
to provide services. The opportunity cost of time was based on Bureau of Labor Statistics 
data for production/non managerial wages (Bureau of Labor Statistics).   
Productivity losses associated with non-fatal ATBD disease were based on the 
results of a study of the cost of patients hospitalized for MDR TB (Rajbhandary, 2004).  
This study, which used the human capital approach to estimate indirect costs, estimated 
productivity losses for survivors based on the number of out-patient clinic visits and days 
and severity of illness, assuming that patients lost a half day of productive work time for 
each outpatient clinic visit to see a physician, and 25% of their productivity if mildly ill 
and 50% if moderately ill for each non-clinic-visit out-patient day. Earnings for non-
supervisory production workers, adjusted for fringe benefits and leave, were used.  
Productivity losses for patients who survive MDR TB were estimated at $32,964 (range: 
$9,208 to $66,099) in 2000 US$.  These results were updated to 2011 US$ using the 
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Bureau of Labor Statistics’ Employment Cost Index (Bureau of Labor Statistics).  As 
treatment for MDR TB lasts approximately three times longer (18 months vs. 6 months) 
than for drug-sensitive TB, this same ratio was applied to productivity losses, which 
therefore were estimated at $15,180 for drug-sensitive cases, and $45,540 for MDR 
cases.  Productivity losses were assigned to all patients, including those aged over 65, to 
represent the value of the time lost to work in the formal or informal sector, household 
production, or leisure. 
The value of life lost from premature mortality due to non-prevented ATBD cases 
was also estimated using the human capital approach.  The most recent estimates of the 
Net Present Value of Lifetime Earnings (NPVLE) available in the literature were for the 
year 2000 (Max, 2004).  They were updated to 2011 US dollars using the Bureau of 
Labor Statistics’ Employment Cost Index (Bureau of Labor Statistics) (Appendix E).  An 
average value of life lost was then calculated for each Markov cycle based on the age 
distribution of expected deaths, as follows.   
1) The number of deaths expected in each one-year age stratum in a given Markov 
cycle was calculated (based on the number of individuals in that age stratum at 
LTBI screening, the risk of developing ATBD and the risk of dying from it).  
2) This number was multiplied by the value-of-life for that age stratum to calculate 
total value-of-life lost for the stratum. 
3) These values were summed up across all age strata to calculate total value-of-life 
lost in the cohort for that cycle 
4) The sum was divided by the total number of expected deaths for the cycle, to 
calculate an average, age-adjusted, value of a life lost for the cycle. 
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5) These steps were repeated for all the cycles 
6) The averages obtained were then discounted depending on how far in the future 
the deaths were expected to occur.   
As the original 2000 estimates were only available for discount rates of 3% and 
5%, the sensitivity analysis that examined the impact of adopting a societal perspective 
and including patient costs was only conducted for these two discount rates.  Because the 
value of life lost was assumed to be determined primarily by age at death, and not by 
cause of death/severity of disease, it was assumed to be the same for DS-TB and MDR-
TB patients.  Table 17 summarizes the age-adjusted average value of a life lost to TB in 
each Markov cycle. 
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Table 17: Value of a life lost from ATBD 
Cycle Average NPVLE 
(US$ 2011) 
Cycle Average NPVLE 
(US$ 2011) 
Cycle Average NPVLE 
(US$ 2011) 
3% 5% 3% 5% 3% 5% 
1 $1,472,402 $1,071,966 30 $503,500 $427,954 59 $28,649 $26,419 
2 $1,456,389 $1,068,426 31 $468,474 $399,870 60 $25,024 $23,131 
3 $1,437,763 $1,061,936 32 $432,693 $371,051 61 $22,090 $20,452 
4 $1,418,603 $1,055,301 33 $401,130 $345,428 62 $19,236 $17,847 
5 $1,397,894 $1,046,857 34 $369,419 $319,514 63 $17,054 $15,854 
6 $1,373,310 $1,035109 35 $339,795 $295,184 64 $15,082 $14,049 
7 $1,346,812 $1,020,990 36 $311,325 $271,473 65 $13,042 $12,179 
8 $1,318,786 $1,004,541 37 $285,942 $250,135 66 $11,601 $10,854 
9 $1,289,601 $987,849 38 $264,827 $232,240 67 $10,208 $9,575 
10 $1,259,710 $970,354 39 $242,619 $213,320 68 $9,197 $8,648 
11 $1,225,805 $949,414 40 $222,102 $195,868 69 $8,263 $7,788 
12 $1,190,748 $927,108 41 $202,208 $178,793 70 $7,348 $6,947 
13 $1,155,898 $903,802 42 $183,852 $163,035 71 $6,735 $6,378 
14 $1,118,758 $879,157 43 $168,898 $150,124 72 $6,099 $5,789 
15 $1,081,145 $853,987 44 $153,185 $136,464 73 $5,607 $5,333 
16 $1,041,234 $826,846 45 $138,784 $123,980 74 $5,180 $4,938 
17 $1,000323 $798,829 46 $125,244 $112,149 75 $4,735 $4,524 
18 $961,536 $771,525 47 $112,549 $101,064 76 $4,462 $4,271 
19 $921,913 $743,601 48 $102,799 $92,531 77 $4,175 $4,004 
20 $882,729 $715,881 49 $92,466 $83,410 78 $3,944 $3,791 
21 $841,038 $685,624 50 $82,545 $74,661 79 $3,789 $3,647 
22 $800,177 $655,736 51 $73,588 $66,698 80 $3,548 $3,424 
23 $762,590 $627,685 52 $65,366 $59,399 81 $3,394 $3,279 
24 $724,504 $599,146 53 $59,041 $53,778 82 $3,144 $3,045 
25 $686,237 $570,375 54 $52,861 $48,250 83 $2,902 $2,818 
26 $646,285 $539,767 55 $46,720 $42,754 84 $2,707 $2,634 
27 $606,996 $509,440 56 $41,420 $37,966 85 $2,505 $2,445 
28 $571,983 $481,993 57 $36,316 $33,358 86+ $2,496 $2,436 
29 $537,277 $454,663 58 $32,351 $29,776    
NPVLE = Net Present Value of Lifetime Earnings 
3% - 5% = Discount rate 
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The value of life lost in the intervention arm from premature mortality associated 
with adverse reactions to INH was estimated by the same method used to gauge the value 
of life lost prematurely due to ATBD.  
The number of expected deaths from ADEs in each age stratum was calculated by 
multiplying the number of expected occurrences of ADEs by the fatality rate.  Again for 
each stratum, the number of expected deaths was multiplied by the NPVLE for that age 
(Appendix E) to determine total value of life lost in the stratum.  Amounts were then 
summed up across all age strata, then divided by the number of expected deaths over all 
age strata to calculate the average value-of-life lost to each death from ADRs.  As all 
deaths from INH-related deaths were assumed to occur during Year 1, at the time of the 
intervention, no further discounting was necessary. 
 
Detail of Services Costs 
Costs are summarized in Appendix F. 
Screening for Risk with Risk Assessment Tool 
Risk assessment (i.e., the administration of the risk assessment questionnaire) was 
estimated to take 15 minutes of patient and staff time.  The staff time cost was estimated 
using the average hourly wage ($29.16/hr.) of a registered nurse (Bureau of Labor 
Statistics, 2011).  No travel time was included for patients, as the assessment was 
conducted when they were already present in the clinic for reasons unrelated to TB/LTBI.  
The risk assessment screening cost was assigned to all patients screened (patients labeled 
as high risk, low risk, and ineligible for reason of previous TB treatment). 
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Tuberculin Skin Testing 
The cost of a skin test was obtained from the Medicare Fee Schedule.  The staff 
time associated with placing the skin test was assumed to be included in the TST’s 
Medicare fee.  Patient time associated with the application of a skin test was estimated at 
15 minutes.  No travel cost was assigned, as the test would be applied during the same 
visit as the risk screening. 
The TN TTT program algorithm recommends that all patients with at least one 
risk factor be offered skin testing.  However, some patients may refuse the test, or health 
workers may fail to offer it.  The cost of a skin test application was assigned to all 
patients for whom it was recorded in PTBMIS that a skin test was placed and to all 
patients with a recorded skin test result (even if not marked as having received a test).   
The staff time associated with reading and recording the test result was estimated to be 5 
minutes for a patient with a negative result and 15 minutes for a patient with a positive 
result.  Patient time required for reading the skin test result includes travel time to and 
from the clinic (25 minutes one way), waiting time (5 minutes) and test reading time (5 
minutes if negative, 15 minutes if positive), for a total of 60 minutes for TST-negative 
patients and 70 minutes in case of a positive TST.  The skin test reading cost was 
assigned to all patients for whom a test result was recorded in PTBMIS.    
 
Examination by a Physician 
This examination was assumed to be conducted for all patients with a positive 
TST result.  The Medicare Fee Schedule rate for a new patient visit with 20 minutes of 
face time was used to represent the health system cost associated with a physician visit.  
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The patient cost associated with a physician visit, including waiting time, was estimated 
at 30 minutes.  As the visit was assumed to take place immediately following the skin test 
reading, no additional travel time cost or transportation costs were included. 
 
Chest X-Ray   
All patients with a positive TST result are assumed to receive a chest X-ray. The 
Medicare Fee Schedule rate for a frontal chest radiograph was used.  The staff time cost 
associated with administering the CXR is assumed to be included in the Medicare rate.  
The patient time cost, including waiting time, was estimated at 15 minutes.   As the chest 
X-ray was assumed to be performed during the same clinic visit as the skin test reading 
and post-test physician examination, no separate travel time cost or transportation cost 
were assigned.   
 
Additional Evaluation for Symptomatic Patients 
The LTBI risk assessment tool includes a series of 7 questions about TB 
symptoms. Any TST-positive patient who answered “Yes” to at least 1 of the 7 questions 
was assumed to have been referred for further evaluation for ATBD, and to have received 
a frontal and lateral chest X-ray and 3 sputum smears and cultures. 
 
HIV Testing 
National guidelines recommend that the HIV status of LTBI and TB suspects be 
ascertained, as HIV infection is a risk factor for evolution to ATBD and negative ATBD 
treatment outcome.  However, TN program staff report that this guideline is not strictly 
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followed (Dr Connie Haley, former TN State TB Controller, personal communication).  
Until 2006, national guidelines recommended that HIV testing efforts focus on 
individuals at high risk for HIV.  We conservatively assumed that all patients who 
reported risk factors for HIV infection and all patients started on treatment for LTBI 
received an HIV test during the risk screening process.  We assumed that rapid HIV tests 
were used and that a positive rapid test would be confirmed by Western Blot (Farnham, 
2008). 
 
Baseline Laboratory Tests 
Laboratory tests conducted prior to initiating LTBI treatment include a complete 
blood count, a hepatic function panel and a basic metabolic panel.  This cost was 
assigned to all TST-positive patients who initiated LTBI treatment.  
 
Treatment for LTBI 
LTBI treatment costs include drug costs, follow-up visit costs (staff time), and 
patient transportation and time costs.  Because a large majority of patients were placed on 
a 9-month regimen of isoniazid, the costs associated with this regimen were used to 
model drug and visit costs, except in the case of HIV-positive patients, for whom a 12-
month regimen is recommended.  The daily INH-only regimen is costlier than its 
alternatives, as it requires a higher number of follow-up visits, therefore the model is not 
biased in favor of the intervention.  Total treatment costs from the health system 
perspective, including drug and visit costs, are detailed in Table 18 below.  Table 19 
shows patient costs related to treatment for LTBI. 
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Drug Costs 
A 9-month course of INH for LTBI treatment consists of 270 doses of isoniazid 
(300 mg per dose).  HIV-positive patients receiving a full 12-month regimen required 360 
doses.  Patients (regardless of HIV status) who did not complete treatment are assumed to 
have received 90 doses of INH (i.e. 3 months of treatment).  It is also assumed that 
patients also took a daily dose of pyridoxine (Vitamin B6) to facilitate INH absorption as 
long as they remained in LTBI treatment (i.e. 270 doses for HIV-negative treatment 
completers, 360 doses for HIV-positive completers and 90 doses for non completers).  
Drug costs were obtained from the 2011 Red Book (Red Book, 2011), which listed a cost 
of $0.38 per 300-mg INH tablet, and $0.10 per pyridoxine tablet.   
 
Visit Costs 
LTBI treatment was self-administered by patients, who received their medicine 
supply in one-month increments during follow-up visits (established patient visits) to the 
Health Department clinic.  No in-kind or financial incentive was distributed to patients to 
increase treatment adherence.  Treatment completers required 8 follow-up visits if HIV-
negative, and 11 if HIV-positive.  Non-completers required only 2.  Patient time for each 
follow-up visit (including travel time, waiting time and time with the practitioner) was 
estimated at 60 minutes.  Patient costs for LTBI treatment are detailed in Table 19.  
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Table 18: Direct health system costs of LTBI treatment 
 
Drug costs 
Visit costs 
Total INH Vitamin B6 
Doses $/dose Doses $/dose Number of visits $/visit 
Treatment 
completers 
HIV - 
270 $0.38 270 $0.01 8 $19.71  
$102.6 $27 $157.68 $287.28 
HIV + 
360  $0.38 360 $0.01 11 $19.71  
$136.8 $36 $216.81 389.61 
Non-completers 
90  $0.38 90 $0.01 2 $19.71  
$34.2 $0.90 $39.42 $74.52 
 
Table 19: Patient costs associated with LTBI treatment 
 
Time cost Transportation cost 
Total  Number 
of visits $/visit 
Number 
of visits 
Miles/ 
visit 
$/visit 
Treatment 
completers 
HIV - 
8 $14.56 8 36 $18.36  
$157.68 $146.88 $304.56 
HIV + 
11 $14.56 11 36 $18.36  
$216.81 $201.96 $418.77 
Non-completers 
2 $14.56 2 36 $18.36  
$39.42 $36.72 $76.14 
 
Costs Related to ADEs 
The TN TTT program followed US guidelines on LTBI treatment.  These 
guidelines do not recommend systematically performing laboratory tests at regular 
intervals to monitor adverse reactions to LTBI treatment drugs.  Therefore, such reactions 
are noted and acted upon only if patients exhibit or report symptoms of toxicity.  In 
addition, the TN program practice has been to act conservatively, and NOT initiate on 
LTBI treatment patients at increased risk of liver dysfunction (such as patients with a 
history of alcohol abuse).  The PTBMIS database did not include information about the 
incidence of ADEs or measures taken to address them in the treated population. No 
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serious ADE (i.e. an event that would result in the patient’s hospitalization and/or death) 
was ever reported and reactions of mild or medium gravity were very rare.  To avoid 
biasing the analysis in favor of the intervention, the model did take into account the risk 
of hepatotoxicity, its possible fatal outcome and related resource use.  Estimates of 
incidence of ADEs were derived from the published literature.  It was assumed that 
0.02% of treated patients reported symptoms severe enough to require a laboratory test.   
 
Active TB Disease 
A full analysis of the direct costs associated with diagnosis and treating active TB 
disease (drug sensitive and MDR) was outside the scope of this research. No exhaustive 
cost analysis has been conducted to date.  Instead, cost analyses have focused on various 
aspects of morbidity and mortality costs (such as the cost of hospitalization).  In addition, 
existing studies were conducted more than a decade ago.  Most economic evaluations 
conducted since have relied on secondary data.  The literature was reviewed.  Published 
estimates of ATBD diagnosis and treatment costs were updated to 2011 dollars using the 
medical services component of the Consumer Price Index.  The median values for drug-
sensitive and MDR TB were $25,000 and $73,000, respectively, with ranges of $12,000 
to $46,000 for drug sensitive TB and $66,000 to $110,000 for MDR TB.  In the base case 
scenario, the median values, augmented by 1% per year to account for changes in health 
care services and technology over time, were used.  The maximum and minimum costs 
estimates, also augmented by 1% per year, were used in sensitivity analyses to determine 
impact of disease cost on cost-effectiveness of targeted testing and treatment and 
threshold at which intervention becomes cost-effective.   
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Program Costs 
Both start-up and annual management costs were considered.  These costs 
concerned primarily staff time costs.  It was assumed that no capital expenses were made 
to implement the TTT program, as public health department clinics are already 
adequately equipped to diagnose and treat patients with LTBI and ATBD. 
Start-up costs included initial program planning costs, local staff training costs, and the 
cost of modifying the PTBMIS database to accommodate new data recording and 
reporting needs.  Information on salaries for relevant staff positions for 2002 were 
obtained from the TN Department of Health and updated to 2011 U.S. dollars using the 
Bureau of Labor Statistics’ Employment Cost Index (Bureau of Labor Statistics).  
Program costs were directly allocated to all patients screened for LTBI risk over the 
2002-2006 period, for a per-patient cost of 2011 $8.50.  Program cost calculations are 
detailed in Appendix I.   
 
Future Costs 
Future health costs other than TB-related costs (e.g., health costs associated with 
increased survival due to the decrease in TB deaths resulting from the intervention) and 
future non-health costs were not taken into account.   
 
Outcome Measures 
Two measures of health outcomes were used: ATBD cases and Quality-Adjusted 
Life Years (QALY).   
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ATBD Cases 
ATBD Cases Prevented in Patients Treated for LTBI 
The model counts the number of ATBD cases that would occur under each 
strategy.  The count includes both cases of drug-susceptible and drug-resistant 
tuberculosis. Presumably, the number of cases would be higher for the PACF strategy 
than for the TTT strategy, and the difference between the two corresponds to the number 
of TB cases prevented by the TTT program, or its incremental benefit.  ATBD cases 
occurring in future years were discounted based on how far in the future they were 
estimated to occur. 
 
Secondary ATBD Cases 
In the base case scenario was assumed that each case of ATBD would cause 
another 0.46 cases (Shepardson, 2013).  These additional cases were assumed to occur as 
follows (and discounted accordingly): one third at the same time as the index case, one 
third 5 years later and one third twenty years later.    
For simplicity, INH-resistant and INH-sensitive were assumed to result in the 
same number of secondary cases (Cohen et al., 2003).  Secondary cases were assumed to 
have the same resistance profile (i.e., the same treatment cost and mortality risk) as the 
index cases that generated them. 
 
Quality-Adjusted Life Years (QALYs) 
The model counts the number of QALYs lost to morbidity and mortality from 
ATBD.  It also counts QALY loss due to LTBI treatment.  The quality of life scale used 
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to assign weights to different health states for QALY calculations typically ranges from 0 
(death) to 1 (full health).  A QALY weight, therefore, represents the level of quality of 
life enjoyed by individuals in a particular health state.  However, it is possible to reverse 
the direction of the scale to focus on losses, rather than gains in quality of life.  In this 
analysis, weights were reversed to represent losses of healthy life.  Each weight 
represents the loss in health quality associated with each year/cycle spent in a given state, 
with 0 representing full health and 1 representing death, assumed to be the worst health 
state.  The difference between the two strategies therefore corresponds to a difference in 
QALY losses, which amounts to an incremental QALY gain.   
 
QALY Weights 
Few original studies have been undertaken to assess the loss in quality of life 
associated with various TB-related states.  Studies not conducted in the U.S. or Canada 
were excluded from the review as the results they report may be influenced by the 
context in which they were conducted and in which persons surveyed experience or 
perceive the disease in terms of clinical prognosis, ease of access to care, and social 
stigma. The utility weights used in this analysis are detailed in Table 20.  Like TB cases 
and deaths from TB, QALY losses were discounted based on how far in the future they 
were predicted to occur. 
 
 
 
 
	  	   131	  
Table 20: Weights used in QALY calculations  
Heath state Weight 
(per year) 
Assumptions about length of 
time in health state or timing 
of health event 
QALY loss 
given 
assumptions 
Source 
LTBI - 
Undiagnosed 
0  0 Assumption 
LTBI – Diagnosed, 
untreated 
0  0 Assumption 
Treatment for LTBI 
– No adverse 
reaction 
0.02  0.02 Tan, 2008 
Treatment for LTBI 
– Adverse reaction 
sufficient to 
warrant 
discontinuation 
0.1 For 1 month 0.0083 Marchand, 
1999 
Treatment for LTBI 
– Fatal adverse 
reaction 
0.1/0.9 0.1 for 2 weeks then 0.9 for 2 
weeks 
0.0384 Marchand, 
1999 
LTBI – Diagnosed, 
post-treatment 
0  0 Assumption 
Death from fatal 
adverse drug 
reaction during 
LTBI treatment 
1 Occurs mid-year 1 Marchand, 
1999 
ATBD – Drug 
sensitive – Treated 
- Non-fatal 
0.24 For one year 0.24 Guo, 2005 
ATBD – Drug 
sensitive 
Survival post 
treatment 
0  0 Assumption 
ATBD – Drug 
sensitive – Treated 
- Fatal 
0.24/0.9/1 0.24 for 3 months, then 0.9 for 2 
weeks in hospital then 1 for 10 
weeks lost to death 
0.2869 Marchand, 
1999 
Treatment for 
MDR TB – Non 
fatal 
0.24 For 2 years  0.4728 Guo, 2005 
Kittikraisak, 
2012 
Treatment for 
MDR TB - Fatal 
0.48/0.9/1 0.48 for 3 months, then 0.9 for 4 
weeks in hospital then 1 for 10 
weeks lost to death 
0.3409 Marchand, 
1999 
ATBD – MDR 
Survival post 
treatment 
0 Every year after disease 0 Assumption 
Death from drug-
susceptible TB or 
MDR TB 
1  1 Assumption 
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QALYs Lost to Mortality from ATBD 
The number of years of life prematurely lost to death from ATBD was calculated 
based on the age distribution of the infected cohort and the 2006 period life table in the 
following manner: 
1) The number of TST-positive patients (i.e., patients susceptible of developing, and 
dying from, ATBD) of each age was calculated.  Then, for each Markov cycle, 
2) The expected number of deaths from TB (risk of developing ATBD multiplied by 
the risk of dying from TB) for each one-year age stratum was computed. 
3) The expected number of deaths in each age stratum was multiplied by the number 
of years of life left for that age group at that point in time, to calculate the number 
of life years lost by each age stratum. 
4) The number of years lost during the given cycle was summed up across all age 
strata.  
5) The sum was divided by the total number of deaths across all age strata during the 
cycle, to calculate the average years of life lost for each death occurring during 
the cycle. 
6) Each year was then appropriately discounted. 
Since the QALY weight associated with death is 1, the number of years of life lost 
is also the number of QALYs lost by patients who terminate in the “Death after ATBD” 
health state.  The estimated number of QALYs lost due to a death from ATBD in each 
year/cycle in the Markov loop in the base case scenario (3% discount rate) is shown in 
Table 21 below.  QALY calculations for 0%, 5% and 8% discount rates are detailed in 
Appendix J. 
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Table 21: Number of QALYs lost to death from ATBD, by Markov cycle 
ATBD 
death in 
Cycle 
QALYs 
lost 
ATBD 
death in 
Cycle 
QALYs 
lost 
ATBD 
death in 
Cycle 
QALYs 
lost 
ATBD 
death in 
Cycle 
QALYs 
lost 
1 25.5 19 12.2 37 4.7 55 1.6 
2 24.5 20 11.6 38 4.4 56 1.5 
3 23.6 21 11.1 39 4.3 57 1.5 
4 22.7 22 10.5 40 4.0 58 1.3 
5 21.8 23 10.0 41 3.8 59 1.3 
6 20.9 24 9.5 42 3.5 60 1.2 
7 20.3 25 9.0 43 3.4 61 1.1 
8 19.5 26 8.5 44 3.2 62-63 1.0 
9 18.7 27 8.1 45 3.1 64-67 0.8 
10 17.9 28 7.8 46 2.8 68 0.7 
11 17.2 29 7.4 47 2.7 69-72 0.6 
12 16.5 30 7.0 48 2.5 73-74 0.5 
13 15.8 31 6.6 49 2.4 75-80 0.4 
14 15.1 32 6.4 50 2.2 81-85 0.3 
15 14.4 33 6.0 51 2.1 86-96 0.2 
16 13.8 34 5.6 52 1.9 97-98 0.1 
17 13.1 35 5.2 53 1.8   
18 12.6 36 5.1 54 1.8   
  
QALYs Lost to Fatal ADEs 
The number of years of life lost prematurely to INH hepatotoxicity was calculated 
based on the age distribution of the subgroup of patients who initiated treatment for 
LTBI, the age-related risk of fatal hepatotoxicity and life expectancy at different ages.  
This number was only computed for stage 0, as all deaths from hepatotoxicity are 
expected to occur during the treatment phase (first year) of the program.   The 
computation was as follows: 
1) The number of patients who initiated treatment for LTBI in each one-year age 
stratum was calculated.   
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2) The expected number of fatal hepatotoxicity cases was computed (probability of 
hepatotoxicity x fatality rate) for each age stratum. 
3) The expected number of deaths at each one-year age stratum was multiplied by 
the number of years of life left for this stratum, to calculate the total number of 
years of life lost to hepatotoxicity for each stratum. 
4) The number of years of life lost was summed up across all age strata. 
5) The sum was divided by the total number of expected deaths from hepatotoxicity 
across all age strata, to calculate the average number of years of life lost to 
hepatotoxicity per death. 
6) Each year was appropriately discounted.  
Since the QALY weight associated with death is 1, the number of years of life lost 
to hepatotoxicity is also the number of QALYs lost by patients who end up in the “Death 
from fatal adverse event” health state. This calculation resulted in an estimated number of 
QALYs lost to premature mortality from adverse drug events of 41.3 per death when 
undiscounted and 24.1 QALYs per death for a discount rate of 3% per year.  With 
discount rates of 5% and 8%, the losses resulting from a death from hepatotoxicity were 
17.3 and 12 QALYs, respectively.  
 
Cost-Effectiveness Criteria 
The ceiling ICER used to adjudicate cost-effectiveness in terms of QALY saved is 
set at $100,000.   
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Sensitivity Analysis 
To facilitate sensitivity analysis, all event probabilities, transition probabilities, 
cost and effect outcomes used in the tree were defined as variables. 
 
Deterministic Sensitivity Analysis 
I conducted one-way sensitivity analyses to ascertain the robustness of the results.  
A first series of sensitivity analyses evaluate the impact of four study design choices on 
the results.  They are: the study perspective (health system vs. societal perspective), the 
scope of health impacts (exclusion vs. inclusion of secondary transmission), the study 
time horizon and the discount rate.  Second, I evaluated the influence of four key aspects 
of the context in which interventions to control TB are implemented and evaluated: the 
prevalence of LTBI in the population screened, the prevalence of INH resistance among 
the infected, the cost of treating a case of ATBD, and the accuracy (sensitivity and 
specificity) of the Mantoux skin test.  Lastly, I evaluated various aspects of the TTT’s 
program performance, including program maturity, LTBI treatment initiation and 
completion, testing among low-risk patients, and screening costs. 
 
Probabilistic Sensitivity Analysis 
Probabilistic sensitivity analysis (PSA) was conducted.  First, variables so far 
defined as point estimates were replaced with distributions.  Then, to identify which 
variables to include in the PSA, a tornado diagram was generated.  A tornado diagram is 
“a set of one-way sensitivity analyses brought together in a single graph” (Treeage, 
2008).  For each variable analyzed, a horizontal bar is displayed in the diagram.  The 
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width of the bar represents the effect of the variable on the outcome (cost or health effect) 
measure of interest, by showing the range of expected values when the variable is varied.  
Variables are displayed in order of decreasing impact, which gives the diagram a funnel 
(“tornado”) shape.  
All variables in the model were included in the tornado diagram.  Ranges over 
which variables were set to vary in the PSA were derived from the dataset, from 
surveillance reports or from the literature, and are summarized in Appendix K.  Those 
variables that accounted for more than 1% of the total variation (across all variables) 
were retained for the PSA. 
In the PSA, I used Monte Carlo simulation (10,000 replications) from both the 
societal and the health system perspective, with values sampled from the probability 
distributions. Cost-effectiveness acceptability curves (CEAC), which represent the 
probability that TTT is the preferred option given different willingness-to-pay/cost-
effectiveness threshold values, were also derived.   
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CHAPTER 5 
RESULTS 
 
Cost–Effectiveness of TTT in Tennessee: Base-Case Scenario Results 
The base case scenario compared the expected cost and health outcomes 
generated by TTT and the baseline strategy of passive ATBD case finding (PACF) from a 
societal perspective over 25 years.  Compared to PACF, TTT should result in increased 
upfront costs, but should also generate health benefits in terms of prevented morbidity 
and mortality that would translate into savings over time.   
The results are shown in Table 22.  In this scenario, under PACF, a total of 303 
cases of ATBD are expected to occur over 25 years.  The total net present value (NPV) of 
ATBD diagnostic and treatment costs for these cases, given the 3% discount rate, would 
amount to US $36,724,998.  In contrast, a Targeted Testing and Treatment intervention 
as implemented in Tennessee would result in the occurrence of only 256 ATBD cases.  
While 47 ATBD cases would therefore be prevented (a 15.5% decrease), total costs under 
this strategy (i.e., intervention costs plus future ATBD diagnosis and treatment costs) 
would amount to US $37,114,935, a $389,937 (1%) increase compared to the baseline 
PACF strategy.  When reported in terms of QALYs, TTT would prevent the loss of 31 
QALYs (523 vs. 554) compared to PACF over 25 years.  The cost per additional QALY 
saved, or incremental cost-effectiveness ratio (ICER) would therefore be $12,579, well 
below the $100,000 threshold set for the study.  TTT is cost-effective and preferred over 
PACF. 
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Table 22: Base case scenario results 
 Total cost* Incremental cost (a) Effect* 
Incremental 
effect (b) 
ICER 
(a/b) 
PACF $36,724,998 
$389,937 
303 TB cases 
47 $8,297 
256 TB cases 
TTT $37,144,935 
554 QALYs lost 
31 $12,579 523 QALYs lost 
*per 100,000 persons screened 
ICER=Incremental Cost-Effectiveness Ratio 
PACF=Passive ATBD Case Finding 
QALY=Quality-Adjusted Life Years 
TTT=Targeted Testing and Treatment 
 
Impact of Study Design on Cost-Effectiveness Results 
The first set of sensitivity analyses concerned aspects of the study design that 
could have a determining impact on results and may therefore play an important role in 
the ultimate choice of an optimal strategy.  Two sensitivity analyses concerned the 
boundaries of the study, as they varied the definition of what is included as relevant costs 
and benefits.  The first looked at the impact on results of excluding patient costs from the 
analysis by shifting to a health system perspective.  The second sensitivity analysis 
concerned variation in the number of individuals who benefit from TTT through the 
prevention of secondary transmission. Two other sensitivity analyses relate to decision 
makers’ valuing of present vs. future costs and benefits: they concern the discount rate 
applied to future costs and health outcomes and the analytical horizon over which costs 
and outcomes are considered. 
 
Impact of Adopting a Health System Perspective  
Conducting cost-effectiveness analyses of medical and public health interventions 
from a societal perspective is recommended practice (Drummond, 2005).  It recognizes 
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the burden that the intervention of interest places on patients in terms of time/opportunity 
costs and out-of-pocket costs.  These are important to consider in the case of TTT, as they 
may determine whether patients complete their course of treatment, and thus whether the 
intervention yields any health benefits.  The societal perspective also takes into account 
the productivity losses associated with ATBD morbidity and the value of life lost to 
premature mortality, which are often invoked to justify TB elimination efforts.  Finally, it 
is the perspective that may best meet the information need of decision makers (such as 
the Tennessee Legislature) responsible for allocating resources across policy areas while 
being mindful of all stakeholders’ interests (including patients and the general public).  
However, because the cost of diagnosing and treating TB is largely borne by the public 
health sector, and the decision to implement different TB control strategies rests with 
public entities at the federal, state and local level, assessing the cost-effectiveness of TTT 
from a health sector perspective is also justified.   
Excluding patient costs should not affect health outcome calculations.  The 
number of TB cases and the QALY loss that occur under each strategy should therefore 
be the same as when the analysis was conducted from the societal perspective.  Total 
costs should decrease however, as excluding patient costs would affect both the cost of 
the intervention and future ATBD disease costs.  It is unclear a priori whether cost-
effectiveness should be expected to increase or decrease compared to scenarios based on 
a societal perspective: it would depend on whether the gap in cost between the two 
strategies increases or decreases once patient costs are excluded.  However, patient costs 
associated with premature mortality from ATBD include the value of life lost, measured 
in terms of lost productivity, which is a much larger value than intervention costs, even 
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with discounting.  Excluding these costs should therefore negatively affect the cost-
effectiveness of TTT relative to PACF, and cost-effectiveness should be harder to 
demonstrate from a health system perspective. 
Results are shown in Table 23.  With a 3% discount rate, total costs for the 
baseline strategy of PACF decrease to $7,815,635 over 25 years when patient costs are 
excluded.  Implementing TTT would result in total costs of $10,739,313, or an 
incremental cost of approximately $3 million.  Cost-effectiveness therefore decreases 
relative to the base case scenario.  The cost per additional case prevented ($64,310) and 
the cost per additional QALYs saved ($97,503) both increase several-fold compared to 
the base case scenario.  However, TTT remains the preferred strategy as the ICER is 
below the cost-effectiveness threshold of $100,000 per additional QALY set for the 
study.  
 
Table 23: Cost-effectiveness results from a health system perspective 
   TB cases QALYs 
 Total cost*  
Increm. 
cost (a) 
Effect* 
 
Increm. 
effect (b) 
ICER 
(a/b) Effect* 
Increm. 
effect (d) 
ICER 
(a/d) 
PACF $7,815,635 
$3,022,596 
303 
47 $64,310 
554 
31 $97,503  TTT $10,838,231 256 523 
* Per 100,000 persons screened 
PACF=Passive ATBD Case Finding 
TTT=Targeted Testing and Treatment 
QALY=Quality-Adjusted Life Year 
ICER=Incremental Cost-Effectiveness Ratio 
 
Impact of Secondary Transmission  
Beside including or excluding patient costs, another way to redefine the 
boundaries and scope of the study concerns the consideration of secondary cases that 
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occur as a result of the TB disease that would develop among cohort patients treated for 
LTBI, and that would also be prevented as a result of TTT’s administration to that cohort.  
The base case scenario included assumptions about the number and timing of secondary 
cases that would occur in a cohort of individuals with LTBI to account for tuberculosis’ 
externalities adequately.  However, modeling the dynamics of TB transmission is a 
complex endeavor, and the potential impact of the uncertainty in the transmission model 
on cost-effectiveness results bears investigating.  In a sensitivity analysis, the 
undiscounted number of secondary cases generated by each index case was varied 
between 0 and 1 in .01 increments; assumptions about the timing of their occurrence 
remained unchanged.  It was anticipated that cost-effectiveness would increase in step 
with the number of secondary cases.   
Results are reported from both the societal perspective and the health system 
perspective, and are in line with expectations.  When patient costs are taken into account 
(Table 24), TTT is cost-effective (ICER below $100,000/QALY saved) as long as it is 
assumed that at least 0.07 additional cases are generated by each index case.  From the 
more limited health system perspective (Table 25), each index case must result in the 
prevention of at least another 0.44 cases for TTT to be cost-effective.   
 
Table 24: Sensitivity analysis around the rate of secondary transmission – Societal 
perspective 
 Optimal strategy ICER/ add. QALY saved by TTT 
Secondary cases PACF TTT  
0.01 – 0.06 x  $130,322 - $100,507 
0.07 – 0.57  x $91,514 - $326 
≥0.58 Dominated x  
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Table 25: Sensitivity analysis around the rate of secondary transmission – Health 
system perspective 
 Optimal strategy ICER/ add. QALY saved by TTT 
Secondary cases PACF TTT  
0.01-0.43 x  $285,983 - $101,327 
0.44-1  x $97,785 - $48,311 
 
Table 26 summarizes the results obtained from the two perspectives, to highlight 
the range of values over which they come to the same conclusion regarding which 
strategy is optimal: if each index case generates less than 0.07 additional cases, both 
perspectives agree that PACF is the preferred strategy.  Similarly, if there can be 
agreement that secondary transmission represents more than 0.43 additional cases (as in 
the base case scenario), decision makers can safely agree that TTT is cost-effective, 
whether they decide to consider patient costs or not.  Table 26 also highlights the fact 
that, over a relatively broad range of values (0.07 to 0.43 additional cases per index case), 
TTT’s cost-effectiveness, and the decision on which strategy bears implementing, will 
very much depend on the perspective that decision makers decide to adopt. 
 
Table 26: Optimal strategy as a function of the rate of secondary transmission 
 Optimal strategy 
Secondary cases PACF TTT 
0.01 – 0.06 ¢n  
0.07 – 0.43 ¢ n 
0.44 – 1  ¢n 
¢ Health system perspective 
n Societal perspective 
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Impact of Varying the Discount Rate 
The next sensitivity analysis related to study design concerns variation in the 
discount rate to account for differences in stakeholders’ time preference and was 
performed from both the societal and the health system perspectives.  However, because 
NPVLE used as a value-of-life-lost proxy were available only for 3% and 5% discount 
rates, the only alternative scenario conducted from a societal perspective was for a 5% 
discount rate.  Alternative discount rates of 0 to 8% in 1 percentage-point increments 
were used in the sensitivity analysis around discount rates conducted from a health 
system perspective.  
On the cost side, changing the discount rate affects the cost of diagnosing and 
treating future ATBD cases; on the health effect side, it affects the number of ATBD 
cases and QALYs lost under each strategy.  It does not affect intervention costs (risk 
screening, LTBI testing and LTBI treatment), as they are all incurred in Year 0 and 
therefore not discounted.  Higher discount rates should result in a decrease in the net 
present value of future ATBD-related costs compared to the base case scenario.  
Intervention costs, which remain unaffected by discounting, would then come to 
represent an increasing proportion of total costs.  A higher discount rate also results in 
lower health outcomes (due to the lower net present value of future ATBD cases) and 
thus a lower denominator in the ICERs.  Therefore, the cost per unit of health gained 
should rise.  Lower discount rates would have the opposite effect of granting more weight 
to future health outcomes relative to the base case scenario (thus increasing the ICER 
denominator) and increasing the relative importance of future costs compared to 
intervention costs.  The ICER should decrease, showing improved cost-effectiveness. 
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When a 5% per year discount rate is used in the societal perspective scenario, 
TTT results in the prevention of 38 ATBD cases and a gain of 30 QALYs, and generates 
an increment of $1,889,040 in total costs (Table 27).  The incremental cost-effectiveness 
ratios are $49,712 per case prevented, and $62,968 per QALY saved (or five-fold the 
base-case ICER).  As expected, the cost per QALY saved increased with the rate 
increase, but TTT is still the preferred strategy since the ICER per QALY saved is well 
below the $100,000 threshold. 
 
Table 27: Cost-effectiveness of TTT with a 5% discount rate – Societal perspective 
 Total cost* Incremental cost (a) Effect* 
Incremental 
effect (b) 
ICER 
(a/b) 
PACF $26,629,149 
$1,889,040 
247 TB cases 
38 $49,712 
209 TB cases 
TTT $28,518,190 
541 QALYs lost 
30 $62,968 511 QALYs lost 
* per 100,000 persons screened 
ICER=Incremental Cost-Effectiveness Ratio 
PACF=Passive ATBD Case Finding 
TTT=Targeted Testing and Treatment 
QALY=Quality-Adjusted Life Years 
The results of the sensitivity analysis around the discount rate conducted from a 
health system perspective are also in line with expectations.  When costs and effects are 
undiscounted (0% rate), TTT prevents 68 cases of TB (442 occur under PACF, against 
only 373 under TTT) and saves an additional 36 QALYs, for an incremental cost of 
$2,234,698, or $62,075 per QALY saved (Table 28).  For a discount rate of 0% to 3%, 
TTT is the preferred strategy, with an ICER per QALY saved that ranges between 
$62,075 and $97,503.  When the discount rate is between 4% and 8% (and presumably 
for higher rates as well), PACF is preferred as the ICER per QALY saved rises above 
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$100,000.  Therefore decision makers’ time preference will very directly affect their 
assessment of the cost-effectiveness of TTT, and their choice of an optimal strategy. 
 
Table 28: Sensitivity analysis around the discount rate – Health system perspective 
 Optimal strategy ICER/ add. QALY saved by TTT 
Discount rate PACF TTT  
0 – 3%  x $62,075 - $97,503 
4% - 8% x  $105,269- $129,132 
 
Impact of Varying the Study’s Analytical Horizon 
Decisions regarding the study’s time horizon also address issues of time 
preference, and decision makers’ willingness to consider costs and outcomes that occur in 
the more or less distant future.  In the initial analysis, the cost and health impact of the 
strategies of interest are considered over an analytical horizon of 25 years to approximate 
the time span between Tennessee’s implementation of TTT and 2030, the date set for TB 
elimination in the United States.  Longer time spans, notably an analytical horizon equal 
to the cohort’s lifetime, have the advantage of providing a more comprehensive measure 
of costs and outcomes, especially since the risk of evolving from LTBI to ATBD 
increases in older age.  However, a longer analytical horizon also entails postulating that 
current conditions, such as the all-cause mortality rate, on which the model is based, will 
remain unchanged for an extended period of time.  A time span shorter than 25 years, on 
the other hand, eliminates the need to gamble on the persistence of trends over the long 
run.   
In a threshold analysis, I varied the analytical horizon from 1 year to 98 years 
(lifetime of the cohort) in 1-year increments.  I anticipated that TTT would appear less 
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attractive, compared to passive detection of ATBD cases, over shorter time spans, as less 
health benefits would be reaped while upfront intervention costs would remain the same.  
The results support the hypothesis that an inverse relationship exists between 
study horizon and TTT’s economic efficiency.  From a societal perspective (Table 29), if 
the analytic horizon is 12 years or less, PACF is the preferred strategy, as it is both less 
costly and more effective than TTT.  Over 12-15 years, TTT generates enough health 
benefits to be considered more effective than PACF, but the cost per additional QALY 
saved, although decreasing rapidly, remains prohibitive.  If decision makers are willing to 
consider the value of the intervention over a span of at least 16 years, TTT becomes cost-
effective, as the ICER drops below the $100,000 threshold.  Over the long term (≥32 
years), TTT is the dominant strategy. 
 
Table 29: Sensitivity analysis around the analytical horizon – Societal perspective 
 Optimal strategy ICER/ add. QALY saved by TTT 
Analytical 
horizon PACF TTT  
≤12 yrs. x Dominated  
13 – 15 yrs. x  $273,516 - $119,327 
16 – 31 yrs.  x $93,168 - $312 
≥32  Dominated x  
 
The overall trend is similar from a health system perspective, but it takes longer 
for TTT to demonstrate cost-effectiveness.  The ICER falls under $100,000 per additional 
QALY saved only after at least 25 years.  In addition, TTT is never dominant (Table 30).   
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Table 30: Sensitivity analysis around the analytical horizon – Health system 
perspective 
 Optimal strategy ICER/ add. QALY saved by TTT 
Analytical 
horizon 
PACF TTT  
1-11 yrs. x Dominated  
12-24 yrs. x  $1,157,658 - $101,662 
25-98 yrs.  x $97,503 - $52,127 
 
As for the rate of secondary transmission, there are ranges of value over which the 
societal and health system perspective come to a similar conclusion over the cost-
effectiveness of TTT.  PACF is the preferred strategy from both perspectives if both costs 
and health impact are considered over a relatively short term of less than 16 years (Table 
31).  Over the long term (more than 24 years), both perspectives agree that TTT is 
worthwhile.  Over the medium term (16-23 years), TTT is cost-effective when patient 
costs are considered, but from a health system perspective PACF will be preferred.  If we 
think of the analytical horizon as the time span left to decision makers before the target 
date set for the elimination of TB (2030), it is clear that the moment approaches when 
decision makers must favor PACF over TTT, even from a societal perspective.  
 
Table 31: Optimal strategy as a function of the analytical horizon 
 Optimal strategy 
Analytical horizon PACF TTT 
1 – 15 yrs. ¢n  
16 – 23 yrs. ¢ n 
≥24  ¢n 
¢ Health system perspective 
n Societal perspective	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Impact of Ecological Factors on Cost-Effectiveness Results 
The economic efficiency of the intervention is also influenced by a number of 
contextual factors related to the health system and to the nature of the TB epidemic in the 
population TTT targets. I, sensitivity analyses, I consider three such factors: the 
prevalence of LTBI in the screened population, the prevalence of resistance to INH 
among infected individuals and the cost of ATBD diagnosis and treatment. 
 
Impact of LTBI Prevalence in the Screened Population 
In the base case scenario, the prevalence of LTBI in the population screened and 
tested was estimated be 9.66%, based on Mantoux skin test results and the assumption 
that the test was perfectly sensitive and specific.  It is expected that prevalence of LTBI 
would influence the cost-effectiveness of TTT: cost-effectiveness should improved as 
prevalence rises, as screening and testing efforts, and the resources associated with those 
efforts, would identify a greater number of infected individuals who can benefit from 
preventive treatment. 
Results show that overall prevalence of LTBI must be at least 6% from a societal 
perspective (Table 37), and at least 10% from a health system perspective (Table 38), for 
TTT to be the preferred strategy.  In contexts where overall prevalence is 10% or higher, 
TTT is cost-effective whether it is evaluated from a societal or from a health system 
perspective.  Here again, it is over the intermediate range (6-9%) that the two 
perspectives differ. 
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Table 32: Sensitivity analysis around the prevalence of LTBI – Societal perspective 
 Optimal strategy ICER/ add. QALY saved by TTT 
LTBI 
prevalence 
PACF TTT  
1% - 5% x  ≥$109,757 
6%-10%  x $76,522 - $5,717 
≥11% Dominated x  
 
Table 33: Sensitivity analysis around the prevalence of LTBI – Health system 
perspective 
 Optimal strategy ICER/ add. QALY saved by TTT 
LTBI 
prevalence 
PACF TTT  
1%-9% x  $922,279– $100,347 
10%-30%  x $92,147 - $36,866 
 
Table 34: Optimal strategy as a function of LTBI prevalence 
 Optimal strategy 
LTBI prevalence PACF TTT 
1% - 5% ¢n  
6% - 9% ¢ n 
10% - 30%  ¢n 
¢ Health system perspective 
n Societal perspective 
 
Impact of Varying the Level of Resistance to INH Among Persons with LTBI 
LTBI treatment with INH is not effective at preventing ATBD in persons infected 
with a strain of tuberculosis that is resistant to INH.  Preventive therapy with other anti-
TB medications is available, but it requires prior knowledge that the patient is likely to be 
infected with an INH-resistant strain.  This information is available in the case of persons 
known to have been in contact with a drug-resistant case.  However, in this model we are 
assuming that the individuals screened for LTBI risk and infection are not recent 
converters and are not necessarily aware of when and how they were exposed to 
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tuberculosis.  Therefore, the model must account for situations in which, although 
patients are offered standard LTBI treatment, they are in fact infected with a strain of TB 
that is INH resistant.  The level of INH-resistance in the pool of infected persons should 
inversely affect cost-effectiveness: the provision of INH treatment to INH-resistant 
patients would represent a use of resources that does not generate any health benefits, as 
the risk of later evolving to ATBD would not be diminished. 
In a sensitivity analysis, the prevalence of drug resistance in the subpopulation of 
screened individuals that tested positive for LTBI was modified between 1% and 30% in 
1 percentage-point increments, as global surveillance reports indicate that the highest 
levels of INH resistance in the world, reported in Eastern Europe, average 33.5% 
(Jenkins, 2011).  I also assume that the ratio of INH-resistant cases in high risk and low 
risk patients remains constant at the level observed in the US in 2002-2006 (10.38% in 
the high risk group, 4.30% in the low-risk group, or 2.4:1).  Maintaining a constant ratio 
between the high-risk and low-risk groups’ rates of INH resistance implies that TB 
disease in the low-risk sub-group is influenced by the dynamics at work among the 
foreign-born and the global epidemic in general.  While prevalence of disease and 
resistance are higher among the foreign-born, there is a “spillover” effect when 
individuals with resistant infection acquired in countries where resistance is endemic 
develop TB in the US and transmit it to low-risk individuals such as the US-born.    
Results show that INH resistance does affect the choice of preferred strategy.  From a 
societal perspective (Table 40), TTT is the preferred strategy as long as the prevalence of 
INH resistance remains below 27% (a very high rate).  If resistance is prevalent in 3% or 
less of LTBI patients, TTT is both more effective and less costly than PACF. 
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Table 35: Sensitivity analysis around the prevalence of INH resistance – Societal 
perspective 
 Optimal strategy ICER/ add. QALY saved by TTT 
INH resistance PACF TTT  
≤3% Dominated x  
4% - 26%  x $463 - $97,742 
27% - 30% x  $109,428 - $157,235 
 
From a health system perspective (Table 41), TTT is cost-effective only as long as 
INH resistance rates remain below 11%.  Overall, the societal and health system 
perspective yield very similar results (Table 42) regarding the choice of optimal TB 
control strategy, but differ over the 6-10% range. 
 
Table 36: Sensitivity analysis around the prevalence of INH resistance – Health 
system perspective 
 Optimal strategy ICER/ add. QALY saved by TTT 
INH resistance PACF TTT  
1% - 10%  x $72,560 - $97,655 
11% - 30% x  $101,373 - $300,441 
 
Table 37: Optimal strategy as a function of INH resistance 
 Optimal strategy 
INH resistance PACF TTT 
1% - 5% ¢n  
6% - 10% ¢ n 
11% - 30%  ¢n 
¢ Health system perspective 
n Societal perspective 
 
Impact of Varying the Cost of ATBD Treatment 
As stated in the methods section, this research did not directly measure the cost of 
treating ATBD.  However, ATBD treatment cost is a key parameter in the model that 
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should influence cost-effectiveness results: the higher the cost of diagnosing and treating 
future cases of the disease, the more attractive an intervention to prevent its occurrence 
should be.   
To assess the impact of ATBD treatment costs on analysis results, two threshold 
analyses were conducted, around the cost of diagnosing and treating drug-susceptible 
(DS) and MDR TB, respectively.  The purpose of the threshold analyses was also to 
determine, first, whether there is a value for the cost of ATBD diagnosis and treatment 
above which TTT would be cost-effective (i.e., have an ICER below the thresholds set 
for the study); whether there is a threshold above which TTT is cost-saving; and whether 
DS and MDR TB diagnosis and treatment costs have the same impact on the cost-
effectiveness of TTT.  
 The cost of DS and MDR TB could arguably be modeled as correlated variables: 
DS and MDR TB are but two variations of the same condition, and the difference in their 
management is only a matter of intensity: drug resistant forms of the disease just require 
“more” of the same services.  However, the two differ enough to be thought of 
alternatively as two different conditions: multidrug-resistant TB requires different drugs 
(more expensive, and with different side-effects), not just more of them; patients with 
MDR TB must be managed at higher-level facilities while drug sensitive cases are in 
almost all instances managed by a local health department, hospital or private provider), 
and are more likely to undergo surgery.  Relaxing the assumption that the costs of DS and 
MDR TB co-vary eliminates the need to model the relationship between the two. 
The cost to diagnose and treat a case of DS TB was allowed to vary between 
$1,000 and $50,000 in $1,000 increments.  From a societal perspective, TTT is cost-
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effective over the entire range of values covered in the threshold analysis (Table 32).  
Even if the cost of diagnosing and treating a case of DS TB were as low as $1,000, the 
cost per QALY saved would be only $49,522.  TTT becomes the dominant strategy 
(more effective and less costly) when the per-case diagnosis and treatment cost reaches 
$34,000.  When cost-effectiveness is assessed from a health system perspective (Table 
33), TTT is cost-effective only if the cost of diagnosing and treating a case of ATBD is at 
least $24,000.  That is also the threshold value above which both perspectives align.  
Below $24,000, TTT is cost-effective only if patient costs are taken into account. 
 
Table 38: Sensitivity analysis around the cost of diagnosing and treating a case of 
DS ATBD – Societal perspective 
Cost of a case of DS ATBD 
Optimal strategy 
ICER/ add. QALY saved by TTT PACF TTT 
$1,000 - $33,000  x $49,522 - $264 
≥$34,000 Dominated x  
 
Table 39: Sensitivity analysis around the cost of diagnosing and treating a case of 
DS ATBD – Health system perspective 
Cost of a case of DS ATBD Optimal strategy ICER/ add. QALY saved by TTT 
PACF TTT  
$1,000 - $23,000 x  $134,447 - $100,582 
$24,000 - $50,000  x $99,042 - $59,020 
 
Table 40: Optimal strategy as a function of DS ATBD diagnostic and treatment cost 
 Optimal strategy 
Cost of a DS ATBD case PACF TTT 
$1K - $23K ¢ n 
$24K – $50K  ¢n 
¢ Health system perspective 
n Societal perspective 
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The cost of diagnosing and treating a case of MDR ATBD has hardly any impact 
on the cost-effectiveness of TTT.  This finding was common to both the societal (Table 
35) and the health system perspective (Table 36).  In spite of the wide range of value 
($5,000 to $100,000 in $1,000 increments) used in the threshold analysis, total costs for 
both interventions varied relatively very little.  As the total cost of TTT remained 
consistently lower than what would be incurred with PACF, TTT is the dominant strategy 
over the entire range of MDR TB cost values. 
Therefore, overall, uncertainty about the cost of diagnosing and treating a case of 
MDR TB has no impact on the cost-effectiveness of TTT and which TB control strategy 
should be preferred, whether one adopts a societal or a health system perspective. 
 
Table 41: Sensitivity analysis around the cost of diagnosing and treating a case of 
MDR TB – Societal perspective 
Cost of a case of DS ATBD 
Optimal strategy 
ICER/ add. QALY saved by TTT PACF TTT 
$5,000 - $100,000  x $11,812 - $12,883 
 
Table 42: Sensitivity analysis around the cost of diagnosing and treating a case of 
MDR TB – Health system perspective 
Cost of a case of DS ATBD Optimal strategy ICER/ add. QALY saved by TTT 
PACF TTT  
$5,000 - $100,000  x $96,737 - $97,807 
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Impact of Variation in Program Performance on Cost-Effectiveness Results 
This third set of sensitivity analyses seeks to identify what impact variation in 
program performance would have on economic efficiency.  
 
Variation in Performance Over Time 
Tennessee’s TTT program has been in place since 2001, and the dataset used for 
this study contains information for the 2002-2006 period.  Thus it provides an 
opportunity to consider whether economic efficiency improved as the program matured.  
On the one hand, the program could become more cost-effective over time, as health staff 
devised ways to better integrate new tasks like the risk assessment, which required that 
staff “think TB” even as they meet patients seeking entirely unrelated services such as 
childhood immunizations or primary care, into existing activities.  Over time, the staff 
may also have honed strategies to convince high-risk persons to accept testing, low-risk 
persons that they do not need it, and LTBI patients that they should undertake treatment 
and complete it.  On the other hand, depending on how much (or how little) turn over 
there is in the population served by any given public health clinic, it may eventually 
become harder and harder to find high-risk individuals that have not been previously 
screened and offered testing and treatment.  In addition, if screening-related tasks 
complicate or slow down other routine activities, they may eventually be performed less 
intensively once the initial push for implementation subsides.  Risk screening’s yield 
could therefore stagnate or decrease, as would cost-effectiveness. 
Using annual estimates for the percentage of screened persons found to be at 
high-risk, persons who received a TST, TSTs read and TST positives, patients started on 
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LTBI treatment and patients who completed treatment (Appendix K), the model was run 
separately for each year in the 2002-2006 time period.   
Results are detailed in Table 43 (societal perspective) and Table 44 (health system 
perspective).  Total and incremental costs fluctuated relatively little from year to year and 
relative to the base case scenario, but variation in health outcomes was substantial: the 
number of ATBD cases prevented ranges from 30 to 56, and the number of QALYs saved 
from 15 to 51.  As a result, cost-effectiveness varied widely as well.  From a societal 
perspective, TTT was cost-effective four out of five years, the exception being 2003 
when the ICER per QALY saved was above $100,000.  Out of those four years, TTT was 
three times the dominant strategy.  When patient costs are excluded, TTT was the 
preferred strategy only three out of five years.  However, no time dependent trend was 
noticeable either in terms of costs, effects, or cost-effectiveness: for example, TTT went 
from being the dominant strategy in 2002 to not being cost-effective in 2003 and back to 
dominance in 2004.  Therefore the results do not support either hypothesis about a 
positive or negative relationship between program maturity and economic efficiency.  
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Table 43: Variation in cost-effectiveness over time – Societal perspective 
   TB cases QALYs 
Strategy Cost* Increm. cost Effect* 
Increm. 
effect 
ICER 
 Effect* 
Increm. 
effect 
ICER 
 
2002    
PACF $34,424,383 ($178,568) 286 49 - 522 41 - TTT $34,602,951 237 481 
2003     
PACF $33,910,327 $2,020,052 280 30 $67,335 512 15 $134,670 TTT $35,930,379 250 497 
2004    
PACF $31,680,928 ($10,589) 262 42 - 478 43 - TTT $31,670,339 220 436 
2005    
PACF $38,783,988 (1,098,582) 320 56 - 585 51 - TTT $37,685,407 264 534 
2006    
PACF $39,053,471 972,181 322 38 $25,584 590 18 $54,010 TTT $40,025,652 284 572 
* Per 100,000 persons screened 
PACF=Passive ATBD Case Finding 
TTT=Targeted Testing and Treatment 
ICER=Incremental cost-effectiveness ratio 
 
Table 44: Variation in cost-effectiveness over time – Health system perspective 
   TB cases QALYs 
Strategy Cost* Increm. cost Effect* 
Increm. 
effect 
ICER 
 Effect* 
Increm. 
effect ICER 
2002    
PACF $7,364,031 $2,889,650 286 47 - 522 29 - TTT $10,253,681 239 493 
2003     
PACF $7,216,630 2,972,618 280 30 $99,087 512 15 $198,175 TTT $10,189,248 250 497 
2004    
PACF 6,725,291 2,755,169 261 42 - 477 43 - TTT 9,480,460 219 434 
2005    
PACF 8,253,819 (2,689,712) 320 56 - 585 51 - TTT 10,943,531 264 534 
2006    
PACF 8,311,169 2,824,417 322 38 $74,327 590 16 $176,526 TTT 11,135,586 284 574 
* Per 100,000 persons screened 
PACF=Passive ATBD Case Finding 
TTT=Targeted Testing and Treatment 
ICER=Incremental cost-effectiveness ratio 
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Impact of Program Activities  
Several analyses were run to assess how key aspects of program performance 
can affect cost-effectiveness.  I focused on three performance measures: the testing rate 
in low-risk patients, and the LTBI treatment initiation and completion rates because 
they relate directly to the three goals the TN TB Control Program had set for the TTT 
initiative: initiating treatment in 75% of TST+ patients, ensuring that 75% of patients 
on treatment completed their course of antibiotics, and skin-testing no more than 20% 
of low-risk patients.  
Increasing treatment initiation and treatment completion among infected 
individuals should both result in the prevention of more ATBD cases.  However, 
increased completion should have a greater impact, as it would directly translate into 
additional cases prevented: since the model assumes that partial completion of treatment 
(less than 80% of recommended doses) provides no protection, simply increasing 
treatment initiation results in a less than proportional preventive impact, as a percentage 
of those new initiations (assumed to be the same as that observed in the base case) will 
not complete treatment, and therefore will reap no health benefits.  Increased treatment 
initiation and completion should also increase costs, by adding to intervention costs, but 
this increase may be partly offset by savings associated with decreased morbidity and 
mortality.  Decreasing the proportion of low-risk individuals who are tested should bring 
about a decrease in the resources spent on patients among whom testing yields much 
fewer positive results, reflected in lower intervention costs.   
The impact of each of the three performance measures was assessed in isolation, 
from both the societal and the health system perspectives.  For simplicity, it was assumed 
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that all other parameters in the model remained the same, and notably that no additional 
resources would be expended (above and beyond the level recorded in the base case 
scenario) to improve performance.  
 
LTBI Treatment Initiation Rate 
The treatment initiation rate was varied between 1 and 100% in 1 percentage 
point increments for all categories of patients (high and low risk, HIV positive and HIV 
negative) found to be infected through LTBI testing.  When patient costs are taken into 
account (Table 45), results show that at least 26% of patients must initiate treatment for 
TTT to be cost-effective.  Below that level, TTT prevents ATBD cases and saves 
QALYs, but its cost per QALY saved is prohibitive.  When more than 57% of patients 
begin treatment, TTT becomes the dominant strategy, as it also generates savings 
compared to PACF.  From a health system perspective however (Table 46), at least 53% 
of patients must begin treatment for TTT to be cost-effective.  Reaching the 75% 
treatment initiation goal would therefore ensure that TN’s implementation of TTT is a 
cost-effective choice whether it is evaluated from a societal or a health system 
perspective (Table 47).   
 
Table 45: Sensitivity analysis around the treatment initiation rate – Societal 
perspective 
 Optimal strategy ICER/ add. QALY saved by TTT 
Initiation rate PACF TTT  
1% - 25% x  $4,272,185 - $106,761 
26% - 57%  x $99,158 - $652 
≥58% Dominated x  
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Table 46: Sensitivity analysis around the treatment initiation rate – Health system 
perspective 
 Optimal strategy ICER/ add. QALY saved by TTT 
Initiation rate PACF TTT  
1% - 52% x  $1,167,796 - $100,785 
53% - 100%  x $97,230 - $45,927 
 
Table 47: Optimal strategy as a function of the LTBI treatment initiation rate 
 Optimal strategy 
Initiation rate PACF TTT 
1% - 25% ¢n  
26% - 52% n ¢ 
53% - 100%  ¢n 
¢ Health system perspective 
n Societal perspective 
 
 
LTBI Treatment Completion Rate 
The treatment completion rate was varied between 1% and 100% in 1 percentage 
point increments for all categories of LTBI patients who initiated treatment.  From a 
societal perspective, at least 44% of patients must complete treatment for TTT to become 
cost-effective.  If treatment completion rates are below 29%, PACF is not only less 
costly, it also generates a lesser QALY loss.  On the other hand, if the completion rate 
rises above 61%, TTT becomes the dominant strategy, saving both QALYs and 
resources.  From a health system perspective, TTT is also dominated when completion 
rates are below 29%, and it does not become cost-effective unless at least 58% of patients 
complete their course of treatment.  As for treatment initiation, meeting the 75% 
treatment completion goal would ensure that TTT is considered cost-effective both from 
a societal and a health system perspective. 
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Table 48: Sensitivity analysis around the treatment completion rate – Societal 
perspective 
 Optimal strategy ICER/ add. QALY saved by TTT 
Completion rate PACF TTT  
1% - 28% x Dominated  
29% - 43% x  $2,589,767 - $100,653 
44% - 61%  x $84,274 - $1226 
≥62% Dominated x  
 
Table 49: Sensitivity analysis around the treatment completion rate – Health system 
perspective 
 Optimal strategy ICER/ add. QALY saved by TTT 
Completion rate PACF TTT  
0% - 28% x Dominated  
29% - 57% x  $3,381,073 - $101,051 
58% - 100%  x $97,389 - $32,826 
 
Table 50: Optimal strategy as a function of the LTBI treatment completion rate 
 Optimal strategy 
Completion rate PACF TTT 
1% - 43% ¢n  
43% - 57% ¢ n 
58% - 100%  ¢n 
¢ Health system perspective 
n Societal perspective 
 
LTBI Testing Rate Among Low-Risk Patients 
The testing rate among low-risk patients was varied between 1 and 100% in 1 
percentage point increments.  From a societal perspective that includes patient costs, TTT 
remains cost-effective no matter what proportion of low-risk patients are tested for LTBI.  
If the 20% goal adopted by the program were met, TTT would actually be both more 
effective and less costly than PACF.  From the health system perspective, TTT remains 
cost-effective only as long as testing among low-risk patients is below 82%.  Once this 
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threshold is reached however, further decreasing the testing rate has little impact on cost-
effectiveness from this perspective: a decrease in testing from 81% to 1% would only 
decrease the ICE by approximately 2,000 or 8%. 
 
Table 51: Sensitivity analysis around the LTBI testing rate in low-risk individuals – 
Societal perspective 
 Optimal strategy ICER/ add. QALY saved by TTT 
Testing rate PACF TTT  
1% - 21% Dominated x  
22% - 100%  x $59 - $23,490 
 
Table 52: Sensitivity analysis around the LTBI testing rate in low-risk individuals – 
Health system perspective 
 Optimal strategy ICER/ add. QALY saved by TTT 
Initiation rate PACF TTT  
1% - 81%  x $91,909 - $99,868 
82% - 100% x  $100,005 - $102,462 
 
Table 53: Optimal strategy as a function of the LTBI testing rate in low-risk 
individuals 
 Optimal strategy 
Initiation rate PACF TTT 
1% - 81%  ¢n 
82% - 100% ¢ n 
¢ Health system perspective 
n Societal perspective 
 
 
Impact of the Mantoux Test’s Characteristics  
To construct a cost-effectiveness model in line with the assumptions made when 
the effectiveness and yield of the Tennessee’s TTT program was evaluated (Caine, 2012), 
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the base case scenario assumed that the Mantoux skin test result accurately reflected 
patients’ actual LTBI infection status.  While there is no gold standard test (i.e., no test 
that is 100% sensitive and specific) for the diagnosis of latent TB infection, the Mantoux 
test is a relatively “good” test.  While it cannot distinguish between a reaction caused by 
LTBI and one caused by previous exposure to the BCG vaccine, the vaccine is usually 
administered in early childhood and its impact wanes relatively quickly.  The Mantoux 
test also fails to distinguish between LTBI and infection by a Non-Tuberculous 
Mycobacteria (NTM).  However, it has been clearly shown that reactions due to a NTM 
tend to be much smaller (1-2 mm) than those considered positive for LTBI.  In addition, 
guidelines concerning interpretation of the test’s results are designed to maximize the 
test’s sensitivity and specificity: cut-off points for positivity vary according to the 
likelihood of infection and patients’ likelihood of responding to the test.  For example, 
since HIV-infected individuals tend to have a weaker immune reaction to tuberculin, the 
threshold for positivity is set lower in HIV-positive patients (5 mm) to avoid false 
negative results.  On the other hand, in persons with no known risk factor for TB 
infection, the bar is set higher (15 mm) to avoid false positive results.  While these 
considerations support the assumption made in the base case scenario that the Mantoux 
test is 100% specific and sensitive, it is still important to consider whether varying from 
this assumption would significantly affect TTT’s cost-effectiveness.   
To determine the extent to which the decreased specificity (i.e., the risk of false 
positive results) has an impact on cost-effectiveness, I vary the specificity of the test from 
1 to 100% in 1-percentage point increments.  Decreased specificity of the Mantoux test 
should bring about a decrease in cost-effectiveness: false positive results trigger 
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unnecessary LTBI treatment that result in an increased use of resources.  The increased 
cost is not counterbalanced by a gain in health benefits in terms of ATBD cases 
prevented, since the patients treated are not infected, and can even increase QALY loss as 
unnecessarily treated patients can experience side effects.   
Results show that, from a societal perspective (Table 54), if the TST incorrectly 
returns a positive result for 8% of more of non-infected patients (i.e., ≤92% specificity), 
TTT is both more costly and less effective than PACF.  If the test is 93 to 95% specific, 
PACF is still the preferred strategy, because the cost per additional QALY saved through 
TTT remains high ($843,633 and $131,660).  Once specificity reaches 96%, TTT is cost-
effective, and the ICER decreases rapidly with every percentage point gain in specificity.   
 
Table 54: Sensitivity analysis around the specificity of the Mantoux skin test – 
Societal perspective 
 Optimal strategy ICER/ add. QALY saved by TTT 
Specificity PACF TTT  
1% - 92% x Dominated  
93% - 95% x  $843,633 – $131,660 
96% - 100%  x $80,804 - $12,579 
 
From a health system perspective (Table 55), the range of specificity values over 
which TTT is cost-effective, all other things being equal, is much narrower: the Mantoux 
skin test must identify 100% of infected individuals correctly for the ICER per additional 
QALY saved to fall under the $100,000 threshold.  The two perspectives agree that if the 
Mantoux skin test is less than 96% specific, PACF is the preferred strategy (Table 56). 
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Table 55: Sensitivity analysis around the specificity of the Mantoux skin test – 
Health system perspective 
 Optimal strategy ICER/ add. QALY saved by TTT 
Specificity PACF TTT  
1% - 92% x Dominated  
93% - 99% x  $1,932,477 - $116,402 
100%  x $97,503 
 
Table 56: Optimal strategy as a function of the specificity of the Mantoux skin test  
 Optimal strategy 
Sensitivity PACF TTT 
1%- 95% ¢n  
96% - 99% n ¢ 
100%  ¢n 
¢ Health system perspective 
n Societal perspective 
 
I also varied the test sensitivity, i.e., its ability to identify truly infected 
individuals.  Results show that TTT is the preferred strategy as long as the Mantoux skin 
test detects at least 58% of infected individuals (Table 57).  From a health system 
perspective however, the Mantoux skin test must perform perfectly for TTT to be cost-
effective (Table 58).  At 97%-99% sensitivity, the ICER for TTT hovers closely around 
the $100,000 cost-effectiveness threshold.  The ratio drops below $100,000 only when 
sensitivity is 100%. 
 
Table 57: Sensitivity analysis around the sensitivity of the Mantoux skin test – 
Societal perspective 
 Optimal strategy ICER/ add. QALY saved by TTT 
Sensitivity PACF TTT  
0% - 3% x Dominated  
4% – 57% x  $3,530,645-$105,689 
58% - 100%  x $98,000 - $12,579 
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Table 58: Sensitivity analysis around the sensitivity of the Mantoux skin test for 
LTBI – Health system perspective 
 Optimal strategy ICER/ add. QALY saved by TTT 
Sensitivity PACF TTT  
0% - 3% x Dominated  
4% - 99% x  $2,768,867 - $100,665 
100%  x $97,503 
 
Table 59: Optimal strategy as a function of the sensitivity of the Mantoux skin test 
 Optimal strategy 
Sensitivity PACF TTT 
1% - 100%  ¢n 
¢ Health system perspective 
n Societal perspective 
 
Risk Screening Cost 
In the base case scenario, screening for LTBI risk was modeled as a 20-minute 
encounter between a public health nurse and a patient visiting their local public health 
clinic.  While the great majority of the people assessed for LTBI risk in Tennessee were 
screened at a clinic, the TB program also reached out to high-risk groups where they 
work or congregate to screen for risk and perform skin testing.  TST-positive persons 
were then encouraged to visit the public health department to continue the evaluation 
process.  Although no cost data was collected, it is likely that these efforts to actively 
seek high-risk persons consumed more resources (notably in terms of staff time and 
transportation to the community sites) than clinic-based risk screening.  They may also 
yield greater benefits (by increasing, for instance, the percentage of patients whose skin 
test result is read and recorded during the nurse’s return visit to the community site, 
provided that those with positive skin tests did comply with follow-up instructions).  
Unfortunately, patients screened for risk at a clinic and those reached at a community site 
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cannot be differentiated in the PTBMIS database or in the dataset used for this analysis.  
Therefore, it is not possible to compare the testing rates, treatment initiation rates and 
treatment completion rates, hence the cost-effectiveness, achieved in the two settings.  
However, it is possible to conduct a sensitivity analysis around the per-person-screened 
cost of administering the Risk Assessment Tool to show how screening costs affect 
TTT’s cost effectiveness.  It is expected that cost-effectiveness would be negatively 
affected as screening costs increase, since total intervention costs would rise while 
effectiveness would remain unchanged.  Knowing whether there is a threshold for 
screening costs above which TTT ceases to be cost-effectiveness, would be useful to 
decision makers trying to determine what additional amount of resources they could 
possibly dedicate to risk screening, holding LTBI testing and treatment costs constant.   
In the base case scenario, the risk screening cost was $11.66 per patient screened.  In the 
threshold analysis, the per-patient cost of administering the RAT was varied between $5 
and $100 in $1 increments.  Screening costs affect cost-effectiveness as expected.  From 
a societal perspective (Table 60), TTT is the preferred strategy as long as the cost of 
administering the risk assessment tool remains below $39 per person.  From this 
viewpoint, the per-capita amount of resources dedicated to risk screening could be tripled 
while the cost-effectiveness of TTT would be preserved.  However, from a health system 
perspective (Table 61), TTT ceases to be cost-effective once risk screening costs amount 
to more than $12 per person, a threshold that is only minimally higher than the value used 
in the base case scenario. 
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Table 60: Sensitivity analysis around the cost of LTBI risk screening – Societal 
perspective 
 Optimal strategy ICER/ add. QALY saved by TTT 
Cost PACF TTT  
$5 -$7 Dominated x  
$8 -$38  x $772 - $97,546 
$39 -$100 x  $100,772 - $297,546 
 
Table 61: Sensitivity analysis around the cost of LTBI risk screening – Health 
system perspective 
 Optimal strategy ICER/ add. QALY saved by TTT 
Cost PACF TTT  
$5 - $12  x $76,019 - $98,600 
$13 - $100 x  $101,826 - $382,471 
 
Table 62: Optimal strategy as a function of the cost of LTBI risk screening  
 Optimal strategy 
Cost PACF TTT 
$5 -$12  ¢n 
$13 - $38 ¢ n 
$39 - $100 ¢n  
¢ Health system perspective 
n Societal perspective 
 
 
Results of the Probabilistic Sensitivity Analysis 
With the exception of annual program performance, the deterministic sensitivity 
analyses (DSA) conducted thus far aimed at identifying value thresholds around which 
the choice of an optimal strategy for TB elimination would change.  Therefore, for each 
variable considered in DSA, broad ranges of value (e.g., 0.1 to 1 for sensitivity and 
specificity) were considered.  Probabilistic sensitivity analysis on the other hand was 
conducted to assess the impact that the combined uncertainty in key parameters would 
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have on cost-effectiveness results.  Overall, the value ranges considered in PSA were 
much narrower than for DSA, and sought to reflect plausible values based on the 
Tennessee experience and the literature. 
Both models (societal perspective and health system perspective) were subjected 
to probabilistic sensitivity analysis using Monte Carlo simulation with 10,000 iterations.  
The variables for which point estimates were replaced with distributions in the PSA are 
listed in Table 63.  These lists were compiled based on the results of the deterministic 
sensitivity analyses and a tornado diagram that included all variables used in the model.  
The scatterplots in Figure 13 and Figure 14 are graphical representations of the 
PSA results.  Each dot on the cost-effectiveness plane represents the expected 
incremental cost and incremental effectiveness obtained in one iteration of the Monte 
Carlo simulation.  Each scatterplot also shows the 95% confidence ellipse, i.e. the region 
in which, in repeated sampling, the point representing the "true" values of incremental 
cost and incremental effect 95% percent of the time, would fall.  The dashed angled line 
represents the cost-effectiveness threshold of $100,000 per QALY. 
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Table 63: Variables replaced with distributions in the Monte Carlo PSA 
Parameter Point estimate Range 
Societal 
perspective 
Health system 
perspective 
Cost of diagnosing and 
treating a case of DS 
ATBD 
$25,000 $10,000 - $50,000 x x 
Cost of risk screening $11.66 $8.75 - $14.58 x x 
Productivity losses 
associated with DS 
ATBD 
 $11,385 - $18,975 x  
Transmission / 
Secondary cases 0.46 0.345 – 0.575 x x 
LTBI prevalence 9.4% 5% - 20% x x 
INH resistance 
prevalence 9.66% 4% - 15% x x 
HIV prevalence 0.77% 0.58% - 0.89% x x 
Testing rate in high-risk 
group 81.55% 76% - 85.15% x x 
Testing result reading 
rate in high-risk group  82.49% 78.25% - 82.98% x x 
Treatment start rate in 
HIV-positive high-risk 
group 
0.5769 33.33% - 83.33% x x 
Treatment start rate in 
HIV-negative high risk 
group 
52.06% 45.25% - 58.19% x x 
Treatment completion 
rate in HIV-positive 
high risk group 
53.55% 40% - 70% x x 
Treatment completion 
rate in HIV-negative 
high risk group 
57.97% 52% - 62.98% x x 
ATBD DS fatality rate 6.13% 4.59% - 7.66% x x 
Test sensitivity 98% 95% - 100% x x 
Test specificity 91% 0.80% - 99% x x 
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Figure 11: PSA scatterplot – Societal perspective 
 
The scatterplots illustrate at a glance how iteration results are distributed over the 
cost-effectiveness plane.  Table 63 summarizes the same results in quantitative terms.  
Area I in the lower right quadrant represents instances when TTT is dominant: it is both 
more effective and less costly.  In the PSA conducted from a societal perspective (Figure 
13), 8.9% of the Monte Carlo replications fall in this area.  The upper right quadrant is 
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divided into two by the $100,000 WTP line.  The area under the line represents iterations 
where TTT is both more effective and more costly than PACF, but the ICER per QALY 
saved remains below $100,000, which makes TTT cost-effective and the optimal 
strategy.  From the societal perspective, this combination of results occurs only 10.19% 
of the time.  The area of the upper right quadrant that is above the WTP threshold line 
(between the WTP line and the upper end of the y-axis) also contains PSA iterations that 
are more costly and more effective than PACF, but that result in an ICER that is above 
$100,000.  This is the case in 13.04% of iterations.  In the upper left quadrant fall 
instances when model results show that TTT yields both higher cost and lower 
effectiveness, and PACF is the dominant strategy.  A majority of iterations in the societal 
perspective PSA (65.84%) met these criteria. A very small proportion of iterations (<1%) 
yield both lower costs and lower effectiveness (lower-left quadrant).  Overall, given the 
range of values used in the PSA, and the cost-effectiveness threshold of $100,000 per 
additional QALY saved, TTT is the preferred strategy only 20.47% of the time. 
 
Table 64: Distribution of Monte Carlo iteration results across areas of the cost-
effectiveness plane 
Area IE IC ICER % of iterations Societal 
perspective 
Health system 
perspective 
I >0 <0  10.28% 0% 
II >0 >0 <$100,000 10.19% 0.56% 
III >0 >0 >$100,000 13.04% 20.82% 
IV <0 >0  65.84% 78.62% 
V <0 <0  0.34% 0% 
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Figure 12 adds further information concerning the generalizability of the model results.  
It represents the cost-effectiveness acceptability curves (CEAC) for TTT and PACF at 
different willingness to pay levels.  While the PSA results described so far show the 
likelihood that TTT is the preferred strategy when the cost-effectiveness threshold is 
$100,000, the CEAC graph shows the likelihood that TTT would be the optimal strategy 
over a range of WTP levels ($10,000 to $200,000 per additional QALY saved).  Each 
graph includes two curves, one for each strategy.  The x-axis represents the different 
willingness to pay levels increasing from left to right.  For each WTP level, the 
corresponding point on the curves represents the probability (read on the y-axis), 
according to the Monte Carlo simulation results, that the strategy would be the optimal 
choice.  Results show that even if WTP were twice as high ($200,000), TTT would be the 
preferred strategy only about 25% of the time. 
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Figure 12: Cost-effectiveness acceptability curve – Societal perspective  
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Figure 13: PSA scatterplot – Health system perspective 
The scatterplot corresponding to the PSA conducted from the health system 
perspective is displayed in Figure 13.  The likelihood that the model results fall in those 
areas of the cost-effectiveness plane that represent situations in which TTT is the 
preferred strategy (areas I and II) is much lower (Table 53) than when the analysis was 
conducted from a societal perspective (less than 1 percent).  Once again, in the majority 
of cases, TTT will prove less effective and more costly than PACF.  The cost-
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effectiveness acceptability curve displayed in Figure 14 shows that even if decision 
makers’ willingness-to-pay for health gains doubled to $200,000, TTT would be the 
preferred TB control alternative less than 5% of the time.  
 
Figure 14: Cost-effectiveness acceptability curve – Health system perspective 
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CHAPTER 6 
DISCUSSION AND IMPLICATIONS 
 
Summary of Study and Findings 
This study sought to contribute to knowledge on TB control strategies by 
palliating some of the limitations noted in the existing literature on TB prevention.  The 
model used a societal perspective that included patient costs in order to provide a more 
comprehensive evaluation of the economic impact of ATBD and its prevention, which 
may be of greater use to decision makers in charge of allocation resources across policy 
areas.  Results corresponding to the more limited health system perspective were also 
reported, as this viewpoint may better meet the information needs of stakeholders within 
the health system, and notably the TB Control Program.  The study also made sure to 
model the costs and probabilities of all relevant components of the Targeted Testing and 
Treatment approach, from risk screening, through testing, to treatment, thus considering 
the cost implications of casting a wide net to identify persons with LTBI within the 
general population of public health clinic patients.  Finally, the study aimed to take into 
account factors that would dampen the efficacy of TTT, such as the presence of INH 
resistance in the target population, and the limitations of the Mantoux tuberculin skin test.   
The results of the base case scenario, which was designed to reflect the most 
reasonable assumptions about the costs and impact of the Tennessee TTT initiative, show 
that TTT was very cost-effective relative to what would have been observed with PACF, 
as the cost per QALY saved was only $12,579 from a societal perspective and $97,503 
from a health system perspective.  However, deterministic sensitivity analyses 
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highlighted the important impact that variation in key parameters would have on cost-
effectiveness, and identified value thresholds that affected the choice of optimal policy.  
Finally, probabilistic sensitivity analysis showed that when uncertainty around influential 
parameters is taken into account, the likelihood that TTT would be cost-effective is low 
overall.  While the study has limitations and caveats are in order, the findings have 
important implications for research, for the Tennessee TB Control Program, and for the 
larger policy debate on TTT and on TB elimination. 
 
Caveats, Limitations and Implications for Future Research 
The encouraging findings in the base case scenario were obtained even though 
conservative assumptions were made throughout the model to avoid biasing the analysis 
in favor of TTT.  All persons identified as having been contacts to an active TB case were 
excluded from the analysis, to avoid including contacts to recent index cases, who are 
entered into the same program database as patients screened for LTBI risk.  These 
patients are at higher risk of being infected with LTBI.  Their inclusion would bias the 
estimate of LTBI prevalence in clinics’ general population.  It is conceivable that some of 
the individuals that listed “contact to a ATBD” case as a risk factor in the database were 
not part of a recent contact investigation conducted by the Tennessee Department of 
Health, but had been labeled so because they reported during the risk assessment that, at 
some point in the past, a parent or relative of theirs had had TB.  Including the contacts in 
the study population would have resulted in a higher percentage of patients meeting the 
definition of being at high risk, and having a positive skin test reaction.  It would also 
have increased the proportion of patients who initiated and completed LTBI treatment, 
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and improved cost-effectiveness.  However, all persons who indicated that they were 
health care workers at risk of exposure, a group in which the rate of TST positivity is 
closer to the rate in the general population than it is to the rate observed in other high-risk 
groups, were also excluded.  Their inclusion would have had the opposite effect of 
decreasing cost-effectiveness.  To assess whether, overall, my cohort selection choices 
biased the results against TTT, the estimated number of prevented ATBD cases was 
recalculated using a dataset that did include contacts and health care workers.  The results 
were not significantly different from the original calculations (data not shown), as the 
impact of including one group cancelled that of including the other. 
Assuming that none of the patients with LTBI were recently infected, and that 
they had therefore a decreased risk of developing active TB disease, was another 
conservative assumption.  Demographic information collected at the time of the screening 
shows that 46% of the foreign-born patients had been in the United States for less than 2 
years.  They may have been infected relatively recently, and the model may have 
underestimated both the number of ATBD cases expected in the absence of TTT, and the 
number of cases prevented by LTBI treatment.  Further analysis could adjust the risk of 
evolving from LTBI to ATBD of the Tennessee cohort to take into account not only 
subjects’ age at detection, but also the number of years that they had been in the US at the 
time of the screening.   
The choice of the human capital approach for valuing life lost to premature 
mortality from ATBD and adverse reactions to LTBI treatment was also conservative.  
This estimate is used primarily in the calculation of societal costs.  The human capital 
approach measures the value of life in terms of productivity, operationalized as the net 
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present value of lifetime earnings.  Alternative approaches that are based on revealed 
preferences or contingent valuation tend to produce larger estimates.  Federal agencies 
that perform cost-benefit analyses to determine the economic impact and acceptability of 
proposed legislation routinely use these higher numbers: the Department of 
Transportation (DOT) uses a value of 3 million, and the Environmental Protection 
Agency (EPA) a mean value of 6.3 million and observers have noted that “every 
regulation issued by the EPA that spent less than 8 million to save a life has been 
approved” (Brannon, 2004).  Using similar values would improve the cost-effectiveness 
of TTT, perhaps even to the point where it would consistently save costs compared to 
PACF, however the study would then be out of step with standard methodological 
practices in the health field.   
This study strove to use as much data as possible from the Tennessee TTT 
initiative, to reflect better the level of performance that can be expected in routine 
programmatic conditions.  However, not all key model parameters could be obtained 
from the PTBMIS dataset, and some parameter values were abstracted from the literature.  
These estimates have their limitations.  For example, while the use of QALYs as the main 
measure of health outcomes is in line with recommendations that the measures of 
effectiveness reflect utility and be comparable across a broad range of health conditions, 
only limited research has been conducted to date on TB-related utility weights.  The 
weights needed to qualify all the health states relevant to this study could not be obtained 
from one single source.  In addition, the existing research is far from exhaustive, as some 
TB health effects have been described but not fully measured or utility-weighted, and 
simplifying assumptions had to be made regarding their extent and timing.  In particular, 
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the model assumes that patients who recover from tuberculosis return to full health.  
However, recent studies have begun to describe the type and gravity of impairment that 
former TB patients experience.  Miller et al. (2009) argue that most health losses from 
ATBD in fact occur after cure, due to chronic morbidity and premature mortality from 
lung injury.  Unfortunately, their attempt to quantify the loss of health associated with 
pulmonary impairment after TB relies on a rating scale that does not measure preference.  
The quality adjustments they propose could not be combined easily with the other 
weights used in this study.  A study conducted in South Africa to assess the cost-
effectiveness of using chest x-rays to diagnose inactive pulmonary tuberculosis in HIV-
infected patients found that when the post-TB treatment utility weight was (arbitrarily) 
reduced from 1 to 0.9 (indicating a 10% decrease in quality of life post-TB), the ICER 
improved, from CAN$5,131 to CAN$3,711 per additional QALY saved (Fisher, 
unpublished).  This model may therefore be underestimating the QALY loss attributable 
to tuberculosis.  It would also be underestimating the number of QALYs saved by TTT 
(which serves as denominator in the ICERs) and, consequently, the cost-effectiveness of 
TTT.  The current study results would therefore represent a conservative estimate of 
TTT’s cost-effectiveness.  
A similar issue with data availability affects the range of ATBD treatment cost 
estimates used in this research.  Estimates available in the literature are from older 
publications.  The most recent cost-effectiveness studies tend to rely on estimates from 
older studies, updated to current dollars.  Abstracting cost data from medical records to 
conduct cost-of-disease studies is a complex task: it requires determining the type and 
quantity of health services consumed by individual patients from records meant to 
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document clinical information, rather than detailed use of health care resources.  This is 
particularly the case for public health clinics that do not practice cost recovery.  The 
alternative of using billing information to derive cost is not a satisfactory alternative, as 
billing systems provide information about charges, rather than resource costs.  In 
addition, compiling a cost inventory for tuberculosis may require collecting data from 
than one provider (a public health clinic and a hospital, for example), which greatly 
increases the magnitude of the task.  Finally, it is difficult to determine what constitutes 
an “average “ case of TB for costing purposes.  TB patients vary widely in the extent to 
which they experience symptoms pre-diagnosis, the gravity of their condition, and the 
type of care needed during treatment.  These may be the reasons why few studies have 
attempted to collect primary data on the cost of diagnosing and treating tuberculosis, and 
why those that have been published have focused on narrowly defined categories of 
patients (hospitalized patients, for example) and/or included only a relatively small 
number of cases: for example, White and Moore-Gillon’s study of MDR TB patients 
(White and Moore-Gillon, 2005) compared the cost of treating 9 MDR TB patients to that 
of 18 drug-sensitive patients; Rajhbandary et al. also focused on 9 hospitalized MDR TB 
patients (Rajbhandary et al., ).  The results of these small studies may provide reasonable 
estimates of the cost to treat the narrowly defined categories of TB patients in question, 
but they are difficult to generalize to the larger population of TB patients.  
In spite of these limitations and caveats, this study highlights the importance of 
study design decisions on cost-effectiveness results.  Over the range of sensitivity 
analyses conducted around the discount rate, the time horizon, and the scope of cost and 
outcomes, TTT ranges from being dominated to commanding an ICER that is well below 
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the cost-effectiveness threshold.  The influence of the chosen study perspective is 
particularly notable.  The cost-effectiveness criterion chosen for the study ($100,000 per 
QALY saved) proved harder to meet when the analysis adopts the health system 
perspective, which excludes patient costs.  Decisions about study design should therefore 
be made very carefully, and study design should be taken into account when evaluating 
the validity and relevance of research results, particularly when there is a need to 
compare and contrast the findings of studies conducted in different contexts and from 
different viewpoints. 
The discount rate proved a particularly influential parameter.  While guidelines 
recommend that a rate of 3% to 5% be used in the base case scenario, it is very possible 
that different stakeholders engaged in TB control in different capacities display different 
rates of time preference.  A 0% discount rate may reflect the views of TB control officers 
concerned with the long-range goal of TB elimination and setting strategic target dates 
for reaching this goal, as they may give equal weight to cases occurring at different points 
in time.  These same officials may also be inclined to view TTT’s impact over a longer 
analytical horizon.  Yet this perspective may be challenged when these same officials are 
called on to defend resource needs and use and asked to prioritize interventions in budget 
discussions with federal, state or local officials whose preferences and decisions may be 
framed by budget or electoral cycles that favor short-term results.  In addition, it is 
possible that, just like willingness-to-pay, time preference (as operationalized in the 
discount rate or in the analytical horizon) fluctuates for a given individual or institution 
(Weinstein, 1996).  For example, time preference may shift in favor of a higher discount 
rate or shorter horizon as target dates or strategic milestones set in policy documents and 
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strategic plans start looming closer on the horizon.  Preference may then shift to 
interventions that can deliver benefits in the short to medium term, and programs that 
require a long-term perspective for effectiveness and value for money to be demonstrated 
may then appear less attractive. 
Finally, the results also show the limitations of conducting only deterministic 
sensitivity analysis to evaluate the robustness of the results.  In all one-way sensitivity 
analyses, with the exception of that around test characteristics, wide value ranges over 
which TTT proves cost-effective can be identified.  When all parameters are varied 
jointly and randomly over a sensible range in the probabilistic sensitivity analysis, the 
likelihood that TTT will be preferred over PACF to control TB efficiently is relatively 
small, especially from the perspective of the health system.  PSA is a useful way to assess 
whether parameter uncertainty undermines the robustness and generalizability of base 
case scenario results, thus helping put these results into perspective.  
 
Implications for the Tennessee TB Control Program 
The findings also have implications for the Tennessee TB Control Program.  
Results of the base case scenario suggest that overall, the TTT program performed cost-
effectively during the study period.  However, stratifying the analysis by year also 
revealed enough variation in program performance to result in considerable swings in 
cost-effectiveness, and the PSA results show that the base case scenario results may be 
outliers.  In addition, the results of the sensitivity analyses around the rate of LTBI 
treatment initiation, treatment completion and screening in low-risk patients confirm that 
program performance matters greatly.  As far as testing low-risk patients for LTBI goes, 
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the Tennessee program’s performance is already at a level sufficient to ensure cost-
effectiveness even from the health system perspective, and improved steadily over time: 
the testing rate decreased continuously throughout the 2002-2006 period, from 75% in 
2002 to 51% in 2006, while it needed only to be below 82% to ensure cost-effectiveness 
when patient costs are excluded.  On the other hand, the average LTBI treatment 
initiation and completion rates observed in Tennessee over the study period are very 
close to the thresholds under which PACF would actually be the preferred strategy from 
the health system perspective.  From that viewpoint, the threshold treatment initiation rate 
to ensure cost-effectiveness was 53%.  The average rate for the 2002-2006 period was 
57.7% in high-risk, HIV+ patients, but it was only 52.1% in high-risk, HIV- patients 
(who are the most numerous, and whose experience therefore more likely to drive overall 
results) and 43.8% in the low-risk group.  Similarly, the sensitivity analysis showed the 
threshold treatment completion rate to be 58%.  This rate was also the average rate in 
high-risk, HIV- patients, while only 53% of high-risk, HIV+ and 57.5% of low-risk 
persons with LTBI completed treatment.  These findings suggest that it is essential for the 
Tennessee TB Control Program to ensure that program performance regarding initiating 
patients on LTBI treatment and ensuring that they complete at least 80% of the prescribed 
regimen, is at least maintained.  How to achieve programmatic improvement could be the 
topic of additional research.  Approaches based on the use of qualitative methods could 
generate useful knowledge regarding various aspects of program performance. Possible 
areas of investigation include health care workers’ perception of the TTT program and its 
benefits, its impact on staff workload, and patients’ perception of the risks and benefits of 
LTBI testing and treatment, as well as their reasons for accepting or refusing testing and 
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treatment.  Operations research could help investigate how tasks associated with TTT 
were integrated into existing routine, or intensified compared to previous activity levels, 
and identify patient- and staff-related barriers to higher uptake of skin testing and 
treatment, including the impact of patient direct and indirect costs.  Such research would 
also help clarify whether it is reasonable to assume that target goals could be reached (or 
at least performance could be improved) without a more-than-proportional increase in the 
resources dedicated to screening, evaluation, and case management. 
Also of particular relevance to the TN TB Control Program are the findings from 
the sensitivity analysis conducted around screening costs.  All other things being equal, 
the value assigned to represent the per-patient risk screening cost ($11.66) was not 
significantly different from the threshold above which TTT ceases to be cost-effective 
($12) from a health system perspective.  This suggest that allocating more resources to 
risk screening, unless it is accompanied with an increase in cases of LTBI identified, 
and/or treatment initiation and completion rates, would be difficult to justify from an 
economic point of view.   
Lastly, another important study finding of interest to the TB Control Program 
concerns the sizeable impact that including patient costs has on cost-effectiveness 
estimates.  When patient costs are left out, it costs approximately $98,000 to save a 
QALY.  When patient costs are counted in, the cost per QALY decreases to less than 
$13,000.  Highlighting the impact that tuberculosis has on patients, in addition to its cost 
to the health system, might be an important argument to make when the TB Control 
Program needs to advocate for continuing the intervention or obtaining additional 
resources.   
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Implications for U.S. TB Control Policy 
and the Goal of TB Elimination in Low-Incidence Settings 
Results also have implications for the broader policy discussion.  Study findings 
suggest that decision makers interested in implementing TTT in a given setting would 
need to carefully assess the characteristics of the TB epidemic in that setting to 
determine, in light of expected program performance, whether TTT should be preferred 
over PACF from a cost-effectiveness viewpoint.  Even though TTT is designed for low-
incidence areas where the TB burden is concentrated in a few high-risk groups, it is still 
best suited for areas and settings where these those high-risk groups are most likely to be 
reached.  The recommendation in the National Strategic Plan and in national TTT 
guidelines  to “take their direction from detailed epidemiologic analysis” (CDC, 2000; 
CDC, 2002) is therefore validated, as are attempts to implement LTBI testing and 
treatment interventions in settings where LTBI is most prevalent, such as homeless 
shelters or prisons, if a sufficiently high level of treatment initiation and completion can 
be maintained.  	  
Some recent technological advances in the diagnosis and treatment of LTBI do, if 
adopted into routine programmatic practice, hold promise to improve the cost-
effectiveness of TTT related to PACF.  Diagnostic tests of a new type, referred to as 
Interferon-Gamma Release Assays, have been approved by the Food and Drug 
Administration and have been commercially available in the United States since the early 
2000’s.  These tests require a blood sample.  The blood is mixed with the testing antigen, 
a substance derived from M. tuberculosis that causes the white cells in the blood sample 
to release interferon-gamma if the person is infected with LTBI.  The test then measures 
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the amount of interferon-gamma present in a volume of blood.  IGRAs have clear 
advantages over the Mantoux skin test.  First, they are based on antigens that are specific 
to M. tuberculosis.  The risk that they will show a reaction because the patients is infected 
with another type of mycobacteria is therefore substantially decreased, and improves the 
specificity of the diagnosis, an important determinant of cost-effectiveness in this study.  
Proponents of IGRAs also argue that they are superior tools because they do not require a 
return visit for the result to be read, which would decrease the health services and patient 
costs associated with LTBI testing.  These two characteristics of IGRAs should 
contribute to improving the cost-effectiveness of TTT if the new tests were integrated 
into the screening algorithm.  By decreasing the number of false positives that needlessly 
receive treatment, they would contribute to a more efficient use of resources.  By limiting 
the number of interactions with health care staff, they would also generate savings and 
help manage the workload associated with TTT.  However, obstacles remain that have 
limited the widespread use of IGRAs.  The principal one is that of unit cost.  The cost of 
the materials for a single IGRA can be as high as 3 to 4 times the cost of the tuberculin 
skin test, labor included.  Also, even though they do not require that the patient return for 
the result to be read (the blood sample is processed in the laboratory), they still require 
that patients with a positive result return to be informed of a positive  result and to 
continue the evaluation process that will lead to treatment.  Several studies have been 
conducted to evaluate the cost-effectiveness of IGRAs relative to TST, and tend to reach 
different conclusions regarding which IGRA to use and whether to use IGRAs alone or as 
the second test, following a TST, in a two-step testing algorithm (Oxlade et al., 2007; 
dePerio et al., 2009; Pooran et al., 2010; Mancuso et al., 2011).   
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Advances have also been registered in the treatment of LTBI.  Since December 
2011, the CDC has added to its list of recommended regimens a 12-dose, once-weekly 
course of Rifapentine and INH (900 mg).  In a clinical trial, this regimen has been shown 
to be equally protective as the standard 6-9 months of INH (Sterling, 2011).  There are 
two downsides to this regimen however.  First, it must be administered under direct 
observation: since it is comprised of only 12 doses, it is all the more important that no 
dose be missed to ensure effectiveness.  This results in increased health staff time costs, 
and perhaps transportation costs if public health nurses provide DOT in patients’ home or 
at their workplace rather than during clinic visits.  Second, the regimen itself is more 
costly: a single dose of RIF/INH costs upward of $12, rendering the cost of 12 RIF/INH 
doses higher than the cost of 270 doses of INH.  However, the clinical trial showed 
improve treatment completion, which would result in the prevention of a greater number 
of future ATBD cases.  Quality-of-life improvements (as measured in QALYs) would 
also result from the shorter treatment duration.  The latter may also lead to an increase in 
treatment initiation rates, as patients may be more likely to agree to taking medication 
once a week for 3 months rather than daily for 6 to 9 months.   A modeling study using 
clinical trial data has shown that, compared to a 6-9 months INH regimen, the 12-dose 
course of treatment would generate a cost of only U.S.$911 per additional QALY saved.  
Steps have been taken to integrate these new tools into diagnosis and treatment 
algorithms: LTBI diagnosis and treatment guidelines have been revised to included both 
the IGRAs and the 12-week INH/RIF regimen, along with TSTs and the standard 6-9 
months INH regimen, among recommended tools.  But funding constraints have limited 
their routine use and not enough evidence has yet been collected to evaluate their cost-
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effectiveness when used on a scale as large as in Tennessee’s TTT program.  As further 
cycles of implementation and research are conducted, future assessments of cost-
effectiveness should include probabilistic sensitivity analysis to ensure that the impact of 
uncertainty around parameter values is more clearly and explicitly taken into account. 
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APPENDIX A. 
TENNESSEE’S RISK ASSESSMENT TOOL INSTRUCTIONS 
Tennessee Department of Health 
TB Elimination Program 
 
INSTRUCTIONS FOR COMPLETING THE RISK 
ASSESSMENT TOOL (RAT) 
 
The RAT’s purpose: 
• To serve as a guide to educate the patient about key issues concerning 
TB/LTBI 
• To determine a patient’s individualized risk for TB/LTBI 
• To serve as documentation that counseling and risk assessment was 
accomplished 
• A method to report findings from the assessment (i.e. # HR patients tested, 
etc.) 
 
Who should be assessed with the RAT? 
• All cases 
• All contacts  
• Anyone requesting a skin test 
• Anyone with TB symptoms or with TB/LTBI risk factors 
• Persons referred for a + TST placed outside of the Health Department (HD) 
• All foreign born individuals 
• Anyone you feel who would benefit from TB/LTBI education and 
individualized assessment  
 
NOTE:  The RAT should be completed by persons TRAINED by TB staff to EDUCATE 
and ASSESS the patient concerning TB/LTBI and related issues.  The patient should 
NOT be asked to complete this form themselves.  
 
FILLING OUT THE FORM:   
 
• The form should be completed by circling “Y” for yes or “N” for no for each 
question.  Do not leave any blanks. 
• There are a few items with blank lines for you to write notes if indicated.   
 
The form is organized into four sections. It is very important that you complete the 
entire form. 
 
I. DEMOGRAPHICS:  
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The data in this section is required for PTBMIS registration.  Place a PTBMIS 
label over the top left side of the demographics section on each page of 
the RAT.  Please do not cover up the items not included on the label, such as 
country of origin etc.   
 
1. NAME/ALIAS: Emphasize to each patient the importance of using the same 
name for all health department visits.  Assure confidentiality and remind the 
patient that their names are recorded for health department records only.  
Inquire about other aliases that the patient may currently be using or may 
have used at the health department or place of employment.   
 
 
2. SS# (social security number): Some patients will not have a social security 
number and some may offer fictitious numbers.  Reassure patient that this 
information will only be used as a way to identify them at the health 
department and is also confidential.  If the patient does not have a social 
security number, record the number as 999-99-9999.   
 
3. DATE OF BIRTH: Encourage patient to give an accurate date.  
   
4. RACE:  Race and ethnicity are not the same.  For example, for reporting 
purposes, “Hispanic” is not considered a race, but an ethnicity.  
All patients should be identified by circling the appropriate “Race” and 
“Hispanic Y/N” and Country of Origin. 
 
NOTE:  No one should assign someone a race based on physical 
characteristics.  In order to determine race, ask each patient:    Which of 
the following is your race? 
W = White  A = Asian  N = Native American 
 
B = Black  P = Pacific Islander O = Other ** 
 
**The “O = Other” category should be reserved for individuals who either 
consider themselves bi-racial, or do not report race as one of the above 5 
categories.  Remind the patient that his/her ethnicity will be recorded by the 
Hispanic category and by Country of Origin.  
 
5. GENDER: M = male, F = female 
 
6. HISPANIC:  If the patient is Hispanic circle “Y”, if they are not Hispanic circle 
“N.”  Hispanic is an ethnicity and not a race. 
 
7. HOME/ CONTACT ADDRESS:  Use the address where the patient can be 
contacted if needed (i.e. emergencies). 
 
8. COUNTRY OF ORIGIN: The country where the patient was born.  If patient 
has arrived from a country other than their birth country, list that country 
under the “Travel/ residence in a high-risk area” section of TB RISK 
FACTORS. 
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9. PRIMARY LANGUAGE: The language the patient prefers to use in a medical 
encounter. 
 
10. HOME/ WORK PHONE:  A phone number where you can reach the patient. 
 
11. INSURANCE/ MEDICAID:  Indicate the type of insurance the patient has (i.e. 
TennCare, Blue Cross Blue Shield, John Deere, Veterans /Military benefits 
etc.).  If the patient does not have insurance, write “none.”  Some services 
can be billed to the patient’s insurance.  See codes manual for more details. 
 
12. MARITAL STATUS: S = single, M = married, D = divorced, W = widowed 
 
13. EDUCATION: List number of years of school completed.  High school grad is 
12 years, 2 years of college is 14 years, college grad is 16 years etc.  
 
14. OCCUPATION: Current occupation 
 
15. MONTH/YEAR OF U.S. ENTRY: The month or year that patient has most 
recently arrived in country.  If they have been here multiple times, list the 
most recent date that patient has returned to the US.   
 
 
II. BOXED AREA (Used for Community Site Patients ONLY):  
The boxed area is only for use when TB/LTBI screening is done at a 
community site. After a community screening, the community site patient 
number will be established when the data is entered in a “community record” in 
PTBMIS, just as a patient number is established when an individual chart is 
opened.  Risk assessment tools filled out on patients screened in the community 
should have all fields listed in the boxed area completed (i.e. name of community 
site, community site patient number, contact person, etc.).   
 
 
III. TB EXPOSURE RISK FACTORS:  
 
1. FOREIGN-BORN: Immigrants and refugees from foreign countries with high 
rates of TB infection.  The countries NOT included in this category are 
Canada, Western Europe, Australia, New Zealand, and Japan.  All immigrants 
and refugees should be tested regardless of length of time they have lived in 
the US. 
 
2. CONGREGATE SETTINGS: Includes persons who have lived or worked in 
one of these settings: jails, prisons, homeless shelters, and other long-term 
care facilities such as nursing homes and mental health facilities.  The 
provider should determine if the patient is high-risk or not, based on the 
individual’s history and last TB skin test result. Patients who have 
documentation of a negative skin test after release/discharge, and have no 
other known exposures or medical conditions, do not need to be retested.   
 
Alcohol and drug facilities should be listed in the “Other” category under 
congregate settings.  Risk Assessment Tools revised in 2/04 will include a 
specific “A&D” category under congregate settings.   
	  	   194	  
 
3. CLOSE TB CONTACT: Individual who has shared air with a person with 
infectious TB and is at high-risk of developing infection with M. tuberculosis 
because of the length of time, frequency or environmental settings of their 
exposure (i.e. close, prolonged contact).  Generally includes family members, 
roommates and housemates, close friends, co-workers, and classmates.   
 
4. CHILD AROUND AN ADULT WITH TB RISK FACTOR: Includes children 
who spend a significant amount of time around an adult with any of the TB 
exposure risk factors listed in this section.  Example:  a child who is born in 
the US, but has foreign-born parents or a child whose parent is HIV+.  Does 
not include adults with “Other medical conditions known to increase the risk of 
TB disease” such as diabetes. 
 
5. HOMELESS WITHIN PAST YEAR: Test all patients who were homeless 
within the last year.  Depending on the individual’s history, a provider may 
determine that a person who was homeless more than 1 year ago is at high 
risk for TB/LTBI and should be tested  
 
6. HIGH-RISK HEALTH CARE WORKER: Any health care worker who has 
direct contact with patients is considered high-risk.  All health care workers 
should be encouraged to receive their skin test either at their place of 
employment or by their local provider. 
The Central Office TB Program recommends that all high-risk occupational 
groups pay for their skin test.  It is important that healthcare workers starting a 
job in a new facility receive a two-step skin test if there is no documented 
negative skin test within the past 12 months.   
 
7. INJECTION DRUG USE: Any patient with a history of past or current IV drug 
use 
 
8. KNOWN HIV: Any patient with HIV or AIDS. Consider testing patients where 
there is suspicion of HIV infection. 
 
9. TRAVEL TO/ RESIDENCE IN HIGH-RISK AREAS: Provider judgment must 
be used to determine if a person traveling to or residing in a high-risk area 
(excludes Canada, Western Europe, Australia, New Zealand, and Japan) is at 
increased risk of TB exposure by considering the length of time abroad, the 
communities visited, the proximity of contact with local persons etc.  IF THE 
PATIENT HAD A NEGATIVE TST (DOCUMENTATION NOT REQUIRED) 
AFTER THE TIME HE/SHE TRAVELED TO OR LIVED IN A HIGH-RISK 
AREA, CODE THIS SECTION AS NO. 
 
10. OTHER: According to the CDC, other groups with high risk of TB infection 
include   “some medically underserved, low-income populations as 
defined locally”, and “high-risk racial or ethnic minority populations, 
defined locally as having an increased prevalence of TB.” For example, 
this might include Latino or Asian, etc., individuals born in the US who live in 
close community settings with others who are more recent immigrants. 
Providers must use their judgment based on local epidemiology to 
define other high-risk groups in the area (i.e. non IV drug users who 
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spend a lot of time around IV drug users, certain minority groups, etc.).  
In the space provided, list the other risk factors this patient identifies. 
 
 
IV. OTHER MEDICAL CONDITIONS KNOWN TO INCREASE THE RISK OF TB 
DISEASE: 
 
NOTE:  IF A PATIENT WITH ANY OF THE CONDITIONS LISTED BELOW HAS HAD 
A TST IN THE LAST YEAR (THE RESULTS MUST BE DOCUMENTED IN 
MILLIMETERS) AND HAS NO NEW OR ON-GOING EXPOSURE RISK FACTORS, DO 
NOT RETEST THIS PATIENT.  CODE THIS PATIENT AS HIGH-RISK.  CONSULT 
THE REGIONAL TB NURSE OR PHYSICIAN FOR FURTHER CLARIFICATION.   
 
1. DIABETES: Ask patient about “high-sugar” or other non-medical descriptions 
if patient doesn’t know what diabetes is. 
 
2. SILICOSIS: Ask patient if they have worked as a miner or have any other 
lung disease related to working in a mine.  
 
3. CORTICOSTEROIDS OR OTHER IMMUNOSUPPRESSIVE THERAPY FOR 
>3WKS: Use of steroids or other medicine for more than 3 weeks that a 
doctor has told them may affect their immune system (Dose of steroids above 
15mg per day or higher). 
 
4. CANCER OF THE HEAD AND NECK OR LUNG: Regardless of whether 
patient is treated for these cancers. Diagnosis of cancer must be confirmed 
and should not be coded for patients who are still undergoing diagnostic 
evaluation for cancer (i.e. have diagnosis of “possible” or “rule out cancer”). 
 
5. END STAGE KIDNEY DISEASE: Patients with severe kidney disease, 
including those on chronic hemodialysis 
 
6. LEUKEMIA, LYMPHOMA: Includes other diseases of the lymph nodes, 
spleen, and bone marrow. 
 
7. INTESTINAL BYPASS OR GASTRECTOMY: Patients who have had 
surgery to remove part of the upper intestine or stomach.  Does not include 
persons who had their colon removed.  
 
8. SOLID ORGAN TRANSPLANT: Particularly kidney and heart transplants 
 
9. CHRONIC MALABSORPTION SYNDROMES: Conditions where a doctor 
has told the patient that they do not absorb enough nutrients from their 
intestines and are consequently undernourished. 
 
10. WEIGHT LOSS >10% IDEAL BODY WEIGHT: Includes a person who has 
lost a significant amount of weight unintentionally or is chronically 
undernourished.  This does not include people who are dieting.   
 
 
V. HISTORY OF POSSIBLE TB/LTBI:    
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1. Previous PPD, mm/date/+/-:  Record millimeters, year of PPD and whether 
PPD was positive (+) or negative (-).  If prior PPD was “negative,” repeat the 
test on high-risk patients.  If documented prior “positive” or prior treatment for 
TB/LTBI, do not repeat test.  If there is no documentation of previous “positive” 
PPD, code this section as “YES” and leave the “mm” section blank (code as 
99 to the TB supplemental screen).  You may repeat the test, unless patient 
describes an extreme reaction such as vesiculation to the previous test. 
 
2. Previous diagnosis of TB/LTBI:  If coded as yes, circle whether the patient 
was diagnosed with TB or LTBI.     
 
3. Previous anti-TB treatment:  By each drug, code when the patient began the 
treatment and how long (in months) they took the medication. 
 
NOTE:  There is no need to place the test again if the patient has 
documentation to show he/she has had a positive TST in the past.  If 
there is no documentation to support a history of positive TST, replace 
the skin test to confirm if the patient had a positive skin test in the past.   
 
4. HIV risk factors:  Circle each risk factor that applies.  
 
NOTE:   
Ø If the patient has had more than 1 sexual partner in the last 5 years, 
“multiple sex partners” should be circled.   
Ø The definition of a “high-risk partner” is anyone who has sex with 
another person who has had any of the listed HIV risk factors (i.e. 
male-male sex, IVDU, multiple sex partners, sex worker, transfusion 
before 1985). 
Ø  “Sex workers” are individuals who provide sex for either money or 
drugs (i.e. prostitute). 
HIV risk factors are important, and a sensitive and culturally competent approach should 
be used to allow the patient to disclose personal information.  If these risk factors are 
present, offer HIV counseling, testing and referral through the HIV/STD program. Also, If 
you suspect that a person has HIV infection based on the presence of HIV risk 
factors or other clinical evidence, proceed to TST even if person refuses HIV test.  
This person would be coded as LOW-RISK   if HIV status is unknown and no other 
TB risk factors or medical conditions associated with High-TB risk are present,  
  
VI. TB SYMPTOMS: This section is included to identify persons with active TB who 
should be immediately isolated and referred for further evaluation. By inquiring about 
classic TB symptoms (i.e. cough, night sweats, fever/chills, weight loss, etc.), it is also 
possible that a person with active TB who does not have any obvious risk factor/s may 
be identified.  In addition, the PPD can be falsely negative in persons with 
immunosuppression or acute or overwhelming disease and these cases must be 
identified by symptoms alone.  If a person other than a nurse is performing the risk 
assessment, they must be educated to notify the nurse or doctor if any of these 
symptoms are present.  It is then up to that medical provider to determine if the symptom 
is truly suggestive of TB or represents a minor complaint as with a cold.  NOTE: IF A 
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PERSON INDICATES NO EXPOSURE OR MEDICAL RISK FACTORS, CODE AS 
LOW-RISK.  YOU MAY STILL CHOOSE TO TEST THIS PERSON IF THEIR 
SYMPTOMS ARE SUGGESTIVE OF TB.  IF THE PATIENT IS SYMPTOMATIC, 
FURTHER EVALUATION MEASURES SHOULD BE TAKEN, SUCH AS SPUTUM 
COLLECTION, CHEST X-RAY, ETC. 
 
VII: RISK OF TB INFECTION:  After the risk assessment is complete and adequate 
education about each section has been provided, a decision should be made as to 
whether a PPD is indicated.  
 
High-Risk: A person with any 1.) TB exposure risk factors (Section III) or 2.) a 
medical condition known to increase the risk of TB (Section IV) should be coded as 
high-risk and receive a skin test.  If the patient only has TB symptoms or a history of 
positive skin test, they are not considered to be “high-risk.”  However, if the nurse/rep 
feels the person may have active TB, it would be appropriate to place a skin test.  The 
patient should be immediately evaluated by a nurse or doctor if their symptoms suggest 
active TB.   
 
Low-Risk: Persons WITHOUT 1.) TB exposure risk factors or 2.) any medical condition 
known to increase the risk of TB can be classified as “low-risk”, and tuberculin testing 
should be strongly discouraged.  (Persons with symptoms suggestive of TB should be 
tested, as above).  The patient should be educated about why he/she is considered low 
risk (based on information provided by the patient).  Instruct the patient to contact the 
Health Department if symptoms develop or if he/she develops one on the risk factors 
listed above. 
 
Recording PPD:  Document at the bottom of the form that the patient has been 
counseled about the risk of TB/LTBI.  Information about the PPD placement and results 
should be documented, and referral to other clinics such as the TB or HIV clinic or other 
disposition should be noted.  Risk Assessment Tools revised on 2/04 will include a 
section to record the 2nd (two step test or retesting a contact).  People needing a two –
step skin test do not need another RAT filled out.  Contacts do not need another 
RAT completed unless they report new TB/LTBI risk factors. 
 
Use of an interpreter:   “Y” or “N” should be noted.  If the nurse/rep administering this 
tool is bilingual, circle “Yes.”  Also, if a patient is notified of his/her rights to free language 
services and declines, the offer and declination should be recorded.  Bi-lingual staff 
administering the service can not code INT1-4 in PTBMIS. 
 
Signing and dating the form: The health department employee who completes the 
assessment must sign the form.  The form should also be dated at the top, using the 
date the assessment was completed.  The TB/LTBI Risk Assessment Tool should only 
be used by health department personnel who have received appropriate training on how 
to administer the assessment and to educate each patient during the process. 
 
If a physician reviews the data on the RAT with the patient, he/she should initial the form 
and may use this documentation to support new and established patient coding (99201-
99215).  A section for the MD to initial the form will be available on the RATs revised on 
2/04. 
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APPENDIX B. 
MODEL ASSUMPTIONS 
Ø 	  All cases of ATBD that will develop in the future in the PACF or TTT strategy will 
be diagnosed and treated appropriately. 
 
Ø Patients who report having been treated for ATBD in the past have not since been 
re-infected with a different strain of TB, and would not benefit from further 
evaluation, testing or treatment for LTBI. 
 
Ø All patients in the low-risk group are HIV negative. 
 
Ø Patients with missing information concerning whether a test had been applied did 
not receive a skin test, unless a test result was recorded. 
 
Ø All patients who were coded as having received a test but whose test result was 
missing did not return for a reading of the test result. 
 
Ø All LTBI cases were non-conversion cases. 
 
Ø The prevalence of LTBI in persons who did not receive a skin test, or whose skin 
test result was not recorded, is the same as among persons of the same risk level 
whose skin test was read. 
 
Ø The prevalence of INH resistance in patients infected with LTBI was the same as 
among cases of ATBD registered nationally during the study period (2002-2006). 
 
Ø The prevalence of INH resistance in persons who did not receive a skin test or 
whose skin test was not read is the same as among persons of the same risk level 
whose skin test was read. 
 
Ø The prevalence of HIV infection in high-risk persons who did not receive a skin test 
or whose skin test was not read is the same as among high-risk persons whose skin 
test result was read. 
 
Ø The risk of developing ATBD is the same whether the individual was infected with 
an INH-resistant or INH-sensitive tuberculosis strain. 
 
Ø Having received complete or partial LTBI treatment will not affect the likelihood of 
survival if the patient later develops ATBD. 
 
Ø Anti-TB drug resistance patterns and LTBI treatment do not affect the likelihood 
that patients infected with LTBI would die from causes other than TB. 
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Ø In non-converters, it is not known whether the patient is infected with a INH-
resistant or INH-sensitive strain of TB.  LTBI treatment initiation and completion 
rates across resistance groups are the same. 
 
Ø The incidence of hepatotoxicity and its case fatality rate are the same regardless of 
anti-TB drug resistance.  
 
Ø The incidence of hepatotoxicity and its case fatality rate are the same regardless of 
HIV status. 
 
Ø Completing 100% of a prescribed LTBI treatment regimen will decrease the risk of 
evolving from LTBI to ATBD by 90%. 
 
Ø Completing 80% of a prescribed LTBI treatment regimen will decrease the risk of 
evolving from LTBI to ATBD by 68%. 
 
Ø Completing less than 80% of a prescribed LTBI treatment regimen will not 
decrease the risk of evolving from LTBI to ATBD. 
 
Ø Patients’ direct costs include only transportation costs.  All procedures, tests and 
drugs associated with targeted testing and treatment for LTBI are provided free of 
charge to the patient. 
 
Ø Patients receive TB-related services at TB clinic of the health department in their 
county of residence. 
 
Ø Patients travel to the TB clinic by motor vehicle. 
 
Ø Patients travel to the TB clinic unaccompanied by a caregiver. 
 
Ø Patients’ travel time, distance travelled and transportation costs to their local health 
department are comparable to the average work commute in the state of Tennessee. 
 
Ø No transportation cost would be incurred by patients to receive the RAT screening 
as they would already be present in the health department clinic for a reason 
unrelated to TB. 
 
Ø All patients with a positive skin test are examined by a physician and receive a 
chest X-ray. 
 
Ø All patients who report at least one (1) TB symptom are further evaluated for 
ATBD. 
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Ø All patients who report risk factors for HIV infection and all TST-positive patients 
who initiated LTBI treatment received an HIV test. 
 
Ø Patients who did not complete LTBI treatment interrupted treatment after 3 months 
or 90 doses of INH. 
 
Ø All LTBI treatment is self-administered. 
 
Ø Laboratory tests for monitoring of hepatotoxicity are only performed if the patient 
reports signs and symptoms of adverse drug reactions. 
 
Ø No capital expenses (i.e., clinic construction, large equipment purchase, etc.) are 
necessary to implement the targeted testing and treatment program. 
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APPENDIX C. 
UNITED STATES PERIOD LIFE TABLE, 2006 
 
Age Expectation 
of life 
Age Expectation 
of life 
Age Expectation 
of life 
0-1 77.7 34-35 45.4 68-69 16.3 
1-2 77.2 35-36 44.4 69-70 15.6 
2-3 76.3 36-37 43.5 70-71 14.9 
3-4 75.3 37-38 42.5 71-72 14.2 
4-5 74.3 38-39 41.6 72-73 13.5 
5-6 73.3 39-40 40.7 73-74 12.8 
6-7 72.3 40-41 39.7 74-75 12.2 
7-8 71.3 41-42 38.8 75-76 11.6 
8-9 70.4 42-43 37.9 76-77 10.9 
9-10 69.4 43-44 37.0 77-78 10.4 
10-11 68.4 44-45 36.1 78-79 9.8 
11-12 67.4 45-46 35.2 79-80 9.2 
12-13 66.4 46-47 34.3 80-81 8.7 
13-14 65.4 47-48 33.4 81-82 8.2 
14-15 64.4 48-49 32.5 82-83 7.7 
15-16 63.4 49-50 31.6 83-84 7.3 
16-17 62.4 50-51 30.7 84-85 6.8 
17-18 61.5 51-52 29.9 85-86 6.4 
18-19 60.5 52-53 29.0 86-87 6.0 
19-20 59.6 53-54 28.2 87-88 5.6 
20-21 58.6 54-55 27.3 88-89 5.2 
21-22 57.7 55-56 26.5 89-90 4.9 
22-23 56.7 56-57 25.6 90-91 4.6 
23-24 55.8 57-58 24.8 91-92 4.3 
24-25 54.8 58-59 24.0 92-93 4.0 
25-26 53.9 59-60 23.2 93-94 3.7 
26-27 53.0 60-61 22.4 94-95 3.4 
27-28 52.0 61-62 21.6 95-96 3.2 
28-29 51.1 62-63 20.8 96-97 3.0 
29-30 50.1 63-64 20.0 97-98 2.8 
30-31 49.2 64-65 19.2 98-99 2.6 
31-32 48.2 65-66 18.5 99-100 2.4 
32-33 47.3 66-67 17.8 100 + 2.3 
33-34 46.3 67-68 17.0   
Source:	  Arias,	  E.	  	  (2010).	  	  United	  States	  Life	  Tables,	  2006.	  National	  Vital	  Statistics	  Reports,	  vol.	  
58,	  no.	  21.	  Hyattsville,	  MD:	  National	  Center	  for	  Health	  Statistics.	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APPENDIX D. 
ANNUAL RISK OF EVOLUTION FROM LTBI TO ATBD IN 
PERSONS WITH NONCONVERSION POSITIVE TST RESULT 
(HORSBURGH, 2004)	  
	  
	  
	  
	  
	  
	  
	  
	  
 Age 
Size of TST 
induration 
0-5 Yr. 6-15 Yr. 16-35 Yr. 36-55 Yr. >55 Yr. 
5-9 mm 0.06 0.04 0.12 0.07 0.07 
10-14 mm 0.19 0.08 0.15 0.10 0.10 
>14 mm 0.24 0.14 0.19 0.12 0.12 
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APPENDIX E. 
NET PRESENT VALUE OF LIFETIME EARNINGS, 2011 US$ 
	  
	   Discounted	  at	  
Age	   3%	   5%	  
<1	   $1,240,221	   $591,195	  
1-­‐4	   $1,304,702	   $652,561	  
5-­‐9	   $1,426,449	   $777,948	  
10-­‐14	   $1,574,645	   $945,445	  
15-­‐19	   $1,719,716	   $1,129,647	  
20-­‐24	   $1,797,492	   $1,266,015	  
25-­‐29	   $1,760,218	   $1,302,373	  
30-­‐34	   $1,636,650	   $1,259,747	  
35-­‐39	   $1,455,693	   $1,160,649	  
40-­‐44	   $1,237,423	   $1,020,218	  
45-­‐49	   $990,525	   $842,990	  
50-­‐54	   $728,298	   $638,098	  
55-­‐59	   $467,971	   $419,926	  
60-­‐64	   $252,805	   $229,967	  
65-­‐69	   $123,500	   $113,401	  
70-­‐74	   $57,015	   $52,963	  
75-­‐79	   $23,740	   $22,198	  
80-­‐84	   $10,355	   $9,819	  
85+	   $2496	   $2,436	  
	  
(UPDATED FROM MAX, 2004)
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APPENDIX F 
COST SUMMARY 
Item Description/Assumptions CPT Code Reimbursemen
t rate (TN 
2011) or cost 
RISK SCREENING 
RAT 
administration 
Staff time: 15 min.  
Public Health Nurse at $26.92/hour 
NA $6.73 
Patient time: 15 min. 
Hourly rate: $14.56/hour 
No travel time or transportation cost, 
patient already at the clinic 
NA $3.64 
TUBERCULIN SKIN TESTING 
Skin test 
application 
 86580 $6.93 
Patient time: 10 min.  
Value of time: $14.56/hour 
No travel time or transportation cost 
(patient already at the clinic) 
NA $2.43 
Skin test reading 
visit (negative) 
5 min. of staff time 
Public Health Nurse at $26.92/hour 
NA $1.80 
60 min. of patient time (including: 25 
min. one-way travel time, 5 min. waiting 
time and 5 min. with the nurse) 
Value of time: $14.56/hour 
NA $14.56 
Skin test reading 
visit (positive) 
15 min. to read 
Public Health Nurse at $26.92/hour 
NA $6.93 
70 min. of patient time (including 25 min. 
one-way travel time, 5 min. waiting time 
and 15 min. with the nurse) 
Value of time: $14.56/hour 
NA $16.98 
EVALUATION 
Physician 
examination for 
all TST+ 
New patient visit, 20 min. face time 99202 $67.94 
75 min. of patient time (25 min. travel 
time one-way, 5 min. waiting time, 20 
min. with physician) 
Value of time: $14.56/hour 
NA $18.20 
Chest X-ray 
Single view 
(single view, frontal) 
71010 $22.55 
   
Baseline 
laboratory tests 
before INH 
initiation 
Complete blood count 
Chem 7 
Hepatic function panel 
G0306 
80047/48 
80076 
$10.94 
$9.71 
$9.71 
HIV test  
Rapid test plus confirmation of positives 
by Western Blot 
86703 
(HIV1 and 
HIV 2 
single 
$19.30 
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assay) 
86689 
(confirmato
ry test) 
 
$27.23 
TREATMENT FOR LTBI 
INH Tablet, 300 mg Source: Red Book, 2011 
 $0.38 
Vitamin B6 Tablet, 100 mg Red Book, 2011 
 $0.01 
Monthly follow-
up visits 
Established patient visit that may not 
require presence of physician, minimal 
presenting problems”, 5 min 
99211 $19.71 
60 min. of patient time (including travel 
time and waiting time) 
Value of time: $14.56/hr. 
NA  
ADVERSE REACTION TO LTBI TREATMENT 
Visit in case of 
adverse event 
“Visit that requires expanded problem 
focused history/examination, problems of 
low to moderate severity, 15 min. of face 
to face physician time 
99213 $66.09 
Laboratory tests 
in case of 
adverse events 
Complete blood count (2) 
Chem 7 (2) 
Hepatic function panel (2) 
Hepatitis profile (if liver profile 
abnormal) (2) 
Physician visit (2) 
G0306 
80047/48 
80076 
80074 
99201 
$10.94 
$9.71 
$9.71 
$24.22 
$39.23 
 1 hour of patient time 
Value of time: $14.56/hour 
NA  
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APPENDIX G. 
PROGRAM COSTS 
START UP COSTS    
 Salary (+ fringe) Time allocated Cost 
Program Management Costs    
TB Controller time cost $149,261.4/yr. 5 months $24,877 
Central office staff (2) $23.68/hr. 20 hours per month, 5 months $18,942 
Regional staff (2) $30.19/hr. 30 hours per month, 5 months $1,812 
    
Training Costs    
Trainer time costs $20/hr. 9 hours per trainer, 2 trainers per region, in 13 regions $4,680 
Trainee time costs    
Nurses $18/hr. 1 hr. per nurse, 8 nurses per region, 13 regions $1,872 
PHR $14/hr. 1 hr. per PHR, 2 PHR per region, 13 regions $364 
Interpreter $30/hr. 1 hr. per interpreter, 1 interpreter per region, 13 regions $390 
Database Costs    
Medical Coding costs (Central office staff 
time) $32.62/hr. 30 hours per staff member, 2 staff members $1,957 
Programming staff $32.62/hr. 30 hours, 1 staff member $979 
Data entry $11.75 20 hrs./week for 5 months $4,700 
Cost to switch to electronic data entry $29.87 40 hours $1,195 
  Total Start-Up Costs $55,891 
ANNUAL COSTS    
TB Controller time cost $149,261.4 30% $44,778.42 
Program Director cost $71,022.96 100% $71,022.96 
Data management costs $56,010.36 80% $44,808.29 
  Total Annual Program Management Costs $160,610 
  Total Management Costs over 5 years $858,941 
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APPENDIX	  H.	  
EVENT	  RATES	  AND	  TRANSITION	  PROBABILITIES	  
Parameter	   Strategy	  
Base	  case	  	   Sensitivity	  analysis	  
Value	   Data	  source	   Value	   Data	  source	  
Patients	  previously	  treated	  for	  ATBD	  
(%)	   PACF/TTT	   0.31%	   PTBMIS	   0.11%-­‐0.45%	   PTBMIS	  
Patients	  at	  high-­‐risk	  (%)	   TTT	  	   55.39%	   PTBMIS	   50.25%-­‐56.75%	   PTBMIS	  
Prevalence	  of	  LTBI	  	   PACF	  	   9.4%	   PTBMIS	   	   Assumption	  
TST	  placed	  (%)	  
TTT	  –	  High	  risk	  group	   81.55%	  
PTBMIS	  
68.0%-­‐85.2%	  
PTBMIS	  
TTT	  –	  Low	  risk	  group	   63.68%	   50.6%-­‐75.1%	  
TST	  read	  (%)	  
TTT	  –	  High	  risk	  group	   82.49%	  
PTBMIS	  
78.1%-­‐86.2%	  
PTBMIS	  
TTT	  –	  Low	  risk	  group	   80.17%	   74.8%-­‐85.3%	  
TST	  positive	  (%)	  
TTT	  –	  High	  risk	  group	   15.48%	  
PTBMIS	  
13.8%-­‐16.6%	  
PTBMIS	  
TTT	  –	  Low	  risk	  group	   2.63%	   2.1%-­‐3.3%	  
Sensitivity	  of	  TST	  	   TTT	   100%	   Assumption	   	   	  
Specificity	  of	  TST	  	   TTT	   100%	   Assumption	   80%	  -­‐	  90%	   	  
LTBI	  treatment	  initiation	  rate	  
TTT	  –	  High	  risk	  group	   52.08%	  
PTBMIS	  
	  
PTBMIS	  
TTT	  –	  Low	  risk	  group	   43.81%	   	  
LTBI	  treatment	  completion	  rate	  
TTT	  –	  High	  risk	  group	   57.54%	  
PTBMIS	  
	  
PTBMIS	  
TTT	  –	  Low	  risk	  group	   57.51%	   	  
Risk	  of	  adverse	  drug	  events	   TTT	   0.13%	   Nolan,	  1999	   	   	  
Percentage	  of	  fatal	  side	  effects	   TTT	   0.17%	   Millard,	  1996	   	   	  
	   PACF	   7.66%	   US	  surveillance	  data	   1%-­‐30%	   Assumption	  
Prevalence	  of	  INH	  resistance	  
TTT	  –	  High	  risk	  group	   10.38%	   US	  surveillance	  
data	  
1.35%-­‐40.61%	   Assumption	  
TTT	  –	  Low	  risk	  group	   4.30%	   0.56%-­‐16.82%	   Assumption	  
Prevalence	  of	  MDR-­‐TB	   PACF	   0.01%	   US	  surveillance	   	   	  
	  	   208	  
data	  
%	  of	  INH-­‐resistant	  patients	  who	  are	  
MDR	  
TTT	  –	  High	  risk	  group	   13.48%	   US	  surveillance	  
data	  
	  
TTT	  –	  Low	  risk	  group	   12.09%	   	  
Annual	  risk	  of	  death	  from	  other	  causes	   PACF/TTT	   Appendix	  x	   2006	  U.S.	  life	  table	   	   	  
Annual	  risk	  of	  developing	  ATBD	   PACF/TTT	   0.0011-­‐0.0015	   Horsburgh,	  2004	   	   	  
Efficacy	  of	  LTBI	  treatment	  
Complete	  treatment	   TTT	   68%	  -­‐	  90%	   IUATL,	  	   	   	  
Incomplete	  treatment	   TTT	   0%	   Assumption	   	   	  
Case	  fatality	  rate	  for	  ATBD	  
DS	  TB	  –	  HIV+	   PACF/TTT	   20.0%	   Shah,	  2010	   	   	  
DS	  TB	  –	  HIV	  neg	   PACF/TTT	   6.13%	   US	  surveillance	  data	   	   	  
MDR	  TB	  –	  HIV	  pos	   PACF/TTT	   20.0%	   Shah,	  2010	   	   	  
MDR	  TB	  –	  HIV	  neg.	   PACF/TTT	   12.0%	   WHO,	  2010	   	   	  
HIV	  prevalence	  
PACF	   0.69%	   PTBMIS	   	   	  
TTT–	  High	  risk	  group	   0.4%-­‐1.8%	   PTBMIS	   	   	  
TTT-­‐Low	  risk	  group	   0%	   PTBMIS	   	   	  
	  	   209	  
APPENDIX	  I	  
NUMBER	  OF	  QALYs	  LOST	  PER	  ATBD-­‐RELATED	  DEATH,	  
BY	  MARKOV	  CYCLE	  
ATBD	  death	  
in	  Year	  
=	  QALYs	  lost	   ATBD	  death	  
in	  Year	  
=	  QALYs	  lost	   ATBD	  death	  
in	  Year	  
	  
	   0%	   5%	   8%	   	   0%	   5%	   8%	   	   0%	   5%	   8%	  
1	   49.1	   18.2	   	   34	   20.1	   2.5	   	   67	   5.7	   0.2	   	  
2	   48.1	   17.2	   	   35	   19.4	   2.3	   	   68	   5.5	   0.2	   	  
3	   47.2	   16.3	   	   36	   18.7	   2.2	   	   69	   5.3	   0.2	   	  
4	   46.2	   15.4	   	   37	   18.0	   2.0	   	   70	   5.1	   0.1	   	  
5	   45.3	   14.6	   	   38	   17.4	   1.9	   	   71	   5.0	   0.1	   	  
6	   44.4	   13.9	   	   39	   16.8	   1.8	   	   72	   4.8	   0.1	   	  
7	   43.6	   13.2	   	   40	   16.3	   1.6	   	   73	   4.7	   0.1	   	  
8	   42.7	   12.5	   	   41	   15.7	   1.5	   	   74	   4.5	   0.1	   	  
9	   41.8	   11.8	   	   42	   15.1	   1.4	   	   75	   4.4	   0.1	   	  
10	   40.9	   11.1	   	   43	   14.6	   1.3	   	   76	   4.3	   0.1	   	  
11	   40.0	   10.5	   	   44	   14.1	   1.2	   	   77	   4.2	   0.1	   	  
12	   39.1	   9.9	   	   45	   13.6	   1.2	   	   78	   4.2	   0.1	   	  
13	   38.2	   9.4	   	   46	   13.1	   1.0	   	   79	   4.1	   0.1	   	  
14	   37.2	   8.9	   	   47	   12.6	   1.0	   	   80	   4.1	   0.1	   	  
15	   36.3	   8.4	   	   48	   12.2	   0.9	   	   81	   4.1	   0.1	   	  
16	   35.	   7.9	   	   49	   11.7	   0.9	   	   82	   4.0	   0.1	   	  
17	   34.4	   7.4	   	   50	   11.2	   0.8	   	   83	   3.9	   0.1	   	  
18	   33.4	   7.0	   	   51	   10.8	   0.7	   	   84	   3.8	   0.1	   	  
19	   32.5	   6.6	   	   52	   10.4	   0.6	   	   85	   3.7	   0.1	   	  
20	   31.6	   6.3	   	   53	   10.0	   0.6	   	   86	   3.6	   0.1	   	  
21	   30.7	   5.9	   	   54	   9.6	   0.6	   	   87	   3.5	   0.1	   	  
22	   29.8	   5.5	   	   55	   9.3	   0.5	   	   88	   3.4	   <0.1	   	  
23	   28.9	   5.2	   	   56	   8.9	   0.5	   	   89	   3.3	   <0.1	   	  
24	   28.0	   4.9	   	   57	   8.6	   0.5	   	   90	   3.2	   <0.1	   	  
25	   27.2	   4.5	   	   58	   8.2	   0.4	   	   91	   3.1	   <0.1	   	  
26	   26.3	   4.2	   	   59	   7.9	   0.4	   	   92	   3.0	   <0.1	   	  
27	   25.5	   4.0	   	   60	   7.6	   0.4	   	   93	   2.8	   <0.1	   	  
28	   24.7	   3.8	   	   61	   7.3	   0.3	   	   94	   2.7	   <0.1	   	  
29	   23.9	   3.5	   	   62	   7.0	   0.3	   	   95	   2.6	   <0.1	   	  
30	   23.1	   3.3	   	   63	   6.7	   0.3	   	   96	   2.5	   <0.1	   	  
31	   22.4	   3.0	   	   64	   6.5	   0.2	   	   97	   2.4	   <0.1	   	  
32	   21.6	   2.9	   	   65	   6.2	   0.2	   	   98	   2.3	   <0.1	   	  
33	   20.8	   2.7	   	   66	   6.0	   0.2	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APPENDIX J 
VARIABLES INCLUDED IN THE PROBABILISTIC SENSITIVITY ANALYSIS  
AND VALUE RANGES USED	  
Parameter	   Point	  Estimate	   Lower	  bound	   Upper	  bound	  
%	  of	  people	  in	  cohort	  who	  already	  had	  TB	   0.0031	   0.001	   0.005	  
Overall	  prevalence	  of	  LTBI	   0.094	   0	   0.25	  
Probability	  of	  HIV	  infection	   0.0069	   0	   0.02	  
Prev.	  of	  INH	  resistance	  among	  all	  patients	   0.0966	   0	   0.25	  
Prevalence	  of	  MDR	  TB	  among	  all	  INH-­‐resistant	  persons	  with	  
LTBI	  
0.1285	   0.05	   0.2	  
Case	  fatality	  rate,	  HIV-­‐	  drug-­‐susceptible	  ATBD	   0.0613	   0	   0.16	  
Case	  fatality	  rate,	  HIV+	  drug-­‐sensitive	  TB	   0.2	   0	   0.4	  
Specificity	  of	  LTBI	  test	   1	   0.8	   1	  
Sensitivity	  of	  LTBI	  test	   1	   0.9	   1	  
Prob.	  of	  a	  false	  positive	  test	  result	  in	  the	  low-­‐risk	  group	   0	   0	   0.5	  
Prob.	  of	  a	  TST	  being	  placed,	  high	  risk	   0.8155	   0.6800	   0.9000	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Prob.	  of	  TST	  being	  read,	  high-­‐risk	   0.8249	   0.7810	   0.8620	  
Prob.	  of	  initiating	  treatment,	  high-­‐risk,	  HIV-­‐	   0.5206	   0.4	   0.6	  
Prob.	  of	  completing	  LTBI	  treatment,	  high-­‐risk,	  HIV-­‐	   0.5797	   0.5	   0.6298	  
%	  of	  HR	  HIV	  neg	  patients	  who	  completed	  80	  to	  99%	  of	  tx	   0.0941	   0.06	   0.1561	  
QALY	  weight	  during	  LTBI	  tx	   0.02	   0	   0.04	  
Risk	  of	  INH	  toxicity	   0.0013	   0.001	   0.0015	  
Risk	  of	  fatal	  INH	  toxicity	   0.0017	   0.001	   0.003	  
Efficacy	  of	  completed	  LTBI	  treatment	   0.1	   0	   0.3	  
Discount	  rate	   0.03	   0	   0.08	  
Annual	  rise	  in	  real	  health	  care	  costs	   0.01	   0	   0.02	  
Treatment	  cost	  of	  drug	  sensitive	  ATBD	  case	   25000	   12000	   66000	  
Treatment	  cost	  of	  a	  MDR	  TB	  case	   73000	   46000	   110000	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APPENDIX K 
PARAMETERS USED IN SENSITIVITY ANALYSIS AROUND  
ANNUAL PROGRAM PERFORMANCE 
 
Parameter 2002 2003 2004 2005 2006 
% TST+ 
 
8.84 8.67 8.10 9.93 10.00 
% HR in TST+ 84.29 86.69 83.99 86.23 84.90 
% HR in TST- 42.26 46.79 46.32 48.66 50.06 
% who had TB previously 0.12 0.20 0.45 0.34 0.35 
% HR 47.25 50.25 49.37 52.39 53.72 
% of HR who received a TST 85.15 78.64 81.73 78.00 68.03 
% HR whose TST was read 79.18 78.13 82.25 84.46 86.24 
% HR who were TST+ 16.64 14.97 13.78 16.35 15.87 
% HIV+ in HR TST+ 0.61 0.46 0.22 0.22 0.53 
% who started LTBI treatment  
among HR HIV+ patients 
83.33 40.00 33.33 50.00 62.50 
% who started LTBI treatment  
among HR HIV- patients 
58.19 39.65 50.07 54.35 55.92 
% who completed LTBI treatment  
among HR HIV+ patients 
40.00 0.00 100.00 50.00 80.00 
% of HR HIV+ completers who completed 
100% of regimen 
100.00 0.00 100.00 100.00 100.00 
% who completed LTBI treatment  
among HR HIV- patients 
56.46 60.00 60.57 62.98 50.00 
% of HR HIV- completers who completed 
100% of regimen 
91.53 92.94 93.61 91.37 84.39 
% LR who received a TST 75.14 73.37 66.97 57.29 50.62 
% LR whose TST was read 74.76 76.05 80.09 85.28 84.92 
% LR who were TST+ 2.13 2.32 2.56 2.87 3.25 
% LR who started LTBI treatment 42.19 34.67 39.71 47.47 52.02 
% LR who completed treatment 64.81 51.92 48.15 61.17 60.19 
% of LR completers who completed 100% of 
regimen 
74.29 100 97.44 93.65 93.54 
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